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A B S T R A C T
Background
Epidemiological evidence has suggested a link between use of beta -agonists and increased asthma mortality. Much debate has
surroundedpossible causal links for this association, andwhether regular (daily) long-acting beta -agonists (LABAs) are safe, particularly
when used in combination with inhaled corticosteroids (ICSs). This is an update of a Cochrane Review that now includes data from
two large trials including 11,679 adults and 6208 children; both were mandated by the US Food and Drug Administration (FDA).
Objectives
To assess risks of mortality and non-fatal serious adverse events (SAEs) in trials that randomised participants with chronic asthma to
regular salmeterol and ICS versus the same dose of ICS.
Search methods
We identified randomised trials using the Cochrane Airways Group Specialised Register of trials. We checked websites of clinical trials
registers for unpublished trial data. We also checked FDA submissions in relation to salmeterol. The date of the most recent search was
10 October 2018.
Selection criteria
We included parallel-design randomised trials involving adults, children, or both with asthma of any severity who were randomised
to treatment with regular salmeterol and ICS (in separate or combined inhalers) versus the same dose of ICS of at least 12 weeks in
duration.
Data collection and analysis
We conducted the review according to standard procedures expected by Cochrane. We obtained unpublished data on mortality and
SAEs from the sponsors, from ClinicalTrials.gov, and from FDA submissions. We assessed our confidence in the evidence according to
current GRADE recommendations.
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Main results
We have included in this review 41 studies (27,951 participants) in adults and adolescents, along with eight studies (8453 participants)
in children. We judged that the overall risk of bias was low for all-cause events, and we obtained data on SAEs from all study authors.
All except 542 adults (and none of the children) were given salmeterol and fluticasone in the same (combination) inhaler.
Deaths
Eleven of a total of 14,233 adults taking regular salmeterol and ICS died, as did 13 of 13,718 taking regular ICS at the same dose.
The pooled Peto odds ratio (OR) was 0.80 (95% confidence interval (CI) 0.36 to 1.78; participants = 27,951; studies = 41; I² = 0%;
moderate-certainty evidence). In other words, for every 1000 adults treated for 25 weeks, one death occurred among those on ICS
alone, and the corresponding risk among those taking salmeterol and ICS was also one death (95% CI 0 to 2 deaths).
No children died, and no adults or children died of asthma, so we remain uncertain about mortality in children and about asthma
mortality in any age group.
Non-fatal serious adverse events
A total of 332 adults receiving regular salmeterol with ICS experienced a non-fatal SAE of any cause, compared to 282 adults receiving
regular ICS. The pooled Peto OR was 1.14 (95% CI 0.97 to 1.33; participants = 27,951; studies = 41; I² = 0%; moderate-certainty
evidence). For every 1000 adults treated for 25 weeks, 21 adults on ICS alone had an SAE, and the corresponding risk for those on
salmeterol and ICS was 23 adults (95% CI 20 to 27).
Sixty-five of 4229 children given regular salmeterol with ICS suffered an SAE of any cause, compared to 62 of 4224 children given
regular ICS. The pooled Peto OR was 1.04 (95% CI 0.73 to 1.48; participants = 8453; studies = 8; I² = 0%; moderate-certainty
evidence). For every 1000 children treated for 23 weeks, 15 children on ICS alone had an SAE, and the corresponding risk for those
on salmeterol and ICS was 15 children (95% CI 11 to 22).
Asthma-related serious adverse events
Eighty and 67 adults in each group, respectively, experienced an asthma-related non-fatal SAE. The pooled Peto OR was 1.15 (95%
CI 0.83 to 1.59; participants = 27,951; studies = 41; I² = 0%; low-certainty evidence). For every 1000 adults treated for 25 weeks, five
receiving ICS alone had an asthma-related SAE, and the corresponding risk among those on salmeterol and ICS was six adults (95%
CI 4 to 8).
Twenty-nine children taking salmeterol and ICS and 23 children taking ICS alone reported asthma-related events. The pooled Peto OR
was 1.25 (95%CI 0.72 to 2.16; participants = 8453; studies = 8; I² = 0%; moderate-certainty evidence). For every 1000 children treated
for 23 weeks, five receiving an ICS alone had an asthma-related SAE, and the corresponding risk among those receiving salmeterol and
ICS was seven children (95% CI 4 to 12).
Authors’ conclusions
We did not find a difference in the risk of death or serious adverse events in either adults or children. However, trial authors reported
no asthma deaths among 27,951 adults or 8453 children randomised to regular salmeterol and ICS or ICS alone over an average of six
months. Therefore, the risk of dying from asthma on either treatment was very low, but we remain uncertain about whether the risk
of dying from asthma is altered by adding salmeterol to ICS.
Inclusion of new trials has increased the precision of the estimates for non-fatal SAEs of any cause. We can now say that the worst-
case estimate is that at least 152 adults and 139 children must be treated with combination salmeterol and ICS for six months for one
additional person to be admitted to the hospital (compared to treatment with ICS alone). These possible risks still have to be weighed
against the benefits experienced by people who take combination treatment.
However more than 90% of prescribed treatment was taken in the new trials, so the effects observed may be different from those seen
with salmeterol in combination with ICS in daily practice.
P L A I N L A N G U A G E S U M M A R Y
Inhaled steroids with and without regular salmeterol for asthma: serious adverse events
Review question
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Is it safe to add regular salmeterol to inhaled corticosteroid (ICS) for adults or children with asthma?
Background
Another Cochrane Review found that using regular salmeterol without regular ICS for adults with asthma led to an increase in serious
adverse events (death or admission to hospital). We wanted to find out if more adverse (harmful) effects occur when people take regular
salmeterol in addition to ICS. We looked only at adverse effects - deaths, being admitted to hospital and life-threatening effects. We
did not look at the benefits of taking salmeterol for other outcomes. We updated this review in 2018 because of new evidence from
large randomised trials of salmeterol in combination with ICS, in 11,679 adults and 6208 children with asthma.
Study characteristics
In total, we have included 41 studies in 27,951 adults and eight studies in 8453 children. Almost all studies used a combination inhaler
to deliver salmeterol with ICS and compared this with the same dose of ICS for an average of six months.
Key results
We did not find a difference in the risk of death or serious adverse events in either adults or children.
Eleven of a total of 14,233 adults taking regular salmeterol and ICS died, as did 13 of 13,718 adults taking regular ICS at the same
dose. For every 1000 adults treated for 25 weeks, researchers reported one death on ICS alone and a corresponding risk on salmeterol
and ICS of one death (95% confidence Interval (CI) 0 to 2 deaths). No deaths in any studies were attributed to asthma, and researchers
reported no deaths at all among children.
A non-fatal serious adverse event of any cause occurred in 332 adults on regular salmeterol with ICS compared to 282 adults on regular
ICS alone. For every 1000 adults treated for 25 weeks, 21 serious adverse events occurred on ICS alone, and the corresponding risk on
salmeterol and ICS was 23 adults (95% CI 20 to 27).
A total of 65 of 4229 children on regular salmeterol with ICS suffered a serious adverse event of any cause compared to 62 of 4224
children on regular ICS alone. For every 1000 children treated for 23 weeks, 15 serious adverse events occurred on ICS alone, and the
corresponding risk on salmeterol and ICS was also 15 children (95% CI 11 to 22).
Quality of the evidence
Reviewers assessed the overall risk of bias for all-cause events as low. The two new large studies performed independent assessment to
identify the cause of asthma-related serious adverse events. This makes current data on asthma events more reliable than previously
reported.
Conclusions
Trials reported no asthma deaths among 27,951 adults or 8453 children randomised to regular salmeterol and ICS or ICS alone over an
average of six months. The risk of dying from asthma while receiving either treatment was therefore very low, but we remain uncertain
about whether the risk of dying from asthma is altered by adding salmeterol to ICS.
We can now say that the worst-case estimate (safety margin) from this review is that at least 152 adults and 139 children must be treated
with combination salmeterol and ICS for six months for one additional person to be admitted to the hospital (compared to ICS alone).
These possible risks must be weighed against the benefits experienced by people who take combination treatment.
People monitored in the new trials took over 90% of their prescribed treatment. This is much more than the average amount of
medication that people take outside a trial. Therefore the effects shown in trials may be different from the effects experienced by people
at home who are not taking their inhalers as prescribed.
Because very few people die of asthma, trials would have to be very large to detect differences in the death rate. Therefore it is probably
not feasible to find out if adding salmeterol to ICS causes more deaths among participants in randomised controlled trials - as these
trials would be very large, difficult to run, and expensive. It might be better to use case-control studies or to review asthma deaths (e.g.
from medical records).
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Inhaled steroids with and without regular salmeterol for asthma
Patient or population: adults and children with chronic asthma
Settings: community
Intervention: regular salmeterol in addit ion to regular inhaled cort icosteroid (ICS)
Comparison: regular ICS (at the same dose)
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Regular ICS Regular salmeterol in
addition to regular ICS
Adults and adolescents
All- cause mortality
Follow-up: mean 25
weeks
1 per 1000a 1 per 1000
(0 to 2)
OR 0.80
(0.36 to 1.78)
27951
(41)
⊕⊕⊕©
moderateb
All- cause non- fatal
SAEc
Follow-up: mean 25
weeks
21 per 1000a 23 per 1000
(20 to 27)
OR 1.14
(0.97 to 1.33)
27951
(41)
⊕⊕⊕©
moderateb
Asthma- related mor-
tality
Follow-up: mean 25
weeks
No deaths due to
asthma
No deaths due to
asthma
- 27951
(41)
⊕⊕⊕©
moderateb
Pooled risk dif f erence
zero (95% CI -0.0009 to
0.0009)
Asthma- related non-
fatal SAEc
Follow-up: mean 25
weeks
5 per 1000a 6 per 1000
(4 to 8)
OR 1.15
(0.83 to 1.59)
27951
(41)
⊕⊕©©
lowb,d
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Children
All- cause mortality
Follow-up: mean 23
weeks
No deaths No deaths - 8453
(8)
⊕⊕⊕©
moderateb
Pooled risk dif f erence
zero (95% CI -0.0013 to
0.0013)
All- cause non- fatal
SAEc
Follow-up: mean 23
weeks
15 per 1000a 15 per 1000
(11 to 22)
OR 1.04
(0.73 to 1.48)
8453
(8)
⊕⊕⊕©
moderateb
Asthma- related mor-
tality
Follow-up: mean 23
weeks
No deaths No deaths - 8453
(8)
⊕⊕⊕©
moderateb
Pooled risk dif f erence
zero (95% CI -0.0013 to
0.0013)
Asthma- related non-
fatal SAEc
Follow-up: mean 23
weeks
5 per 1000a 7 per 1000
(4 to 12)
OR 1.25
(0.72 to 2.16)
8453
(8)
⊕⊕⊕©
moderateb
* The basis for the assumed risk is the mean control event rate in the included studies. The corresponding risk (and its 95% conf idence interval) is based on the assumed risk
in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; ICS: inhaled cort icosteroid; OR: odds rat io; SAE: serious adverse event
GRADE Working Group grades of evidence.
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect.
aMean control event rate.
bImprecision (-1). We regard the upper end of the 95% conf idence interval as too high to rule out a potent ially important
increase. See also Table 3 and Appendix 5.
cNon-fatal SAEs were def ined as lif e-threatening adverse events, inpat ient hospitalisat ions or prolongat ion of exist ing
hospitalisat ions, persistent or signif icant disabilit ies or incapacit ies, or congenital anomalies or birth defects.
dMore than half of the events came f rom trials that did not independent ly assess the causat ion of SAEs.5
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B A C K G R O U N D
Description of the condition
For people whose asthma is not controlled by low-dose in-
haled corticosteroids (ICSs) alone, many asthma guidelines rec-
ommend adding long-acting beta -agonists (LABAs). Several
Cochrane Reviews have addressed the efficacy of LABA in ad-
dition to ICS (Ni Chroinin 2004; Ni Chroinin 2005), in com-
parison with placebo (Walters 2007), short-acting beta -agonists
(SABAs; Walters 2002), leukotriene receptor antagonists (LTRAs;
Ducharme 2006), and increased doses of ICS (Greenstone 2005).
The beneficial effects of LABA on lung function, symptoms, qual-
ity of life, and exacerbations requiring oral steroids have been
demonstrated.
However, long-standing controversy surrounds the regular use of
beta -agonists for people with asthma. Sears 1986 suggested that
excessive use of SABAs might have contributed directly or indi-
rectly to an increase in asthma deaths in New Zealand between
1960 and 1980. Study authors comment that “most deaths were
associated with poor assessment, underestimation of severity and
inappropriate treatment (over-reliance onbronchodilators andun-
der use of systemic corticosteroids), and delays in obtaining help”.
Concern remains that the symptomatic benefit resulting from
treatment with LABA might lead to underestimation of attack
severity in acute asthma, and could lead to an increase in asthma-
related deaths. Furthermore, regular treatment with beta -ago-
nists can lead to tolerance to their bronchodilator effects, and this
phenomenon may become more marked with longer-acting, as
opposed to shorter-acting, compounds (Lipworth 1997). Several
molecular mechanisms have been proposed to explain the possible
detrimental effects of long-term beta -agonist use in asthma, in-
cluding receptor down-regulation and desensitisation (Giembycz
2006).
Ameta-analysis of the effects of LABAs on severe asthma exacerba-
tions and asthma-related deaths concluded that “long-acting beta-
agonists have been shown to increase severe and life-threatening
asthma exacerbations, as well as asthma-related deaths” (Salpeter
2006). However, these researchers considered only trials that com-
pared LABA versus placebo, and 28 of the included trials on 6000
participants did not report asthma-related deaths, reducing cer-
tainty in the strength of review author conclusions.
Description of the intervention
Salmeterol and formoterol are examples of LABAs that are avail-
able to treat asthma. These two drugs are known to have differ-
ences in receptor activity, and they are used in different ways (e.g.
salmeterol has a slower onset of action than salbutamol and for-
moterol, and is therefore unsuitable for use as a reliever) (Beach
1992). “The Fenoterol Story” is a reminder that all beta -agonists
may not carry the same risks (Pearce 2007), so in view of potential
differences in adverse effects between salmeterol and formoterol,
we have considered the two drugs separately.
How the intervention might work
Since the publication of SMART 2006, much debate has sur-
rounded the interaction between ICS and LABA in relation to
serious adverse events (SAEs). This study did not randomise par-
ticipants to ICS but nevertheless conducted a subgroup analysis
of results on the basis of ICS use at baseline. It is tempting to be
reassured by the fact that researchers did not find a statistically
significant increase in asthma-related mortality in the subgroup
using ICS, but this is not the correct way to test for interaction
(Altman 2003), and investigators carried out no assessment during
the trial in relation to actual use of ICS during the study. There is
a need to systematically review all available data from controlled
trials that randomised participants to regular salmeterol in com-
bination with ICS, and to consider all SAEs (fatal and non-fatal),
whether or not they are deemed by investigators to be related to
trial medication.
Why it is important to do this review
The focus of this review is on regular salmeterol that has been ran-
domised in combination with ICS (in a single inhaler or in sepa-
rate inhalers). Due to the difficulty involved in deciding whether
adverse events are asthma-related (particularly in the many stud-
ies that do not perform independent outcome assessment of ad-
verse events), the authors of this review are concerned with studies
that capture mortality and SAEs, and we have recorded both all-
cause outcomes and those considered by trial investigators to be
asthma-related events. This approach differs from that reported
in Bateman 2008, in which review authors restricted outcomes to
asthma-related events.
Regular salmeterol alone is the topic of a previous review (Cates
2008a), as is regular formoterol alone (Cates 2012b). In both of
these reviews, review authors demonstrated an increase in SAEs
with regular LABA. Another review considered formoterol with
ICS (Cates 2009a). Review authors have also provided overviews
of the safety of combination therapy in children and in adults
(Cates 2012a; Cates 2014, respectively).
Due to ongoing concern over the safety of LABAs, the FDA man-
dated large trials of salmeterol and ICS in both adults and chil-
dren. We have included results of these studies in this updated
review. The two large new studies were designed to test whether
salmeterol was safe when added to ICS; to do this, trial authors
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used a safety margin derived from the worst end of the 95% confi-
dence interval of the comparative risk for a combined endpoint in
these trials (death, intubation, or hospital admission). In adults,
the safety margin was a hazard ratio of 2.0; in children, the hazard
ratio was 2.675.
O B J E C T I V E S
To assess risks of mortality and non-fatal SAEs in trials that ran-
domised participants with chronic asthma to regular salmeterol
and ICS versus the same dose of ICS.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We sought randomised controlled trials (RCTs), with or without
blinding, in which researchers randomly assigned salmeterol and
ICS to participants with chronic asthma.
Types of participants
We included participants of any age with a clinical diagnosis of
asthma, unrestricted by disease severity or previous or current treat-
ment. We did not include studies on acute asthma and exercise-
induced bronchospasm.
Types of interventions
We searched for trials in which investigators prescribed ICS and
salmeterol regularly for a period of at least 12 weeks, at any daily
dose, and delivered by any single or separate devices (i.e. chloroflu-
orocarbon metered dose inhaler (CFC-MDI), hydrofluoroalkane
metered dose inhaler (HFA-MDI), or dry powder inhaler (DPI)).
We included studies that used comparison groups given the same
dose of ICS; co-interventions with LTRAs, cromones, oral corti-
costeroids (OCSs), or theophylline were allowed as long as they
were not part of the randomised intervention.We excluded studies
that compared different doses of salmeterol or different delivery
devices or propellants (with no placebo arm), or that compared
salmeterol versus formoterol.We excluded from this review studies
that randomised salmeterol without an inhaled steroid; a separate
Cochrane Review has considered these studies (Cates 2008a).
Types of outcome measures
Primary outcomes
• All-cause mortality
• All-cause non-fatal serious adverse events
Secondary outcomes
• Asthma-related mortality
• Asthma-related non-fatal serious adverse events
• Respiratory-related mortality
• Respiratory-related non-fatal serious adverse events
• Cardiovascular-related mortality
• Cardiovascular-related non-fatal serious adverse events
• Asthma-related non-fatal life-threatening events (intubation
or admission to intensive care)
• Respiratory-related non-fatal life-threatening events
(intubation or admission to intensive care)
Search methods for identification of studies
Electronic searches
We searched the Cochrane Airways Trials Register up to 10 Oc-
tober 2018, with no restrictions on language or type of publica-
tion. The Cochrane Airways Trials Register is maintained by the
information specialist for Cochrane Airways and contains studies
identified from the following sources.
• Monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL), in the Cochrane Library,
through the Cochrane Register of Studies (CRS).
• Weekly searches of MEDLINE Ovid SP.
• Weekly searches of Embase Ovid SP.
• Monthly searches of PsycINFO Ovid SP.
• Monthly searches of the Cumulative Index to Nursing and
Allied Health Literature (CINAHL) EBSCO.
• Monthly searches of Allied and Complementary Medicine
(AMED) EBSCO.
• Handsearches of the proceedings of major respiratory
conferences.
We identified studies contained in the Trials Register using search
strategies based on the scope of Cochrane Airways. We have pro-
vided details of these strategies, as well as a list of handsearched
conference proceedings, in Appendix 3. See Appendix 4 for search
terms used to identify studies for this review.
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Searching other resources
We checked the reference lists of all primary studies and review
articles for additional references.We checked the websites of clini-
cal trial registers for unpublished trial data. We also checked FDA
submissions in relation to salmeterol.
Data collection and analysis
Selection of studies
Two review authors independently assessed studies identified via
literature searches by examining title, abstract, and keyword fields.
We obtained in full text studies that potentially fulfilled the in-
clusion criteria. CJC and TL independently assessed these for in-
clusion (CJC, BS, and SW for the 2018 update). We resolved dis-
agreements by consensus.
Data extraction and management
We extracted data using a prepared checklist before one review au-
thor (CJC) with assistance from Susan Hansen (information spe-
cialist) entered data into RevMan 5.3, and another review author
(TL, MF, SS, BS, or SW) checked data on trial characteristics.
A third review author (RJ, MF, SS, BS, or SW) independently
extracted outcome data and resolved discrepancies by discussion
and correspondence with study sponsors. Data included charac-
teristics (methods, participants, interventions, outcomes) and re-
sults of included studies. We contacted authors and sponsors of in-
cluded studies for unpublished adverse event data, andwe searched
manufacturers’ websites for further details of adverse events. We
also searched FDA submissions. We collected all-cause SAEs (fatal
and non-fatal), and in view of the difficulty involved in deciding
whether events were asthma-related, we noted details of the cause
of death and SAEswhere available.We also recorded the definition
of SAEs, and we sought further information if this was not clear
(particularly in relation to hospital admissions and SAEs).
Assessment of risk of bias in included studies
Two review authors (of CJC, Susan Hansen, MF, SS, BS, SW)
assessed included studies for bias protection (including sequence
generation for randomisation, allocation concealment, blinding of
participants and assessors, loss to follow-up, and completeness of
outcome assessment).
Measures of treatment effect
The outcomes of this review were dichotomous, and we recorded
the number of participants with one or more outcome events by
allocated treated group.
Unit of analysis issues
We confined our analysis to participants with one or more SAEs,
rather than analysing the number of events that occurred (as the
latter are not independent when one participant experiences mul-
tiple events and therefore are not suitable for meta-analysis).
Dealing with missing data
When we did not find full data on mortality or SAEs in published
papers, we searched the sponsors’ trial results sites and clinicaltri-
als.gov to obtain the missing data.
Assessment of heterogeneity
We assessed heterogeneity by using I² to indicate how much of
the total heterogeneity was evident between studies (rather than
within studies).
Assessment of reporting biases
We found full data on all-cause mortality and SAEs, so we did not
assess reporting biases any further for these outcomes. For asthma-
specific SAEs, we looked for evidence of independent outcome
assessment in these studies.
Data synthesis
The outcomes of this review are dichotomous, and we recorded
the number of participants with at least one outcome event by al-
located treatment group. We calculated pooled odds ratios (ORs)
and risk differences (RDs). We used the Peto OR for the primary
analysis, as no adjustment for zero cells is required. This prop-
erty wasmore important than potential problemswith unbalanced
treatment arms and large effect sizes (in view of the high propor-
tion of zero cells), but we used the Mantel-Haenszel method for
sensitivity analysis. ORs do not include the large body of evidence
derived from trials with no event in either arm, but we included
such data in the analysis of absolute rates using RDs. We inspected
funnel plots to assess publication bias.
For the 2018 update, we assessed the safety of adding salmeterol to
ICS from the worst-case number needed to treat for an additional
harmful outcome (NNTH) for one additional SAE or death to
occur. We calculated the NNTH using Visual Rx to transform the
upper end of the 95% confidence interval (CI) of the pooled Peto
OR, by applying it to the mean event rate in trial control arms
(Visual Rx).
Subgroup analysis and investigation of heterogeneity
We planned subgroup analyses on the basis of age (adults vs chil-
dren), severity of asthma, dose of salmeterol, and dose of inhaled
corticosteroid in comparison arms. We made subgroup compar-
isons using tests for interaction (Altman 2003).
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Sensitivity analysis
We carried out sensitivity analysis to assess the impact of the
method used to combine study events (PetoOR,Mantel-Haenszel
OR, and RD). We included the degree of bias protection in study
designs as part of the sensitivity analysis.
’Summary of findings’ tables
We assessed the certainty of evidence as high, moderate, low, or
very low in accordance with recommendations outlined by the
GRADE Working Group for meta-analyses of randomised tri-
als (GRADE website). We have presented these assessments in
Summary of findings for the main comparison, alongside the re-
sults of our analyses for key outcomes in adults and children (all-
cause mortality, all-cause non-fatal SAEs, and asthma-relatedmor-
tality and SAEs).
R E S U L T S
Description of studies
Results of the search
We included40 studies in the previous version of this review (Cates
2013). The literature search for this review update covered the pe-
riod from 2011 to October 2018 and yielded 436 references after
removal of duplicates. We excluded 403 references on the basis of
title and abstract alone, and we selected 33 records for full-text
review. We identified nine new studies and two references to previ-
ously included studies. Among adults and adolescents, we identi-
fied six new studies including 14,504 adult participants (AUSTRI
2016; Bernstein 2017;Mansfield 2017; Raphael 2017; Sher 2017;
Slankard 2016), alongwith three new studies including 6783 child
participants (MASCOT 2013; Ploszczuk 2014; VESTRI 2016).
We excluded six full-text articles (describing four studies - Bateman
2011; Lotvall 2014; NCT01172808; NCT01172821), as partic-
ipants used background inhaled corticosteroids, but this was not
part of the randomised treatment (Bateman 2011; Casale 2013;
Casale 2014; Kerstjens 2014; Kerstjens 2015; Lotvall 2014).
The review now includes a total of 49 studies (Figure 1).
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Figure 1. Study flow diagram: review update.
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Included studies
We included 41 studies in adults and adolescents (27,951 par-
ticipants) over the age of 12, 16, or 18 years, according to
Characteristics of included studies. We included eight studies
in children up to the age of 11 years (8453 participants). The
weighted mean duration was 25 weeks in adult studies, and 23
weeks in studies in children.
Most studies were sponsored or supported by GlaxoSmithKline
and compared combination fluticasone and salmeterol versus flu-
ticasone alone. Teva Pharmaceuticals sponsored Mansfield 2017
and Raphael 2017, and Mundipharma Research Ltd sponsored
Ploszczuk 2014. The NIHR Health Technology Assessment pro-
gramme sponsored MASCOT 2013.
All except 542 adults (and none of the children) randomised to
salmeterol were given fluticasone in the same (combination) in-
haler (Table 1). The dose of salmeterol used was 50 µg twice daily
in most studies (Table 1). The dose of fluticasone varied from 100
to 1000 µg/d (Table 1), and some studies stratified participants
to different daily doses of fluticasone but used the same daily dose
of fluticasone in each stratum for comparison with additional sal-
meterol.
Excluded studies
We excluded 81 studies with reasons described in Characteristics
of excluded studies.
Risk of bias in included studies
We have provided an overview of the risk of bias in individual
studies in Figure 2. We did not downgrade our certainty in the
findings for risk of bias in this update, for the reasons outlined
below.
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Figure 2. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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Allocation
Studies did not report clear details of sequence generation and
allocation concealment, but we found from correspondence with
study sponsors that standard methods (as required by regulatory
authorities) had been used to protect against selection bias in these
studies. We therefore regarded the risk of selection bias as low,
even though sequence generation and allocation concealment are
marked as unclear in most studies in Figure 2.
Blinding
All studies were reported as double-blind (with the exception of
Mansfield 2017, which was open-label). Researchers incorporated
double-dummy design when inhaler devices were not the same in
each arm.We therefore assessed risks of performance and detection
bias as low for all-cause events.
Indepedent assessment of causation
Previously, no independent assessment had examined the causa-
tion of SAEs, so it is possible that asthma-related events were sub-
ject to detection bias.However the two large new trials, which con-
tributed 42% of asthma-related events in adults (AUSTRI 2016),
as well as 92% in children (VESTRI 2016), used independent
panels to assess causation for asthma-related hospitalisation, in-
tubation, or mortality. The risk of bias is therefore reduced for
asthma-related events in this update (compared to the previous
version of this review).
Incomplete outcome data
Researchers generally reported safety analyses for all randomised
participants who had taken at least one dose of treatment. Some
studies reported high proportions of withdrawals; these con-
tributed only a small proportion of participants to the meta-anal-
yses, so we did not downgrade the overall quality of evidence for
attrition bias.
Selective reporting
Sponsors have not found or provided data for all-cause fatal and
non-fatal SAEs by treatment group for all studies, so we regarded
the risk of reporting bias as low for the outcomes considered in
this review.
Other potential sources of bias
GlaxoSmithKline sponsored or supported most studies, which
compared combination fluticasone and salmeterol to flutica-
sone alone. Teva Pharmaceuticals sponsored Mansfield 2017
and Raphael 2017, and Mundipharma Research Ltd sponsored
Ploszczuk 2014. The NIHR Health Technology Assessment pro-
gramme sponsored MASCOT 2013. However we do not regard
sponsorship as necessarily increasing the risk of bias when studies
are well designed.
Effects of interventions
See: Summary of findings for the main comparison Serious
adverse events (SAEs) in adults and children
Primary outcomes
All-cause mortality
Adults and adolescents
Eleven deaths occurred in 14,233 adults on regular salmeterol with
inhaled corticosteroid (ICS), and 13 deaths in 13,718 adults on
regular ICS at the same dose. The pooled odds ratio was Peto
OR 0.80 (95% CI 0.36 to 1.78; participants = 27,951; studies
= 41; I² = 0%; moderate-certainty evidence; Analysis 1.1; Figure
3). In other words, for every 1000 adults treated for 25 weeks,
one death occurred on ICS alone, and the corresponding risk for
salmeterol and ICS was also one death (95% CI 0 to 2 deaths).
We assessed this as moderate-certainty evidence because only 24
deaths in total occurred across all trials (Summary of findings for
the main comparison). Moreover, even one extra death per 1000
is not a level of risk that we would regard as acceptable (Appendix
5), so we are unable to conclude with a high level of certainty that
regular salmeterol with ICS is as safe as regular ICS alone.
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Figure 3. Forest plot of comparison: 1 Regular salmeterol in addition to regular inhaled corticosteroids,
outcome: 1.1 All-cause mortality.
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We have listed the causes of death in Table 2. Study authors re-
ported none of the deaths as related to asthma.
Children
Eight studies on children (8453 participants) reported no deaths.
It is not possible to calculate any ORs from these data, but the
pooled RD can be assessed with a confidence interval (RD 0.0000,
95% CI -0.0013 to 0.0013; Analysis 2.1; Table 3; Figure 4). In
other words, for every 1000 children treated with salmeterol and
ICS for 23weeks, the 95%confidence interval is compatible with a
possible increase or decrease of one death (Summary of findings for
the main comparison).We also assessed this as moderate-certainty
evidence because no deaths occurred among children across all
trials, and even one extra death per 1000 is not a level of risk that
we would regard as acceptable (Summary of findings for the main
comparison; Appendix 5).
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Figure 4. Forest plot of comparison: 2 Risk difference meta-analysis: regular salmeterol in addition to
regular ICS, outcome: 2.1 All-cause mortality.
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Serious adverse events (non-fatal all-cause)
A serious adverse event in general is defined as an event that falls
into any of the following categories.
• Results in death.
• Is life-threatening.
• Requires inpatient hospitalisation or prolongation of
existing hospitalisation.
• Results in persistent or significant disability/incapacity.
• Is a congenital anomaly/birth defect.
This is the definition from the International Conference on Har-
monisation (ICH), and we have assumed that investigators in the
included trials used this definition (even though this often was not
explicitly reported in the papers, it is the standard definition for
regulatory trials (ICHE2a 1995)).
Adults and adolescents
Trials reported non-fatal SAEs of any cause in 332 of 14,233 adults
on regular salmeterol with ICS compared to 282 of 13,718 adults
on regular ICS; the pooled Peto OR was 1.14 (95% CI 0.97 to
1.33; participants = 27,951; studies = 41; I² = 0%; moderate-
certainty evidence; Figure 5). For every 1000 adults treated for
25 weeks, 21 adults on ICS alone experienced an SAE, and the
corresponding risk for salmeterol and ICS was 23 adults (95% CI
20 to 27; Summary of findings for the main comparison).
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Figure 5. Forest plot of comparison: 1 Regular salmeterol in addition to regular inhaled corticosteroids,
outcome: 1.2 All-cause non-fatal SAE.
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We assessed this as moderate-certainty evidence because the upper
boundary of the confidence interval for the Peto OR translates
into an NNTH of 152 for additional adults to suffer a non-fatal
SAE over six months (Table 3).We regarded the upper limit as too
high a risk to have a high level of certainty that salmeterol is safe.
Children
Data show 65 of 4229 children with SAEs on regular salmeterol
with ICS compared to 62 of 4224 on regular ICS; the pooled
odds ratio was Peto OR 1.04 (95% CI 0.73 to 1.48; participants
= 8453; studies = 8; I² = 0%; moderate-certainty evidence; Figure
5).
For every 1000 children treated for 23 weeks, 15 children expe-
rienced an SAE on ICS alone, and the corresponding risk on sal-
meterol and ICS was also 15 children (95% CI 11 to 22).
We assessed this as moderate-certainty evidence because the upper
boundary of the confidence interval for the Peto OR translates
into an NNTH of 139 for an additional child to suffer a non-fatal
SAE over six months (Table 3).We regarded the upper limit as too
high a risk to have a high level of certainty that salmeterol is safe.
The test for interaction between adults and children did not show
a significant impact of age on the treatment effect (Figure 5).
Secondary outcomes
Mortality related to asthma
None of the deaths were reported to be related to asthma. Never-
theless, when all studies were combined in a risk difference meta-
analysis, we were able to use this to estimate the maximum in-
crease in asthma deaths that is compatible with the numbers of
adults and children included (using the upper end of the 95%
confidence interval). For adults, this yields RD 0.0000 (95% CI
-0.0009 to 0.0009; participants = 27,951; studies = 41), and for
children RD 0.0000 (95% CI -0.0013 to 0.0013; participants =
8453; studies = 8; Table 3; Figure 6). In other words, for both
adults and children, the pooled risk difference is compatible with
one more or one fewer death per 1000 treated for six months.
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Figure 6. Forest plot of comparison: 2 Risk difference meta-analysis: regular salmeterol in addition to
regular ICS, outcome: 2.5 Asthma-related mortality.
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We assessed this as moderate-certainty evidence because no deaths
were related to asthma, and even one extra death per 1000 is not
a level of risk that we would regard as acceptable (Summary of
findings for the main comparison; Appendix 5).
Non-fatal serious adverse events related to asthma
Adults and adolescents
Researchers reported asthma-related SAEs in 80 and 67 adults in
each group, respectively, and the pooled odds ratio was Peto OR
1.15 (95% CI 0.83 to 1.59; participants = 27,951; studies = 41;
I² = 0%; low-certainty evidence; Figure 7).
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Figure 7. Forest plot of comparison: 1 Regular salmeterol in addition to regular inhaled corticosteroids,
outcome: 1.3 Asthma-related SAE.
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For every 1000 adults treated for 25 weeks, five experienced an
asthma-related non-fatal SAEon ICS alone, and the corresponding
risk on salmeterol and ICS was six adults (95% CI 4 to 8).
We assessed this as low-certainty evidence because the upper
boundary of the confidence interval for the Peto OR translates
into an NNTH of 351 for an additional adult to suffer a non-fa-
tal asthma-related SAE over six months (Table 3). We also down-
graded our certainty in this outcome because more than half of
the events occurred during trials that provided no independent
assessment of the causation of asthma-related events.
Children
Study results show 29 and 23 children in each treatment group
with asthma-related events (Peto OR 1.25, 95% CI 0.72 to 2.16;
participants = 8453; studies = 8; I² = 0%; moderate-certainty ev-
idence; Figure 7). For every 1000 children treated for 23 weeks,
five experienced an asthma-related SAE on ICS alone, and the cor-
responding risk on salmeterol and ICS was seven children (95%
CI 4 to 12).
We assessed this as moderate-certainty evidence because the upper
boundary of the confidence interval for the Peto OR translates
into an NNTH of 128 for an additional child to suffer a non-
fatal asthma-related SAE over six months (Table 3). We regarded
this upper limit as too high a risk to have a high level of certainty
that salmeterol is safe, but we did not downgrade our certainty
in the evidence for detection bias as almost all events occurred in
VESTRI 2016 (in which causation was independently assessed).
The difference between children and adults again was not statis-
tically significant (Figure 7). We did not find sufficient data to
assess the other proposed secondary outcomes (such as intensive
care unit admission and intubation).
Sensitivity analyses
Risk of bias
We identified one unblinded study that did not report any deaths
(Mansfield 2017); removal of this study for non-fatal SAEs of
any cause made very little difference to the pooled Peto OR of
1.13 (95% CI 0.96 to 1.34; participants = 27,278; studies = 41).
Removal of the four studies thought to be at high risk of attrition
bias also made little difference to the OR of non-fatal SAEs in
adults (PetoOR1.11, 95%CI 0.94 to 1.31; participants = 26,763;
studies = 37) (Figure 2). A funnel plot of non-fatal SAEs did not
suggest obvious publication bias (Figure 8).
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Figure 8. Funnel plot of comparison: 1 Regular salmeterol in addition to regular inhaled corticosteroids,
outcome: 1.2 All-cause non-fatal SAE.
Restricting the results for asthma-related SAEs to trials with in-
dependent outcome assessment made very little difference to the
results in children (OR 1.28, 95% CI 0.73 to 2.27; participants =
6208; studies = 1) but decreased the precision of results in adults
(OR 1.03, 95% CI 0.64 to 1.67; participants = 11,679; studies =
1).
Methods of analysis
Risk difference
We have summarised the results of using pooled risk differences in
Table 4; data show very similar absolute treatment effects to those
calculated from the pooled Peto OR in Table 3 and Summary of
findings for the main comparison.
For all-cause mortality in adults and adolescents, the pooled RD
was -0.0002 (95% CI -0.0013 to 0.0009; Table 4; Figure 4). In
other words, for every 1000 adults treated with salmeterol and
ICS for 25 weeks, the results are compatible with one more or
one fewer death (in comparison with one death on regular ICS
alone). In children (with no reported deaths andOR that could not
be calculated), the pooled RD for all-cause mortality was 0.0000
(95% CI -0.0013 to 0.0013; Analysis 2.1; Table 4; Figure 4). In
other words, for every 1000 children treated with salmeterol and
ICS for 23 weeks, the 95% confidence interval of the pooled RD
is compatible with a possible increase or decrease of one death
(Summary of findings for the main comparison).
For adults and adolescents with a non-fatal SAE of any cause,
the pooled RD was 0.0027 (95% CI -0.0008 to 0.0062; Table
4; Figure 9). For children, the pooled RD was 0.0006 (95% CI -
0.0047 to 0.0058; Table 4; Figure 9).
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Figure 9. Forest plot of comparison: 2 Risk difference meta-analysis: regular salmeterol in addition to
regular ICS, outcome: 2.2 All-cause non-fatal SAE.
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When the upper end of the 95% confidence interval is translated
into the worst-case NNTH, this yields results very similar to those
obtained with the Peto OR and the pooled RD (Table 3; Table 4).
For adults, the worst-case NNTH is 152 from the Peto OR and
161 from the RD. Similarly in children, the worst-case NNTH is
139 from the Peto OR and 172 from the RD.
The absolute difference for asthma-related non-fatal SAEs in
adults was RD 0.0007 (95%CI -0.0012 to 0.0026). Similarly, the
absolute difference for children was RD 0.0014 (95% CI -0.0022
to 0.0049; Table 3; Figure 10). These results are very similar to
the absolute differences derived from the Peto OR in Summary of
findings for the main comparison.
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Figure 10. Forest plot of comparison: 2 Risk difference meta-analysis: regular salmeterol in addition to
regular ICS, outcome: 2.4 Asthma-related SAE.
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Mantel-Haenszel odds ratio
We analysed primary outcomes using Mantel-Haenszel fixed-ef-
fect and random-effects models. The result of the fixed-effect
model for mortality in adults was OR 0.80 (95%CI 0.40 to 1.63),
and for the random-effectsmodelOR0.81 (95%CI 0.38 to 1.72);
both were very similar to the Peto OR result of 0.80 (95% CI
0.36 to 1.78). The Mantel-Haenszel method uses a correction for
zero cells that is not required for the Peto OR. With this method,
the addition of 0.5 to all cells when the arms include similar ran-
domised numbers will generate an OR of 3 when only one event
occurs in the treatment group, and none in the control group.
When outcomes are very sparse (as for mortality), the calculated
OR is dependent on the size of the zero cell adjustment and on
whether treatment arms are balanced.
For non-fatal serious adverse events in adults, the Peto method
(Peto OR 1.14, 95% CI 0.97 to 1.33) yielded almost identical
results to the Mantel-Haenszel fixed-effect model (OR 1.13, 95%
CI 0.97 to 1.33) or the Mantel-Haenszel random-effects model
(OR 1.12, 95% CI 0.95 to 1.32).
Fatal and non-fatal serious adverse events combined
When fatal and non-fatal serious adverse events were combined,
the results for adults were almost identical to the pooled result for
non-fatal events in adults (Peto OR 1.12, 95% CI 0.96 to 1.31;
Analysis 1.3), and results were unchanged in children, as no deaths
occurred in children.
Dose of salmeterol
The dose of salmeterol used in seven studies was less than the
usual daily dose of 50 µg twice daily, so we carried out sensitiv-
ity analysis out on the primary outcomes while excluding these
studies (Mansfield 2017; Raphael 2017; SAS30021; SAS30022;
SAS30023; Sher 2017; Slankard 2016). Sher 2017 reported one
death, and without this event, the pooled odds ratio was Peto OR
0.72 (95% CI 0.32 to 1.65); among studies in children, no deaths
occurred, so mortality results were unaffected. Results for an SAE
of any cause without these studies in adults (Peto OR 1.11, 95%
CI 0.94 to 1.31; participants = 25,398) and in children (Peto OR
1.08, 95% CI 0.75 to 1.54; participants = 7845) are very similar
to the full data set.
Subgroup analyses
Mortality data were too sparse for any subgroup analysis to be
performed. For non-fatal SAEs of any cause, tests for interaction
between adults and children did not show a significant difference
between results according to age group (test for subgroup differ-
ences: Chi² = 0.20, df = 1 (P = 0.65); I² = 0%), nor was there a
difference in asthma-related events between adults and children
(test for subgroup differences: Chi² = 0.07, df = 1 (P = 0.79); I²
= 0%). Studies that included patients on separate salmeterol and
fluticasone inhalers were too few to permit a subgroup comparison
between separate and combined inhalers (Table 1).
D I S C U S S I O N
Summary of main results
The number of adults included in this review has doubled and the
number of children quadrupled with the addition of new studies
to the 2018 update of this review. As a consequence, estimates of
risk of non-fatal serious adverse events have become more precise.
The previous upper 95% confidence interval (CI) was Peto odds
ratio (OR) 1.44 for adults and 3.91 for children, and is now 1.33
and 1.48, respectively.
However, nodeaths in children andnodeaths in adultswere caused
by asthma, so we are not able to draw firm conclusions about the
risks of dying from asthma when regular salmeterol is added to
inhaled corticosteroid (ICS).
All-cause mortality in adults
Eleven of a total of 14,233 adults on regular salmeterol and ICS
died, as did 13 of 13,718 on regular ICS at the same dose. The
pooled Peto OR was 0.80 (95% CI 0.36 to 1.78; participants =
27,951; studies = 41; I² = 0%; moderate-certainty evidence). In
other words, for every 1000 adults treated for 25 weeks, one death
occurred on ICS alone, and the corresponding risk on salmeterol
and ICS was also one death (95% CI 0 to 2 deaths).
All-cause non-fatal serious adverse events
A total of 332 adults on regular salmeterol with ICS suffered a non-
fatal serious adverse event of any cause compared to 282 adults
on regular ICS. The pooled Peto OR was 1.14 (95% CI 0.97
to 1.33; participants = 27,951; studies = 41; I² = 0%; moderate-
certainty evidence). For every 1000 adults treated for 25 weeks,
21 adults on ICS alone experienced a serious adverse event, and
the corresponding risk on salmeterol and ICS was 23 adults (95%
CI 20 to 27).
Sixty-five of 4229 children on regular salmeterol with ICS expe-
rienced a serious adverse event of any cause compared to 62 of
4224 on regular ICS. The pooled Peto OR was 1.04 (95% CI
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0.73 to 1.48; participants = 8453; studies = 8; I² = 0%; moderate-
certainty evidence). For every 1000 children treated for 23 weeks,
15 children on ICS alone had a serious adverse event, and the cor-
responding risk on salmeterol and ICS was also 15 children (95%
CI 11 to 22).
Overall completeness and applicability of
evidence
Two large surveillance studies examined the use of regular sal-
meterol without randomised ICS (SMART 2006 SNS 1993).
As a result of the increase in serious adverse events reported in
these studies, the FDA mandated surveillance studies of regular
salmeterol in adults and children. These two large surveillance
studies - in adults (AUSTRI 2016 - previously ongoing study
NCT01475721) - and in children (VESTRI 2016 - previously
ongoing study NCT01462344) - assessed the safety of regular sal-
meterol in combination with an ICS; these studies have now been
published, and the results have been incorporated into this updated
review. The two large new studies were designed to test whether
salmeterol was safe when added to ICS; to do this, investigators
used a safety margin that was derived from the worst end of the
95% confidence interval of the comparative risk for a combined
endpoint in these trials (death, intubation, or hospital admission).
The FDA pre-defined safety margins for the composite outcomes
in these studies of a relative measure of 2.0 in adults and 2.675 in
children; confidence intervals of the pooled odds ratios from this
review for serious adverse events for adults and children (all-cause
and asthma-related) now fall within these margins.
Using the same approach - by transforming the worst-case 95%
confidence interval of the pooled odds ratio and the pooled risk
difference from all trials in this review - we determined the upper
limits of the confidence intervals for both odds ratios and risk
differences, andwe have presented them inTable 3 andTable 4.We
usedVisual Rx to convert these upper limits toworst-case numbers
needed to treat for an additional harmful effect (NNTH), for one
additional person to suffer an event from these upper limits listed
in Table 3 and Table 4.
Although the new FDA studies do not exceed their pre-defined
safety margins for non-fatal serious adverse events on salmeterol in
combination with ICS, the levels of adherence in AUSTRI 2016
(median 95.1%) and VESTRI 2016 (median 94%) were much
higher than is usual in day-to-day practice. These trials, as well as
many recent trials, also excluded participants with life-threatening
asthma. This may limit the applicability of findings from these
new studies and from this review.
Almost all studies used combination inhalers; therefore the results
of this review do not apply to the use of salmeterol and ICS in
separate inhalers.
Quality of the evidence
We assessed risk of bias in the included studies as low for all-
cause outcomes, as the procedures for randomisation and blinding
were appropriate, having been designed for regulatory purposes
(thereby ensuring common definitions of serious adverse events
and minimising the likelihood of selection bias, even though this
was not well reported in published papers or trial registers). Al-
though we judged most studies to be at high risk of detection bias,
we are not concerned about detection bias for asthma-related seri-
ous adverse events in children, because most events were reported
from the new study VESTRI 2016, which provided independent
assessment of causation. However we were more concerned about
detection bias affecting the treatment effect in adults because the
only studywith independent assessment of causationwas AUSTRI
2016, which yielded a wider confidence interval when data from
this study alone were considered.
We previously assessed our confidence in the evidence as moder-
ate due to statistical imprecision. This reflected the low rates of
mortality and non-fatal adverse events across studies included in
the review (Summary of findings for the main comparison).
Our confidence in the findings of this review remains moderate.
Included studies reported no deaths from asthma and a total of 24
deaths of any cause among adults. Even with additional data for
the 2018 update, the upper confidence intervals for all-cause non-
fatal serious adverse events remain at a possible NNTH of 152 for
adults and 139 for children over six months. We believe that this
risk boundary remains too high to grade the evidence with a high
level of certainty to show that adding salmeterol to regular ICS
was entirely safe.
Potential biases in the review process
Selection of the best method to combine studies with rare events
is contentious when event rates are low - not least because of the
corrections required to calculate ORs with zero events (Sweeting
2004). Because it became apparent in the course of carrying out
our reviews that the pooled ORs were heavily dependent on the
zero adjustment used in Mantel-Haenszel and inverse variance
methods, we used the Peto OR and RDs to report results of this
review. The likely bias in using the Peto OR is small, as only
three trials - Aubier 1999, Bateman 2001, and van Noord 2001
- showed any imbalance in the number of patients in each arm
(Sweeting 2004). In these studies, twice the number of patients
were randomised to regular salmeterol with ICS in comparison to
ICS alone.
Similarly, the included studies were influenced by the decision to
restrict the review to trials that randomised participants to salme-
terol and ICS, but this decision reduces the risk of bias arising
from patients discontinuing their usual inhaled steroid medica-
tion if they feel better on the randomised treatment. This pre-
supposes a similar risk of serious adverse events when salmeterol
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and fluticasone are delivered via one inhaler, and when salmeterol
is added to inhaled corticosteroid therapy via a separate inhaler,
when both are randomised treatments in a controlled trial.
Agreements and disagreements with other
studies or reviews
An overview of Cochrane Reviews on the safety of regular salme-
terol or formoterol in children (with and without combination
ICS) does not reveal any significant differences between the safety
of regular salmeterol and regular formoterol in children, but the
number of children studied remains small in comparison to the
number of adults (Cates 2012a Cates 2014). Moreover, no sepa-
rate safety results are currently available for adolescents who were
recruited in the adult and adolescent trials.
Two systematic reviews on the use of salmeterol with ICS have
shown results similar to the findings of this review. Bateman 2008
concentrated on asthma-related outcomes, and Jaeschke 2008a
considered both salmeterol and formoterol in adults in compari-
son to ICS at the same dose and at higher doses. Neither of these
reviews showed a significant increase in the risk of serious adverse
events, but results were not precise enough to rule out a clinically
important increase or decrease in serious adverse events with reg-
ular salmeterol.
Minor discrepancies between results recorded in serious adverse
event reports on the GlaxoSmithKline website and in the data
provided by Bateman 2008 and Jaeschke 2008a became apparent
during preparation of this review. An example of this is the death
in Aubier 1999, which is related to the question of whether the
adverse event was classified as being “on-treatment” (see Aubier
1999 notes in Characteristics of included studies). Overall the
magnitude of these differences is small, and this relates most often
to an external review of company data and inclusion of reviewed
data in some analyses; this has not altered the conclusions of this
review.
Administration of inhaled corticosteroid (ICS)
No clear difference can be seen between the point estimate and the
confidence interval of the OR for non-fatal serious adverse events
in adults (Peto OR 1.14, 95% CI 0.97 to 1.33) or children (Peto
OR 1.04, 95% CI 0.73 to 1.48) presented in this review, nor in
the Peto OR given in the review comparing salmeterol to placebo
(OR 1.14, 95% CI 1.01 to 1.28) (Cates 2008a). However the
average non-fatal serious adverse event rate in control arms of the
trials in this review that included randomised ICS in adults was
2.0% over 25 weeks compared to 3.6% over 28 weeks in SMART
2006 (which accounted for most patients in Cates 2008a).
This may reflect greater asthma severity among patients who had
been started by their own physician on background ICS (as shown
by Sears 2009 in the RELIEF study), but it could also be com-
pounded by known poor adherence to treatment with ICS in rou-
tine practice. This raises uncertainty about application of results
reported for patients in clinical trials, which usually include much
more intensive monitoring of adherence to therapy. For example,
the two new large trials added to this review in 2018 show very
high adherence rates; the median level of adherence in AUSTRI
2016 was 95.1%, and in VESTRI 2016 94%. Given that we can-
not assume that adherence to treatment in trials will be matched
in routine practice, care must be exercised in both interpretation
and application of trial results (Weiss 2008).
We were not able to investigate possible differences between com-
bined and separate inhalers in trial findings due to the paucity of
patients on separate inhalers included in the trials in this review
(fewer than 300 patients were randomised to separate fluticasone
and salmeterol inhalers; see Table 1).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Wehave now included two large safety trialsmandated by the FDA
and have provided data from 27,951 adults and 8453 children
with asthma. In spite of the large additional studies added for
this update, data show no asthma deaths in either age group, so
we remain uncertain about the safety of salmeterol and ICS with
respect to the risk of dying from asthma.
This additional information has increased the precision of the
estimates, such that the upper confidence interval for all-cause
non-fatal serious adverse events is the number needed to treat for
an additional harmful outcome (NNTH) of 152 for adults and
139 for children over six months for salmeterol in combination
with ICS for six months (compared to ICS alone).
Decisions regarding regular use of salmeterol in combination with
ICS must take into account the balance between known symp-
tomatic benefits of salmeterol when used in combination with an
inhaled corticosteroid and the remaining degree of uncertainty as-
sociated with potential harmful effects.
Implications for research
Following publication of the new surveillance studies, we suggest
that further randomised trials undertaken to test the safety of sal-
meterol in combination with inhaled corticosteroids would have
to include very large numbers of participants to change the con-
clusions of this review (particularly in relation to risks of asthma
mortality). The increased precision afforded by such large studies
may not be worth the substantial costs they would incur. How-
ever, there remains a sparsity of evidence from adolescents and
from people who have suffered a life-threatening asthma attack,
whichmerits further research through randomised trials, case-con-
trol studies, or reviews of asthma deaths.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Aubier 1999
Methods A randomised, double-blind, double-dummy, multi-centre, parallel-group study over
28 weeks from May 1996 to November 1997, at 55 centres in 3 countries (Germany,
France, and the Netherlands). Run-in 2 weeks and follow-up 2 weeks
Participants Population: 503 adolescents and adults (12 to 79 years) with asthma
Baseline characteristics: mean age 48 years; FEV 73% predicted
Concomitant ICS used by 100% of participants
Inclusion criteria: at least 12 years old with a documented clinical history of reversible
airways disease; received treatment with any inhaled corticosteroid continuously for 12
weeks before run-in; FEV % predicted between 50% and 100%. At the end of the
2-week run-in period, symptomatic (symptom score ≥ 2 on at least 4 of the last 7
consecutive days), with mean morning PEF > 50% and < 85% of the maximum PEF
15 minutes after administration of inhaled salbutamol 400 µg
Exclusion criteria: taking long-acting beta -agonists
Interventions • Fluticasone propionate and salmeterol 500/50 µg twice daily
• Fluticasone propionate 500 µg + salmeterol 50 µg twice daily (separate inhalers)
• Fluticasone propionate 500 µg twice daily
Delivery was by Diskus device
Outcomes Primary outcome: mean morning PEF during weeks 1 to 12
The paper reports: “The incidence of drug-related adverse events was similar for the
three treatments”
Full SAE data from Web report. One death from bronchial carcinoma on salmeterol
and fluticasone (separate inhalers). This death was not included in Jaeschke 2008b, as
the participant stopped taking study medication to allow for elective surgery and died
of surgical complications but was still included in the trial and had intended to restart
treatment postoperatively
Notes Sponsored by GSK
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind, double-dummy
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Aubier 1999 (Continued)
Independent Assessment of causation (de-
tection bias)
Asthma-related events
High risk Causation of SAEs not independently as-
sessed
Incomplete outcome data (attrition bias)
All outcomes
Low risk 403/503 (80%) completed the study
Selective reporting (reporting bias) Low risk Full data on GlaxoSmithKline website
AUSTRI 2016
Methods A randomised, double-blind,multi-centre, parallel-group study carried out over 26weeks
Participants Population: 11,679 adults and older children (> 12 years) with persistent asthma; all
participants had a history of severe asthma exacerbation in the past year but no events
in the past month
Baseline characteristics: mean age 43.4 years
Inclusion criteria: main further inclusion criteria were the following: peak expiratory
flow ≥ 50% of predicted normal value, use of daily medication for asthma control and
≥ 1 asthma exacerbation requiring treatment or hospitalisation within 12 months before
randomisation
Exclusion criteria: main exclusion criteria were the following: history of life-threaten-
ing asthma, concurrent respiratory disease, > 10-pack-year smoking history, respiratory
infection, unstable asthma status
Interventions • Fluticasone propionate and salmeterol (at a dose of 100 µg of fluticasone and 50 µg
of salmeterol, 250 µg and 50 µg, or 500 µg and 50 µg, respectively) twice daily
• Fluticasone propionate (at a dose of 100 µg, 250 µg, or 500 µg) twice daily
Outcomes Primary outcome: time until first serious asthma-related adverse outcome
Notes Sponsored by GSK
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisationwas performedwith the use
of an interactive voice-response systemwith
stratification
Allocation concealment (selection bias) Low risk Randomisationwas performedwith the use
of an interactive voice-response systemwith
stratification
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind with respect to salmeterol
but not dose of fluticasone
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AUSTRI 2016 (Continued)
Independent Assessment of causation (de-
tection bias)
Asthma-related events
Low risk Independent assessment of safety outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk For mortality, the status of all participants
who took at least 1 dose of treatment was
assessed after 6 months
Selective reporting (reporting bias) Low risk Data were extracted for all outcomes of the
review
Bailey 2008
Methods A randomised, double-blind, multi-centre, parallel-group study over 52 weeks from
November 2004 to April 2007, at 59 centres in the USA. Run-in 2 weeks on usual ICS,
and then 4 weeks on fluticasone 250 µg twice daily
Participants Population:475 adolescents and adults (12 to 65 years) of African descentwith persistent
asthma and symptomatic while taking low-dose ICS
Baseline characteristics: mean age 32 years; FEV 85% predicted
Concomitant ICS used by 100% of participants
Inclusion criteria: 12 years of age or older with documented clinical history of persistent
asthma for at least 6 months; had been symptomatic when using ICS (fluticasone propi-
onate 200 µg daily or equivalent) for at least 4 weeks before entering the run-in period;
FEV % predicted between 60% and 90%, with at least 12% reversibility following 2
to 4 puffs of albuterol
Exclusion criteria: participants were included in the 52-week study period only if when
on the 2-week run-in taking low-dose ICS twice daily, they showed FEV ≥ 60%
predicted, and in the last 7 days of run-in, they had ≥ 4 days of albuterol use or were
symptomatic; theywere excluded if they had an exacerbation in the 4weeks on fluticasone
250 µg twice daily
Interventions • Fluticasone propionate and salmeterol 100/50 µg Diskus twice daily
• Fluticasone propionate 100 µg Diskus twice daily alone
Outcomes Primary outcome: rate of asthma exacerbation
Notes Sponsored by GSK
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
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Bailey 2008 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Double-blind treatment period”
Independent Assessment of causation (de-
tection bias)
Asthma-related events
High risk Causation of SAEs not independently as-
sessed
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 70/239 lost to follow-up on combined
treatment, and 85/236 on fluticasone alone
Selective reporting (reporting bias) Low risk Full data on GlaxoSmithKline website (
SFA103153)
Bateman 2001
Methods A randomised, double-blind, double-dummy, multi-centre, parallel-group study over 12
weeks from March 1998 to June 1999, at 69 centres in 10 countries. Run-in 2 weeks
and 2 weeks’ follow-up
Participants Population:497 adolescents and adults (12 to 79 years)with documented clinical history
of reversible airways obstruction
Baseline characteristics: mean age 40 years; FEV 76% predicted
Concomitant ICS used by 100% of participants
Inclusion criteria: 12 years or older with documented clinical history of reversible
airway obstruction, smoking history < 10 pack-years, and using ICS (beclomethasone
dipropionate, budesonide, or flunisolide 400 to 500 µg/d or fluticasone propionate 200
to 250 µg/d) for ≥ 4 weeks before entering the run-in period; FEV % predicted ≥
50%. Mean PEF over last 7 days of run-in period between 50% and 85% measured after
inhalation of salbutamol (400 mg); symptomatic (i.e. cumulative total symptom score
(daytime plus night-time) > 8 for last 7 days of the run-in period; and taking salbutamol
up to 800 µg/d
Exclusion criteria: received a long-acting beta -agonist or an oral beta -agonist within
2 weeks of the run-in period, changed asthma medication, had a lower respiratory tract
infection within 4 weeks of the run-in period, or had an acute asthma exacerbation
requiring hospitalisation within 12 weeks of study entry. Other exclusion criteria were
prior treatment with oral, depot, or parenteral corticosteroids or combination therapy
(containing a beta -agonist and/or ICS)
Interventions • Fluticasone propionate and salmeterol 100/50 µg HFA MDI
• Fluticasone propionate and salmeterol 100/50 µg Diskus
• Fluticasone propionate 100 µg CFC MDI
Outcomes Primary efficacy variable: mean morning PEF over the 12-week treatment period
A serious adverse event was described as any event that was fatal, life-threatening, dis-
abling, or incapacitating, or that required or prolonged hospitalisation
Paper reports: “During treatment, serious adverse events were reported by three patients
(2%) in each group. These included asthma exacerbations (n.5), breast neoplasia (n.1)
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and events associated with the gastrointestinal system (n.2) and ear, nose and throat (n.
1). The only serious adverse events considered by the investigator to be drug-related were
asthma exacerbations in two patients (one each in the fluticasone propionate/salmeterol
MDI and Diskus groups)”
SFCB3022 reports 5 participants with asthma SAE in fluticasone propionate/salmeterol
groups (333 participants) and none in the fluticasone propionate alone group (165
participants)
Bateman reports 4 asthma hospitalisations in fluticasone propionate/salmeterol groups
Notes Sponsored by GSK
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind, double-dummy
Independent Assessment of causation (de-
tection bias)
Asthma-related events
High risk Causation of SAEs not independently as-
sessed
Incomplete outcome data (attrition bias)
All outcomes
Low risk 430/497 (87%) completed the study
Selective reporting (reporting bias) Low risk Full data on GlaxoSmithKline website
Bernstein 2017
Methods A randomised, double-blind, double-dummy, parallel-group, 24-week study
Participants Population: intent-to-treat population included 1504 adults and adolescents (aged > 12
years) with an asthma diagnosis for at least 12 weeks who were well controlled on ICS/
LABA
Baseline characteristics: 82% of participants were white; 64% female; mean age 43.5
years. At randomisation, participants had a mean per cent predicted FEV of 90.24%
Inclusion criteria: required to have FEV ≥ 80% of predicted normal value, and to have
received treatment with ICS/LABA (equivalent to fluticasone propionate and salmeterol
250/50 twice daily), either as a fixed-dose combination or through separate inhalers, for
at least 12 weeks. Patients had to be able to replace their current SABA with albuterol/
salbutamol
Exclusion criteria: history of life-threatening asthma in previous 5 years; evidence of
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concurrent respiratory disease or other clinically significant medical condition; ongoing
respiratory infection within previous 4 weeks; use of tobacco products within previous
3 months or historical use ≥ 10 pack-years; severe milk protein allergy or specific drug
allergy; asthma exacerbation that required oral corticosteroids within previous 12 weeks,
or that resulted in overnight hospitalisation requiring additional asthma treatmentwithin
previous 6 months
Interventions • Fluticasone furoate and vilanterol 100/25 µg once daily (this arm of the study was not
used in the review)
• Fluticasone propionate and salmeterol 250/50 µg twice daily
• Fluticasone propionate 250 µg twice daily
Outcomes Primary outcome: change frombaseline in evening troughFEV ; safetywas also assessed
Notes Sponsored by GSK
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Eligible patients were randomised 1:1:1 via
an interactive voice response system to re-
ceive 1 of 3 blinded study treatments
Allocation concealment (selection bias) Unclear risk Methods used for allocation concealment
were not clearly reported
Blinding (performance bias and detection
bias)
All outcomes
Low risk Study authors reported that it was carried
out in a double-blinddouble-dummyman-
ner, and described how this was achieved.
Therefore it is unlikely that blinding was
broken
Independent Assessment of causation (de-
tection bias)
Asthma-related events
High risk No report of independent assessment of
SAEs carried out
Incomplete outcome data (attrition bias)
All outcomes
Low risk Reasons for attrition were given by study
authors. Moreover the proportion of with-
drawals, in both arms of the study, is rela-
tively small: more than 80% of participants
completed the study
Selective reporting (reporting bias) Low risk Data were extracted for all outcomes of the
review
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Methods A randomised, double-blind, multi-centre, stratified, parallel-group study over 12
months from December 2000 to December 2002, at 326 centres in Europe, North
America, Latin America, and Asia Pacific. Run-in 4 weeks
Participants Population: 3416 adolescents and adults (9 to 83 years) with uncontrolled asthma
Baseline characteristics: mean age 40 years; FEV 77% predicted; concomitant ICS
not previously used in stratum 1, low dose in stratum 2, and medium to high dose in
stratum 3 at baseline
Inclusion criteria: 12 years old or older but younger than 80 years, with at least a 6-
month history of asthma, bronchodilator reversibility by an increase of at least 15% in
FEV over baseline (and 200 mL) based on FEV measured pre- and post-inhalation
of any short-acting beta -agonist within last 6 months or to demonstrate reversibility
at visit 1, at visit 2, or between visit 1 and visit 2 using 200 to 400 µg of salbutamol/
albuterol
Eligible for stratum 1 of the study if had not received ICS for at least 6 months before
visit 1; for stratum 2, if receiving ≤ 500 µg BDP or equivalent daily; for stratum 3, if
receiving > 500 and ≤ 1000 µg BDP or equivalent daily
During 2 or more of the 4 weeks before visit 2, participants should have failed to achieve
the criteria for ’well-controlled’ asthma
Exclusion criteria: assessed as having well-controlled asthma on more than 3 of the
4 weeks during run-in; change in regular asthma medication; emergency visits due to
asthma; treatment with systemic corticosteroids; respiratory tract infection; more than
3 days of morning PEF < 50% predicted; non-compliance with diary record card
Interventions • Fluticasone propionate and salmeterol 100/50, 250/50, or 500/50 µg twice daily (by
strata)
• Fluticasone propionate 100, 250, or 500 µg twice daily (by strata)
Delivery was Diskus device
Outcomes Primary efficacy variable: proportion of participants who achieved ’well-controlled’
asthma with the fluticasone propionate/salmeterol combination compared with flutica-
sone propionate alone during phase 1 of the study
Paper states: “Serious adverse events were observed during the double-blind period in
4% and 3% of patients in the salmeterol/fluticasone and fluticasone arms, respectively”
Web report gives the numbers of participants (67 and 53, respectively)
Website reports 2 deaths on fluticasone propionate (both myocardial infarction) and 3
deaths on fluticasone propionate/salmeterol (2 myocardial infarction and 1 pneumonia)
. No asthma-related deaths were reported
Notes Sponsored by GSK
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was done telephonically
from a computer-generated allocation
schedule balanced per stratum and per
country
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Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind
Independent Assessment of causation (de-
tection bias)
Asthma-related events
High risk Causation of SAEs not independently as-
sessed
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2890/3416 (85%) completed the study
Selective reporting (reporting bias) Low risk Full data on GlaxoSmithKline website
Godard 2008
Methods A randomised, double-blind, 24-week, multi-centre study at 124 centres in France; 8-
week open run-in on SFC (50/250 µg twice daily)
Participants Population: 308 adults (18+ years) with asthma controlled on ICS (1000 µg CFC
beclomethasone equivalent daily) and LABA
Baseline characteristics: mean age 44 years; FEV 90% predicted
Concomitant ICS used by 100% of participants
Inclusion criteria: currently receiving ICS at a dose of 1000 µg daily of inhaled BDP
or equivalent and LABA. Asthma controlled on a stable dose for at least 4 weeks were
entered into run-in, and then entered into the full study if asthma was well controlled (as
defined in GOAL) in last 2 weeks of 8-week run-in on fluticasone propionate/salmeterol
Exclusion criteria: excluded from entry into the run-in period if smoking history of
≥ 10 pack-years, respiratory tract infection during last 4 weeks before initial clinic visit
(V1), acute asthma exacerbation requiring emergency room treatment or hospitalisation
within 4weeks before V1, use of oral/parenteral corticosteroids during last 4 weeks before
V1 (12 weeks for depot corticosteroids), any change in asthma maintenance treatment
in previous 4 weeks
Interventions • Fluticasone propionate and salmeterol 250/50 µg twice daily
• Fluticasone 250 µg twice daily
• Fluticasone propionate/salmeterol 100/50 µg twice daily (not analysed in this review)
Delivery device Diskus
Outcomes Primary efficacy endpoint: variation in mean morning PEF over first 12 weeks of the
treatment period compared to last 2 weeks of the run-in period (baseline)
Notes Sponsored by GSK
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Double-blind randomised 24-week
study”
Independent Assessment of causation (de-
tection bias)
Asthma-related events
High risk Causation of SAEs not independently as-
sessed
Incomplete outcome data (attrition bias)
All outcomes
High risk Uneven withdrawals (18/159 on fluticas-
one propionate/salmeterol and 30/159 on
fluticasone)
Selective reporting (reporting bias) Low risk Full SAE data reported in paper
Ind 2003
Methods A randomised, double-blind, double-dummy, multi-centre, parallel-group study over
28 weeks from January 1995 to December 1996, at 99 centres in Canada, Denmark,
Iceland, Ireland, Italy, and the United Kingdom. Run-in 4 weeks
Participants Population: 502 adolescents and adults (16 to 75 years) with asthma poorly controlled
on current ICS
Baseline characteristics: mean age 45 years; FEV 2.3 L
Concomitant ICS used by 100% of participants
Inclusion criteria: currently receiving ICS at a dose of 1000 to 1600 µg daily of inhaled
BDP or equivalent; asthma poorly controlled (demonstrated by PEF < 85% of maximal
achievable PEF after inhaling 400 µg salbutamol) and had experienced at least 2 exac-
erbations of asthma in the last year that required a change in asthma therapy. Therefore,
over the last 10 days of the baseline period, had to demonstrate an average morning PEF
< 90% of maximal achievable PEF measured at screening and diurnal variation in PEF
≥ 15%; had to have asthma symptoms on≥ 4 of the last 7 days or nights of the baseline
period
Exclusion criteria: receiving continuous OCS; having any serious uncontrolled systemic
disease or participation deemed unsuitable by the physician; had to demonstrate a period
variation in PEF≥ 15% (highest evening value - lowest morning value as a percentage of
highest PEF) over last 10 days and/or nights of the run-in period and to have suboptimal
PEF, with average PEF over last 10 days of the run-in not exceeding 90% of post-
bronchodilator PEF (measured at visit 1)
Interventions • Fluticasone propionate 250 µg + salmeterol 50 µg twice daily (in separate inhalers)
• Fluticasone propionate 250 µg twice daily
• Fluticasone propionate 500 µg twice daily
Delivery was MDI (fluticasone propionate 500 arm not used in this review)
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Outcomes Primary efficacy variables:mean morning PEF; incidence and severity of asthma exac-
erbations
No SAE information found in paper publication. Full SAE data on web report. One
fatal pneumothorax on salmeterol and fluticasone (separate inhalers)
Notes Sponsored by GSK
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind, double-dummy
Independent Assessment of causation (de-
tection bias)
Asthma-related events
High risk Causation of SAEs not independently as-
sessed
Incomplete outcome data (attrition bias)
All outcomes
Low risk 432/502 (86% completed study)
Selective reporting (reporting bias) Low risk Full data on GlaxoSmithKline website
Katial 2011
Methods A52-week, randomised, double-blind, parallel-group study of fluticasone propionate/sal-
meterol combination product 250/50 µg twice daily and fluticasone propionate Diskus
250 twice daily in treatment of participants with asthma, at 61 centres in North and
South America, Canada, and the Philippines, from May 2007 to May 2009
Participants Population: 621 adults and adolescents (12+ years) with asthma that was not controlled
on ICS at low dose (with or without LABA), or at medium dose without LABA; clinical
diagnosis of asthma, defined by the ATS, for ≥ 6 months before screening
Baseline characteristics: mean age 38 years; FEV 74% predicted
Concomitant ICS used by 100% of participants
Inclusion criteria: participants were required to have treatment with a low to medium
dose of ICS or combination ICS/LABA controller medications if the ICS was given at a
low dose for ≥ 4 weeks before screening; must have reported being symptomatic while
taking controller medication in the 4 weeks before screening
Exclusion criteria: life-threatening asthma in the 12 months before screening; seasonal
or exercise-induced asthma without other manifestations of persistent asthma; concur-
rent respiratory disease or any other significant concurrent condition/disease; patients
57Inhaled steroids with and without regular salmeterol for asthma: serious adverse events (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Katial 2011 (Continued)
were excluded if they had worsening asthma in the 4 weeks before screening, including
an emergency room visit, hospitalisation, or use of oral/ parenteral corticosteroid. Con-
current use of medications that could have affected the course of asthma or interacted
with study medication was prohibited
Interventions • Fluticasone propionate and salmeterol 250/50 µg twice daily
• Fluticasone 250 µg twice daily
Delivery device Diskus
Outcomes Primary outcome: FEV over a 52-treatment week period. SAE data fully reported in
the published paper and in the GlaxoSmithKline Web report (ADA109055)
Notes Sponsored by GSK. ClinicalTrials.gov identifier NCT00452699 (identical design to
Kerwin 2011)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Double-blind”
Independent Assessment of causation (de-
tection bias)
Asthma-related events
High risk Causation of SAEs not independently as-
sessed
Incomplete outcome data (attrition bias)
All outcomes
High risk 81/306 on fluticasone propionate/salme-
terol and 73/315 on fluticasone propionate
withdrew. Of these, 14 and 4, respectively,
withdrew due to adverse events or lack of
efficacy
Selective reporting (reporting bias) Low risk SAE data fully reported
Kavuru 2000
Methods A randomised, double-blind, double-dummy, parallel-group, placebo-controlled study
over 12 weeks at 42 centres in the USA. Run-in 2 weeks single-blind placebo
Participants Population: 356 adolescents and adults (12 to 70 years) with asthma
Baseline characteristics: mean age 37 years; FEV 64% predicted
Concomitant ICS used by 100% of participants in group 1 and 0% of participants in
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group 2
Inclusion criteria: at least 12 years old with medical history of asthma (as defined by
the ATS) of at least 6 months’ duration; FEV % predicted between 40% and 85%;
bronchodilator reversibility by an increase ≥ 15% in FEV over baseline 30 minutes
after 2 puffs (180 µg) of inhaled albuterol
Stratified into 2 groups according to type of asthma therapy used at enrolment
Exclusion criteria: history of life-threatening asthma; hypersensitivity reaction to sym-
pathomimetic drugs or corticosteroids; smoking within the previous year or a history of
> 10 pack-years; use of oral, inhaled, or injectable corticosteroid therapy within previ-
ous month; use of intranasal corticosteroid therapy except for Flonase (GlaxoWellcome
Inc.); use of daily oral corticosteroid treatment within previous 6 months; use of any
other prescription or over-the-counter medication that could have affected the course of
asthma or interacted with sympathomimetic amines; abnormal chest x-ray films; clini-
cally significant abnormal 12-lead electrocardiograms (ECGs); or a history of significant
concurrent disease (e.g. glaucoma, diabetes, hypertension)
Interventions • Fluticasone propionate and salmeterol 100/50 µg twice daily
• Fluticasone 100 µg twice daily
Delivery was Diskus inhaler
Outcomes Mean morning pre-dose FEV at endpoint; area under 12-hour serial FEV curve
relative to baseline after I week of treatment (mean FEV AUC); probability of remaining
in the study over time without withdrawal due to lack of efficacy
Paper reports no serious drug-related adverse events and reports 2 serious adverse events
that led to withdrawal. Website records 2 events on fluticasone propionate/salmeterol
and 1 event on fluticasone propionate. (Unclear whether the 2 fluticasone propionate/
salmeterol events occurred in separate participants, so treated as 1 participant)
Notes Sponsored by GSK
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind, double-dummy
Independent Assessment of causation (de-
tection bias)
Asthma-related events
High risk Causation of SAEs not independently as-
sessed
Incomplete outcome data (attrition bias)
All outcomes
Low risk 142/182 (78%) completed the study
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Selective reporting (reporting bias) Low risk Data available on GlaxoSmithKline web-
site
Kerwin 2011
Methods A 52-week, randomised, double-blind, parallel-group study of fluticasone propionate/
salmeterol combination product (fluticasone propionate/salmeterol) 250/50 µg twice
daily and fluticasone propionate Diskus 250 twice daily in treatment of people with
asthma, at 76 centres in North and South America, Canada, and the Philippines, from
May 2007 to April 2009
Participants Population: 628 adults and adolescents (12+ years) with asthma that was not controlled
on ICS at low dose (with or without LABA), or at medium dose without LABA; clinical
diagnosis of asthma, defined by the ATS, for ≥ 6 months before screening
Baseline characteristics: mean age 40 years; FEV 74% predicted
Concomitant ICS used by 100% of participants
Inclusion criteria: required to have received treatment with a low to medium dose
of ICS or combination inhaled corticosteroid/long-acting beta -agonist (ICS/LABA)
controller medications, if ICS was at a low dose, for ≥ 4 weeks before screening; must
have reported being symptomatic while taking fluticasone propionate/salmeterol Diskus
100 µg twice daily in the 4 weeks before screening
Exclusion criteria: life-threatening asthma in the 12 months before screening; seasonal
or exercise-induced asthma without other manifestations of persistent asthma, concur-
rent respiratory disease, or any other significant concurrent condition/disease; patients
were excluded if they had worsening asthma in the 4 weeks before screening including
an emergency room visit, hospitalisation, or use of oral/ parenteral corticosteroid. Con-
current use of medications that could have affected the course of asthma or interacted
with study medication was prohibited
Interventions • Fluticasone propionate and salmeterol 250/50 µg twice daily
• Fluticasone 250 µg twice daily
Delivery device Diskus
Outcomes Primary outcome: FEV over a 52-treatment-week period; SAE data fully reported in
the published paper and in the GlaxoSmithKline Web report (ADA109057)
Notes Sponsored by GSK. ClinicalTrials.gov identifier NCT00452348 (identical in design to
Katial 2011)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
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Blinding (performance bias and detection
bias)
All outcomes
Low risk “Double-blind therapy”
Independent Assessment of causation (de-
tection bias)
Asthma-related events
High risk Causation of SAEs not independently as-
sessed
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 79/310 on fluticasone propionate/salme-
terol and 84/318 on fluticasone withdrew,
but withdrawals were balanced for adverse
events and lack of efficacy
Selective reporting (reporting bias) Low risk Full SAE data reported in paper and in the
GlaxoSmithKline Web report
Koenig 2008
Methods A randomised, double-blind, multi-centre, parallel-group study over 40 weeks from
February 2003 to October 2004, at 55 sites (50 in the USA, 3 in Latin America, 2 in
Latvia). Run-in 2 weeks
Participants Population: 466 adolescents and adults (12 to 81 years) with asthma
Baseline characteristics: mean age 34 years; FEV 78% predicted
Concomitant ICS used by 100% of participants
Inclusion criteria: 12 years of age or older, with a diagnosis of asthma, as defined by
the ATS, for ≥ 3 months before visit 1; must have been treated with a short-acting beta
-agonist, an anticholinergic, or an allowed ICS at a fixed dosing regimen (within an
allowed total daily dose) for at least 4 weeks before screening visit; FEV % predicted
between 60% and 95%; bronchodilator reversibility by an increase of ≥ 12% in FEV
over baseline within 30 minutes of inhalation of 2 puffs of inhaled albuterol (180 µg)
Exclusion criteria: pregnancy, life-threatening asthma, hospitalisation attributable to
asthma within the last 6 months, current smoker or > 10-pack-year history of smok-
ing, recent (within 2 weeks) upper or lower respiratory tract infection or significant
concurrent disease. Medications that could confound evaluation of study treatments or
treatment strategies were prohibited before and throughout the study, including inhaled
(up to 250 µg fluticasone propionate allowed before randomisation), oral, or parenteral
corticosteroids (with the exception of protocol-defined use of oral corticosteroids fol-
lowing second consecutive assignment to highest dose of fluticasone propionate/salme-
terol), theophylline or other bronchodilators, leukotriene modifiers, anticholinergics,
cromolyn, and nedocromil
Interventions • Fluticasone propionate and salmeterol 100/50, 250/50, or 500/50µg twice daily (BHR
strategy)
• Fluticasone propionate 100, 250, or 500 µg (BHR strategy)
• Fluticasone propionate 100, 250, or 500 µg (reference strategy) - data from this arm
not used
Delivery was Diskus device
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Outcomes Primary efficacy variable: average inhaled corticosteroid treatment dose over the treat-
ment period
Paper reports: “There were no non-fatal serious adverse events in any treatment group
that were considered to be drug related. One patient in the fluticasone propionateBHR
treatment group died due to convulsions and cardiac arrest following deep vein throm-
bosis”
Web report indicates 1 participant with SAE related to asthma on fluticasone propionate/
salmeterolBHR and 1 with ear infection and sinusitis on fluticasone propionateBHR
Notes Sponsored by GSK
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind
Independent Assessment of causation (de-
tection bias)
Asthma-related events
High risk Causation of SAEs not independently as-
sessed
Incomplete outcome data (attrition bias)
All outcomes
Low risk 321/466 (69%) completed the study
Selective reporting (reporting bias) Low risk Full data on GlaxoSmithKline website
Koopmans 2006
Methods A randomised, double-blind, single-centre, parallel-group study over 12 months from
September 2000 to December 2003, in the Netherlands. Run-in 4 weeks
Study conducted to compare long-term effects on airway inflammation of seretide vs
flixotide in adult patients with asthma
Participants Population: 54 adults (19 to 59 years) with mild to moderate persistent allergic asthma
Baseline characteristics: mean age 32 years; FEV 89% predicted
Concomitant ICS used by 100% of participants (median dose 600 µg/d)
Inclusion criteria: between 18 and 50 years of age with reversible airways obstruction,
informed consent, allergic to house dust mite, PC20 histamine < 8 mg/mL, FEV >
70% predicted
Exclusion criteria: serious concurrent disease likely to interfere with the study, lower
respiratory tract infection, use of antibiotics in the previous 4 weeks
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Interventions • Fluticasone propionate and salmeterol 250/50 µg twice daily
• Fluticasone propionate 250 µg twice daily
Delivery was Diskus device
Outcomes Primary efficacy variables: percentage of eosinophils and eosinophil cationic protein
(ECP) in induced sputum (baseline and after allergen challenge) at randomisation and
1, 3 6, 9, and 11 months later
Notes Sponsored by GSK
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind
Independent Assessment of causation (de-
tection bias)
Asthma-related events
High risk Causation of SAEs not independently as-
sessed
Incomplete outcome data (attrition bias)
All outcomes
Low risk 50/54 (93%) completed the study
Selective reporting (reporting bias) Low risk Data available on GSK website
Li 2010
Methods A randomised, double-blind, double-dummy, 12-week, parallel-group study evaluating
the safety of fluticasone propionate/salmeterol 100/50 µg HFA (2 inhalations of 50/
25 µg) twice daily compared with fluticasone propionate 100 µg HFA (2 inhalations
of 50 µg) twice daily in patients 4 to 11 years of age with persistent asthma. Ran from
February 2007 to February 2008, at 25 centres in North America, 13 centres in Latin
America, and 18 centres in Europe
Participants Population: 350 children (age 4 to 11 years) with persistent asthma who were symp-
tomatic on an ICS
Baseline characteristics: 22% were aged 4 to 5 years, and 78% 6 to 11 years. Spacers
were used by 78% of children at baseline
Inclusion criteria: male and female patients 4 to 11 years of age with a diagnosis of
asthma requiring ICS for control of asthma symptoms for at least 1 month before
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screening. Patients 6 to 11 years of age were required to have FEV ≥ 60% of predicted
value, and those 4 and 5 years of age were required to have a clinic AM PEF ≥ 60%
of predicted value at the screening visit. Patients also had to demonstrate reversibility ≥
12% to albuterol over baseline or to have historical documentation of≥ 12% reversibility
within 24 months before the screening visit
Exclusion criteria: life-threatening asthma or hospitalisation for asthma twice or more
often in the past year
Interventions • Fluticasone propionate and salmeterol 100/50 µg HFA (administered as 2 inhalations
of 50/25 µg ex-valve strength via HFA MDI) twice daily
• Fluticasone propionate 100 µg HFA ex-valve strength, HFA (administered as 2 inhala-
tions ex-valve strength of 50 µg via HFA MDI) twice daily
Delivery was via MDI (with spacer if inhalation technique was not well co-ordinated)
Outcomes Adverse events and serious adverse events on treatment. No fatal events occurred, and 1
participant on fluticasone propionate/salmeterol had a head injury after a fall (reported
on the GSK website 25 September 2008, study ID SFA106484, but not found in the
paper publication)
Notes Sponsored by GSK
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Double-blind, double-dummy”
Independent Assessment of causation (de-
tection bias)
Asthma-related events
High risk Causation of SAEs not independently as-
sessed
Incomplete outcome data (attrition bias)
All outcomes
Low risk 93% completed
Selective reporting (reporting bias) Low risk Data on GSK website
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Lundback 2006
Methods A randomised, double-blind, parallel-group study over 12 months from August 1997 to
December 2002, in Sweden. Run-in 2 months
An interventional 3-year study for asthma control - In what way and in what kind of
population is it possible to get asthmatic patients free from symptoms, keep patients at
work, restore normal lung function, diminish hyperreactivity, and normalise quality of
life?
Participants Population: 282 adults (18 to 70 years) with mild to moderate persistent asthma
Baseline characteristics: mean age 40 years; FEV 93% predicted
Concomitant ICS used by 68% of participants
Inclusion criteria: clinically representative mild to moderate asthma, symptoms, or use
of rescuemedication at least twice a week; required to have airway hyperreactivity (AHR)
demonstrated by methacholine challenge with a PC20 (the concentration required to
provoke a 20% reduction in FEV ) < 8 mg/mL. If AHR was not demonstrated via
methacholine challenge, then one of the following: diurnal variability in PEF≥ 20% on
more than 3 days during the last 14 days of the run-in; at least 30% difference between
highest and lowest PEF readings during any 7 days in the run-in period; increase≥ 15%
in FEV or PEF after salbutamol inhalation (0.8 mg)
Exclusion criteria: taking daily doses of ICS > 1200 µg, had experienced ≥ 1 life-
threatening exacerbation requiring hospitalisation during previous 12 months, were hy-
persensitive to beta-agonists or ICS, were pregnant or lactating, had a respiratory tract
infection during the 4 weeks before run-in
Interventions • Fluticasone propionate and salmeterol 250/50 µg twice daily
• Fluticasone propionate 250 µg twice daily
• Salmeterol 50 µg twice daily
Delivery was Diskus device (arm 3 was not used in this review)
Outcomes Primary efficacy variable: requirement for an increased dose of study medication
Notes Sponsored by GSK
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind
Independent Assessment of causation (de-
tection bias)
Asthma-related events
High risk Causation of SAEs not independently as-
sessed
65Inhaled steroids with and without regular salmeterol for asthma: serious adverse events (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Lundback 2006 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 263/282 (93%) completed the study
Selective reporting (reporting bias) Low risk Data on GSK website
Malone 2005
Methods A randomised, double-blind, active-controlled, multi-centre, parallel-group study over
12 weeks from April 2002 to January 2003, at 79 centres (66 in the USA and 13 in
Canada). Run-in 2 weeks
Participants Population: 203 children (4 to 11 years) with persistent asthma
Baseline characteristics: mean age 8 years; FEV mean 80% predicted (6 to 11 years);
PEF mean 87% predicted (4 to 5 years)
Concomitant ICS used by 100% of participants
Inclusion criteria: 4 to 11 years of age with diagnosis of asthma (ATS definition), who
required physician-prescribed treatment for at least 2 months and were taking an inhaled
corticosteroid for asthma for at least 1 month before visit 1; FEV % predicted between
50% and 95% (6 to 11 years), AM PEF % predicted between 50% and 95% (4 to 5
years). Bronchodilator reversibility by an increase ≥ 12% in FEV (6 to 11 years) or
AM PEF (4 to 5 years) over baseline within 30 minutes of 2 to 4 actuations of albuterol
(180 to 360 µg), or with historical documentation of ≥ 12% reversibility within the
previous year
Exclusion criteria: history of life-threatening asthma; hospitalisation due to asthma
twice or more often in the previous year; significant concurrent disease (e.g. cystic fi-
brosis, malignancy, immunological compromise); recent upper or lower respiratory tract
infection; current chickenpox or recent exposure to chickenpox in a non-immune pa-
tient; severe milk protein allergy; hypersensitivity to beta -agonist, sympathomimetic,
or corticosteroid therapy; clinically significant abnormal laboratory test results
Interventions • Fluticasone propionate and salmeterol 100/50 µg twice daily
• Fluticasone propionate 100 µg twice daily
Delivery was Diskus device.
Outcomes This was a safety study, and no primary efficacy endpoint was identified
No SAEs occurred in this study
Notes Sponsored by GSK
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
66Inhaled steroids with and without regular salmeterol for asthma: serious adverse events (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Malone 2005 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind
Independent Assessment of causation (de-
tection bias)
Asthma-related events
High risk Causation of SAEs not independently as-
sessed
Incomplete outcome data (attrition bias)
All outcomes
Low risk 168/203 (83%) completed the study
Selective reporting (reporting bias) Low risk Full data on GSK website
Mansfield 2017
Methods A 26-week, open-label, randomised, active drug-controlled trial with a 14-day run-in
period
Participants Population: 758 participants with persistent asthma were enrolled
Baseline characteristics: mean age ranged from 38.4 to 46.1 years; mean baseline FEV
ranged from 2.31 to 2.70 L
Inclusion criteria: those with FEV > 40% of relevant predicted value, those already on
an established treatment regimen of SABA for use as needed and either a mid- or high-
dose ICS or ICS/LABA combination as preventive therapy for over 8 weeks, those with
demonstrated reversibility of FEV > 12% within 30 minutes after short-acting beta-
agonist administration
Exclusion criteria: treatment with low-dose ICS without LABA, history of life-threat-
ening asthma exacerbation, asthma exacerbation within 30 days of screening, hospital-
isation for asthma 2 months before screening, use of immunosuppressive medications
4 weeks before screening, documented or suspected bacterial or viral infection within
2 weeks of screening, any illness that in the judgement of investigators would put the
patient at risk during the study, current smokers and those with a 10-pack-year smoking
history, patients who used tobacco products within the past year
Interventions • Fluticasone propionate and salmeterol given as a multi-dose dry powder inhaler at
doses of 100 µg/12.5 µg or 200 µg/12.5 µg twice daily, or via a dry powder inhaler at
doses of 250 µg/50 µg or 500 µg/50 µg twice daily
• Fluticasone propionate given as a multi-dose dry powder inhaler at doses of 100 µg
or 200 µg twice daily, or in a hydrofluoroalkane inhaler at doses of 220 µg or 440 µg
twice daily
Outcomes Primary outcome: change from baseline in morning trough FEV over the 26-week
treatment period
Notes Sponsored by Teva Pharmaceuticals
Risk of bias
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Mansfield 2017 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Methods used for sequence generationwere
not clearly reported - only that participants
were randomised
Allocation concealment (selection bias) Unclear risk Methods used for allocation concealment
were not clearly reported
Blinding (performance bias and detection
bias)
All outcomes
High risk This was an open-label study
Independent Assessment of causation (de-
tection bias)
Asthma-related events
High risk No report of independent assessment of
SAEs
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition was below 80%, and all partici-
pants randomised were available for the sa-
fety study, even if they did not complete
the full study
Selective reporting (reporting bias) Low risk Data were extracted for all outcomes of the
review
MASCOT 2013
Methods A prospective, controlled, double-blind, multi-centre, randomised clinical trial lasting
48 weeks, with a 4-week open run-in
Participants Population: 63 children aged 6 to 14 years with asthma uncontrolled on low-dose ICSs
were randomised
Baseline characteristics: average age of children included was 10.39 years; 63.5% were
male
Inclusion criteria: childrenwho required frequent short-acting beta -agonist relief ther-
apy:≥ 7puffs in the past 7 days; childrenwith symptomsof asthma (i.e. wheeze, shortness
of breath but not cough alone) that resulted in (I) nocturnal wakening in the last week
and/or (ii) interference with usual activities in the last week and/or (iii) exacerbations,
defined as a short course of oral corticosteroids, an unscheduled general practitioner or
accident and emergency (A&E) department visit, or a hospital admission within the past
6 months
Exclusion criteria: children who received long-acting beta -agonists, leukotriene re-
ceptor antagonists, regular theophylline therapy, or high-dose ICSs (> 1000 µg) and
unlicensed beclomethasone dipropionate or equivalent (at the discretion of the inves-
tigator); also children with other respiratory diseases, cystic fibrosis, cardiac disease, or
immunological disorders
68Inhaled steroids with and without regular salmeterol for asthma: serious adverse events (Review)
Copyright © 2018 The Cochrane Collaboration. Published by J
MASCOT 2013 (Continued)
Interventions During the 4-week run-in period, all patients were commenced on fluticasone propionate
inhalers (Flixotide, GSK) at 200µg per day (100µg twice daily). Childrenwho remained
symptomatic at the end of the run-in period were randomised to 1 of 3 double-blind
treatment regimens.
• Inhaled fluticasone propionate 100 µg and salmeterol 50 µg twice daily (combination
inhaler) plus placebo tablet once daily
• Inhaled fluticasone propionate 100 µg twice daily plus placebo tablet once daily
• Inhaled fluticasone propionate 100 µg twice daily plus montelukast 5-mg tablet once
daily (this arm was not used in the review)
Outcomes Primary outcome: number of asthma exacerbations requiring treatment with oral cor-
ticosteroids over the planned 48-week study period
Secondary outcomes: number of hospital admissions due to respiratory problems and
adverse events
Notes Funded by NIHR Health Assessment Technology Programme
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation code lists were generated
(by an individual at the MCRN CTU who
was not involved with the MASCOT trial)
with the software package Stata (Release 9,
StataCorp LP, College Station, TX, USA)
using block randomisation with variable
block length, stratified by secondary care
centre, with allocation to the 3 treatment
arms in the ratio 1:1:1
Allocation concealment (selection bias) Low risk The pharmacy at each secondary care cen-
tre held the randomisation list for that cen-
tre, with treatment allocations labelled A,
B, and C. After determining a participant’s
treatment allocation from the list, the phar-
macist selected an appropriate treatment
pack and removed a serrated label showing
A, B, or C before dispensing to the partic-
ipant
Blinding (performance bias and detection
bias)
All outcomes
Low risk Study drugs were identical in appearance
and were identically packaged, with all
patients, clinicians, and trial personnel
blinded to treatment allocation throughout
Independent Assessment of causation (de-
tection bias)
Asthma-related events
High risk Independent assessment of causation was
not clearly described
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MASCOT 2013 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Early trial closure due to difficulty in re-
cruiting makes the effect of attrition bias
due to the small sample size unclear
Selective reporting (reporting bias) Low risk Adverse events andhospitalisationswere re-
ported
Murray 2004
Methods A randomised, double-blind, active-controlled, multi-centre, parallel-group study over
12 weeks from November 1999 to September 2000, at 33 centres in the USA. Run-in
2 weeks, single-blind placebo
Participants Population: 267 adolescents and adults (12 to 73 years) with persistent asthma
Baseline characteristics: mean age 34 years; FEV 66% predicted
Concomitant ICS used by 0% of participants
Inclusion criteria: 12 years of age or older with a 6-month history of asthma; must have
been treated with as-needed SABA alone during the previous month with no oral or
ICS use within 1 month, or LABA within 72 hours of study entry; FEV % predicted
between 40% and 85%; bronchodilator reversibility by an increase ≥ 15% in FEV
over baseline within 30 minutes of inhalation of 2 puffs (180 µg) of albuterol
Exclusion criteria: pregnancy and/or lactation, life-threatening asthma, hospitalisation
attributable to asthma twice or more in the last year, current smoker or > 10-pack-year
history of smoking, significant concurrent disease including a recent upper or lower
respiratory tract infection. Medications prohibited before and throughout the study in-
cluded inhaled, oral, or parenteral corticosteroids, theophylline or other bronchodilators,
anticholinergics, leukotriene modifiers, cromolyn, and nedocromil
Interventions • Fluticasone propionate and salmeterol 100/50 µg twice daily
• Fluticasone propionate 100 µg twice daily
Delivery Diskus
Outcomes Primary efficacy variables: mean change from baseline in AM predose FEV at end-
point for fluticasone propionate/salmeterol 100/50 compared to salmeterol 50; area un-
der the serial FEV curve at treatment week 12 relative to treatment day 1; baseline for
fluticasone propionate/salmeterol 100/50 compared to fluticasone propionate 100
Notes Sponsored by GSK
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Treatment assignments were generated in
blocks of 6 by a computer-based random
codes system
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Murray 2004 (Continued)
Allocation concealment (selection bias) Unclear risk Not stated
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind
Independent Assessment of causation (de-
tection bias)
Asthma-related events
High risk Causation of SAEs not independently as-
sessed
Incomplete outcome data (attrition bias)
All outcomes
Low risk 228/267 (85%) completed the study
Selective reporting (reporting bias) Low risk Full data on GSK website
Nathan 2006
Methods A parallel-group, multi-centre study over 12 weeks
Participants 365 adults and adolescents randomised
Age range: 12 to 82 years; mean FEV 68% predicted
Inclusion criteria: fluticasone propionate 440 to 660 µg/d for≥ 3 months before study
entry; FEV 40% to 85%; reversibility ≥ 15%
Interventions Fluticasone propionate and salmeterol HFA 110/42 twice daily (220/84) vs CFC sal-
meterol 42 twice daily (84) vs CFC fluticasone 110 twice daily (220) vs HFA placebo
Inhaler devices: MDI
Run-in: 2 weeks
This review includes only data from the fluticasone propionate and salmeterol and
fluticasone arms
Co-interventions: ICS at usual dose was an inclusion criterion, but it appears to have
been withdrawn in the salmeterol and placebo arms of the study
Outcomes The paper publication mentions 1 drug-related SAE (an upper gastrointestinal bleed
from the placebo group)
Website: SAS30004
No fatal SAE. No SAE on fluticasone propionate/salmeterol or fluticasone propionate
Notes Sponsored by GSK
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
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Nathan 2006 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind
Independent Assessment of causation (de-
tection bias)
Asthma-related events
High risk Causation of SAEs not independently as-
sessed
Incomplete outcome data (attrition bias)
All outcomes
Low risk 243/365 (67%) completed the study; no
SAEs occurred
Selective reporting (reporting bias) Low risk Full data on GSK website
NCT01192178
Methods A randomised, double-blind, 16-week, parallel-group study in paediatric patients from
2 August 2010 to 16 December 2010, at 39 centres in the USA
Participants Population: 339 children (4 to 11 years) with persistent asthma who were symptomatic
on an ICS
Baseline characteristics: 22% aged 4 to 5 years; 78% 6 to 11 years. Spacers were used
by 78% of children at baseline
Inclusion criteria:male and female children 4 to 11 years of age with diagnosis of asthma
requiring an ICS for control of asthma. Patients were required to have an AM PEF ≥
70% of predicted value at the screening visit. Patients also had to have a history of ≥ 1
exacerbation of asthma during the previous respiratory viral season that required use of
outpatient systemic corticosteroids or an urgent care visit, an emergency room visit, or
hospitalisation
Exclusion criteria: life-threatening asthma, unstable asthma, evidence of concurrent
respiratory disease, history of any upper or lower respiratory tract infectionwithin 4weeks
of randomisation that required use of an antibiotic or was accompanied by worsening
asthma, other clinically significant medical conditions
Interventions • Fluticasone propionate and salmeterol Diskus 100/50 µg, 1 inhalation twice daily
• Fluticasone propionate Diskus 100 µg, 1 inhalation twice daily, for 16 weeks
Outcomes Primary outcome: number of exacerbations of asthma during the double-blind period.
No deaths were reported; 2 children suffered SAEs on fluticasone propionate/salmeterol
(1 was status asthmaticus) and 1 child suffered an SAE (syncope) on fluticasone propi-
onate
Notes Sponsored by GSK
Risk of bias
Bias Authors’ judgement Support for judgement
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NCT01192178 (Continued)
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Double-blind”
Independent Assessment of causation (de-
tection bias)
Asthma-related events
High risk Causation of SAEs not independently as-
sessed
Incomplete outcome data (attrition bias)
All outcomes
Low risk 86% in both groups completed treatment
Selective reporting (reporting bias) Low risk Full data on GSK website
Nelson 2003
Methods A randomised, double-blind, active-controlled, parallel-group study over 12 weeks, at
33 centres in the USA. Run-in 2 weeks (run-in was single-blind placebo)
Participants Population: 283 adolescents and adults (12 to 77 years) with asthma
Baseline characteristics: mean age 32 years; FEV 66% predicted
Concomitant ICS used by 0% of participants
Inclusion criteria: at least 12 years old with medical history of asthma (as defined by
the ATS) requiring asthma pharmacotherapy for at least 6 months; FEV % predicted
between 40% and 85%; bronchodilator reversibility by an increase ≥ 15% in FEV
over baseline within 30 minutes after 2 inhalations of inhaled albuterol (180 µg)
Exclusion criteria: history of life-threatening asthma; hypersensitivity reaction to sym-
pathomimetic drugs or corticosteroids; smoking within previous year or history of >
10 pack-years; use of oral, inhaled, or injectable corticosteroid therapy within previ-
ous month; use of intranasal corticosteroid therapy except for Flonase (GlaxoWellcome
Inc.); use of daily oral corticosteroid treatment within previous 6 months; use of any
other prescription or over-the-counter medication that could have affected the course of
asthma or interacted with sympathomimetic amines; abnormal chest x-ray films; clini-
cally significant abnormal 12-lead electrocardiograms (ECGs); or history of significant
concurrent disease (e.g. glaucoma, diabetes, hypertension)
Interventions • Fluticasone propionate and salmeterol 100/50 µg HFA twice daily
• Fluticasone propionate 100 µg CFC twice daily
• Salmeterol 502 µg CFC twice daily (not considered in this review)
Delivery was MDI
Outcomes Primary efficacy measures: area under the serial FEV curve for 12 hours following
administration of study medication; change from baseline at endpoint in morning pre-
dose FEV
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Nelson 2003 (Continued)
The paper reports: “no serious drug related adverse events”
Notes Sponsored by GSK
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind
Independent Assessment of causation (de-
tection bias)
Asthma-related events
High risk Causation of SAEs not independently as-
sessed
Incomplete outcome data (attrition bias)
All outcomes
Low risk 257/283 (91%) completed the study
Selective reporting (reporting bias) Low risk Full data on GSK website
Pearlman 2004
Methods A randomised, double-blind, active-controlled, parallel-group study over 12 weeks, at
36 centres in the USA and 1 centre in Puerto Rico
Participants N = 360. Fluticasone propionate/salmeterol arm n = 92, fluticasone propionate arm n =
89
Population:males and females 12 years of age or older with a diagnosis of asthma, using
the ATS definition, were screened. All patients were required to have FEV 40% to 85%
predicted normal and > 15% reversibility following 2 puffs of ventolin at screening. Study
population was stratified according to whether or not participants were treated with ICS
or inhaled beta -agonists at screening (salmeterol or short-acting beta -agonists only).
Patients treated with ICS must have been treated for at least 3 months before visit 1 and
must have been receiving a daily dose of 252 to 336 µg beclomethasone dipropionate,
600 to 800µg triamcinolone acetonide, 1000µg flunisolide, 400 to 600µg budesonide,
176 µg fluticasone propionate inhalation aerosol, or 200 µg fluticasone propionate
inhalation powder for at least 1 month before visit 1 with no change in regimen. Eligible
patients using only as-needed short-acting beta-agonist therapy were required to have
received treatment for at least 1 week before visit 1 with a 7-day total symptom score
> 7 for the 7 days before visit 2. Eligible patients using salmeterol at baseline were
required to have received only salmeterol and as-needed, short-acting beta -agonists for
at least 1 week before visit 1. No details were provided on distribution between groups.
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Pearlman 2004 (Continued)
Participants were described as symptomatic. Baseline medication included prn SABA
alone - 142; salmeterol - 84; and ICS - 134 (37%)
Interventions • Fluticasone propionate and salmeterol 100/50 µg twice daily
• Fluticasone 100 µg twice daily
The other treatment arms were not used for this review
Outcomes Paper reports no serious drug-related adverse events
Website: SAS3003. No fatal SAEs in the fluticasone propionate/salmeterol or fluticasone
propionate group. One tachyarrhythmia on fluticasone propionate
Notes Sponsored by GSK
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind
Independent Assessment of causation (de-
tection bias)
Asthma-related events
High risk Causation of SAEs not independently as-
sessed
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 279/360 (77%) completed the study
Selective reporting (reporting bias) Low risk Data on GSK website
Ploszczuk 2014
Methods A randomised, double-blind, parallel-group, multi-centre study over 12 weeks from
March 2012 to November 2013, across multiple sites (Bulgaria, Czech Republic, Hun-
gary, India, Poland, Romania, Russian Federation, Ukraine). Run in 2 to 4 weeks of ICS
Participants Population: 512 children 5 to < 12 years of age with asthma
Baseline characteristics: 66% males, 33% females included in the study
Inclusion criteria:male and female children 5 to < 12 years of age with a known history
of moderate to severe persistent reversible asthma for ≥ 6 months before screening visit,
FEV ≥ 60% to≤ 90% predicted during the screening period followed by appropriate
withholding of asthma medications (no LABA within 12 hours and/or no SABA within
6 hours of PFT; no ICS on the day of screening), documented reversibility ≥ 15% FEV
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Ploszczuk 2014 (Continued)
in the screening period, current ICS use at a stable dose for≥ 4 weeks before screening,
inadequate asthma control on ICS alone at ≤ 500 µg fluticasone equivalents per day
or controlled asthma on ICS-LABA combination at ICS dose ≤ 200 µg fluticasone
equivalents per day, demonstrated satisfactory pMDI and spacer technique, adequate
spirometry performed, willing and able to add information in electronic diary with
help of parent or guardian, attending all study visits, willing and able to substitute pre-
study inhaler medication for entire study duration; if female post menarche, a urine
pregnancy test may be undertaken at the discretion of the investigator and parents/legal
representative (test must be negative); written informed consent and assent obtained as
per national law
Exclusion criteria: near fatal or life-threatening asthma within past year (including in-
tubation), hospitalisation or emergency visit for asthma within past 6 months, history of
systemic (injectable/oral) corticosteroid medication within 1 month of screening visit,
current or prior non-response or partial response only to ICS/LABA combination, ev-
idence of clinically unstable disease (determined by medical history, clinical laboratory
tests, physical examination), clinically significant upper and lower respiratory infection
within 4 weeks before screening, significant non-reversible active pulmonary disease,
known HIV positive status, current smoking history within 12 months before screen-
ing, current alcohol//substance abuse within 12 months before screening, beta-blocking
agents, tricyclic antidepressants, monoamine oxidase inhibitors, astemizole (Hismanal)
, quinidine-type antiarrhythmics, or potent CYP 3A4 inhibitors such as ketoconazole
within 1 week before screening; current use of medications that may affect outcomes of
study; hypersensitivity/idiosyncratic reactions to test medications/components; investi-
gational medicinal product within 30 days of screening; current participation in a clinical
study
Interventions • Fluticasone propionate and salmeterol 100/50 µg twice daily (total 200/100 µg/d)
• Fluticasone propionate 100 µg twice daily (total 200 µg/d)
• Fluticasone propionate /formoterol 100/10 µg twice daily (total 200/20 µg/d); this
arm was not used in the analysis of this review
Outcomes Primary efficacy variables: change from baseline in pre-dose to 2 hour post-dose FEV
over 12 weeks
Safety and tolerability profiles were reported to be similar in all treatment groups, but
data were not reported
Notes This is a conference abstract that was also published in another journal (Ploszczuk 2014a)
This trial was published at clinicatrials.gov and EudraCT websites. Sponsored by
Mundipharma Research Ltd
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Not clearly reported but trial was con-
ducted for regulatory purposes
Allocation concealment (selection bias) Low risk Randomisation schedule was filed securely
by Interactive response technology
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Blinding (performance bias and detection
bias)
All outcomes
Low risk Blinding was properly maintained
throughout the study. Each participant re-
ceived 2 inhalers (double-dummy)
Independent Assessment of causation (de-
tection bias)
Asthma-related events
High risk No independent assessment of causation
was reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants who took at least 1 dose of
treatment were included in the safety anal-
ysis
Selective reporting (reporting bias) Low risk Serious adverse events were reported on the
EU Clinical Trials register
Raphael 2017
Methods A randomised, double-blind, multi-centre, parallel-group, placebo-controlled phase 3
study carried out over 12 weeks
Participants Population: 787 adults and older children (> 12 years old) with persistent asthma
previously treated with low- or mid-dose inhaled corticosteroids (ICSs) or ICS/long-
acting beta-agonists were enrolled in this study; 647 were randomised
Baseline characteristics: mean age was 41.5 years; 71% of participants were receiving
inhaled glucocorticoids at baseline, and 29% were receiving combined ICS/LABA; 44%
of the cohort was male and 80% white
Inclusion criteria: at the screening visit, patients were required to have FEV 40% and
85%of predicted value for age, height, sex, and race, as perNationalHealth andNutrition
Examination Survey III reference values. Previous treatment had to include low- or mid-
dose ICS or ICS/LABA for at least 1 month before consent was obtained (those taking
ICS/LABA were required to have a pre-screening visit to change to a comparable dose of
ICS monotherapy). All patients were required to be able to replace their current SABA
with albuterol/salbutamol HFA MDI inhalation aerosol at the screening visit for use as
required for the duration of the study. Participants were to withhold all inhaled SABA
bronchodilators for at least 6 hours before all study visits. In addition, participants had
to demonstrate reversibility of disease (15% reversibility (all participants) and 200-mL
increase (participants 18 years old) from baseline FEV ) within 30 minutes following
SABA administration at the screening visit
Exclusion criteria: history of life-threatening asthma exacerbation; asthma exacerbation
requiring systemic corticosteroids 30 days before the screening visit, any hospitalisation
for asthma 2 months before the screening visit
Interventions • Fluticasone propionate and salmeterol (50 or 100 fluticasone propionate/12.5 µg
salmeterol) twice daily
• Fluticasone propionate (50 or 100 µg) twice daily
A novel inhalation-driven device (multi-dose dry powder inhaler (MDPI); Teva Phar-
maceuticals, Inc., Frazer, PA) was used to administer all doses of the interventions
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Outcomes Safety was assessed by monitoring of vital signs, physical and oropharyngeal examina-
tions, ECGs, concomitant medication usage, and adverse events (AEs). All AEs were
coded using theMedical Dictionary for Research Activities, version 17.10, preferred terms.
Participants who demonstrated oropharyngeal signs consistent with oral candidiasis were
to have a culture to confirm the diagnosis. SAEs were defined as an AE occurring at any
dose that resulted in death, a life-threatening AE, inpatient hospitalisation or prolon-
gation of existing hospitalisation, persistent or significant disability or incapacity, or a
congenital anomaly or birth defect. Asthma exacerbations, defined as any worsening of
asthma requiring an emergency department visit or hospitalisation, were documented
Notes Sponsored by Teva Pharmaceuticals
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study states: ”At the randomisation visit,
patients were randomized to one of the five
treatment groups in equal proportions“ but
does not specify how they were assigned to
each treatment group”
Allocation concealment (selection bias) Unclear risk No details
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Reported to be carried out in a double-
blind manner, but further information de-
tailing how this was maintained through-
out the study was not readily available in
this publication
It appears that blinding was maintained
throughout the intervention and follow-up
period, but again it is unclear how this was
done
Independent Assessment of causation (de-
tection bias)
Asthma-related events
High risk No clearly documented independent as-
sessment of causation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Reasons for participant withdrawal were
clearly stated and discussed in the Results
section: “AEs were the most frequent rea-
son for study withdrawal, occurring in 12
patients overall, including six patients in
the placebo group. Another 10 patients
withdrew due to disease progression or lack
of efficacy, including six in the placebo
group” with overall attrition rates relatively
low in both arms of the study - 6.5% for
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fluticasone propionate and 4.2% for FS, re-
spectively, from a relatively large popula-
tion (N = 787). Safety data were reported
for all included participants bar 6 people,
with details as to why they were not re-
ported made clear
Selective reporting (reporting bias) Low risk Study was registered with an NCT number
and had clearly prespecified primary and
secondary outcomes. Data for safety out-
comes were clearly reported and were easily
accessible
Renzi 2010
Methods A 24-week, multi-centre, randomised, double-blind, parallel-group trial to compare the
efficacy and tolerability of salmeterol/fluticasone propionate (ADVAIR®) Diskus in-
halation device 50/100 µg twice daily vs fluticasone propionate Diskus inhalation device
100µg twice daily as initial maintenance treatment in adult and adolescent patients with
symptomatic persistent asthma not controlled on short-acting bronchodilators alone
Participants Population: 532 adults and adolescents (12+ years) with a documented history of asthma
treated with SABA only
Inclusion criteria:male and female patients≥ 12 years of age with a documented history
of asthma treated with SABA only and with FEV ≥ 80% predicted were eligible for
recruitment to the 2-week run-in period. They were recruited to the trial if they were
symptomatic for the last 7 days of run-in on SABA alone
Exclusion criteria: key exclusion criteria were use of asthma controller medications in
the previous month or systemic corticosteroids in the previous 12 weeks; exacerbations
requiring emergency room treatment in the previous 6 weeks or hospitalisation in the
previous 12 weeks; smoking history of ≥ 10 pack-years
Interventions • Fluticasone propionate and salmeterol 100/50 µg twice daily
• Fluticasone 100 µg twice daily
Delivery device Diskus
Outcomes Change in morning PEF over 24 weeks; SAEs fully reported in paper and in GSK Web
report (SAS40068)
Notes Sponsored by GSK
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
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Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Double-blind”
Independent Assessment of causation (de-
tection bias)
Asthma-related events
High risk Causation of SAEs not independently as-
sessed
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 53/262 on fluticasone propionate/salme-
terol and 46/270 on fluticasone propionate
lost to follow-up (withdrawndue to adverse
events, 6 and 11, respectively)
Selective reporting (reporting bias) Low risk SAEs fully reported in paper and in GSK
Web report (SAS40068)
Rojas 2007
Methods A randomised, double-blind, multi-centre, parallel-group study over 12 weeks from
February 2003 to September 2003, at 48 centres worldwide (Argentina (4), Czech Re-
public (8), France (9), Israel (4), Italy (9), Poland (4), Slovakia (6), Turkey (4)). Run-in
2 weeks
Participants Population: 362 adolescents and adults (12 to 78 years) withmoderate persistent asthma
Baseline characteristics: mean age 41 years; FEV 72% predicted
Concomitant ICS used by 0% of participants
Inclusion criteria: 12 to 80 years with documented clinical history of persistent asthma
for at least 6 months and currently receiving inhaled short-acting beta -agonists alone.
FEV % predicted between 60% and 80%, bronchodilator reversibility by an increase
of at least 15% in FEV over baseline after 400 µg salbutamol, or a mean morning
PEF during the last 7 days of the run-in of < 85% of post-bronchodilator value, and a
daytime symptom score ≥ 2 on at least 4 of the last 7 days of the run-in
Exclusion criteria: taken corticosteroids within 12 weeks; LTRA within 4 weeks or
long-acting inhaled or oral beta -agonists, sodium cromoglycate, nedocromil sodium,
ketotifen, methylxanthines, or inhaled anticholinergics within 2 weeks of entering the
study; had an acute asthma exacerbation requiring hospital treatment within 6 weeks;
had a respiratory tract infection within 4weeks of entering the study or a smoking history
of > 10 pack-years
Interventions • Fluticasone propionate and salmeterol 250/50 µg twice daily
• Fluticasone propionate 250 µg twice daily
Delivery was Diskus inhaler
Outcomes Primary efficacy variable: mean morning PEF
Paper reports: “Only three serious adverse events occurred and none were considered
related to study treatment”
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Notes Sponsored by GSK
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind
Independent Assessment of causation (de-
tection bias)
Asthma-related events
High risk Causation of SAEs not independently as-
sessed
Incomplete outcome data (attrition bias)
All outcomes
Low risk 350/362 (97%) completed the study
Selective reporting (reporting bias) Low risk Full data on GSK website
SAM30007
Methods A randomised, double-blind, multi-centre, parallel-group study over 30 weeks from
September 2000 to May 2002, at 5 centres in Denmark. Run-in 2 weeks
A comparative investigation of the corticosteroid-saving potential of the combination
therapy fluticasone propionate and salmeterol (SERETIDE) vs fluticasone propionate
alone, given to adults with asthma, when the ICS dose was reduced from an initially
high level of 500 µg twice daily
Participants Population: 61 adults (18+ years) with stable asthma
Baseline characteristics: mean age 37 years; FEV not reported % predicted
Concomitant ICS used by 100% of participants
Inclusion criteria: at least 18 years old with a clinical diagnosis of stable asthma; treated
with 1500 to 2000 µg of budesonide, beclomethasone dipropionate, or flunisolide, or
750 to 1000 µg of fluticasone propionate, for at least 10 weeks before the study; FEV
% predicted ≥ 60%; had to be able to use the data capture method (electronic diary,
AM-2) correctly
Exclusion criteria: not reported
Interventions • Fluticasone propionate and salmeterol 500/50, 250/50, or 100/50 µg twice daily
• Fluticasone propionate 500, 250, or 100 µg twice daily
Outcomes Primary efficacy endpoint: minimum dose at which the participant’s asthma remained
controlled - the minimum acceptable dose (MAD)
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Notes Sponsored by GSK
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind
Independent Assessment of causation (de-
tection bias)
Asthma-related events
High risk Causation of SAEs not independently as-
sessed
Incomplete outcome data (attrition bias)
All outcomes
Low risk 55/61 (90%) completed the study
Selective reporting (reporting bias) Low risk Data on GSK website
SAM40004
Methods A multi-centre, randomised, double-blind, placebo-controlled, parallel-group study to
compare effects on airway inflammation and remodelling of treatment with salmeterol/
fluticasone propionate combination product (50/100 µg strength) twice daily via the
Accuhaler inhaler, or fluticasone propionate 100 µg twice daily via the Accuhaler inhaler,
or placebo via the Accuhaler inhaler for 16 weeks, followed by double-blind treatment
for 52 weeks with the salmeterol/fluticasone propionate combination product (50/100
µg strength) twice daily via theAccuhaler inhaler, or fluticasone propionate 100 µg twice
daily via the Accuhaler inhaler, in adults with reversible airways obstruction (SIRIAS -
Seretide in Inflammation and Remodelling In Asthma Study)
Participants Population: 63 adults (18 to 50 years) with mild asthma.
Baseline characteristics:mean age 32 years; FEV unknown % predicted; concomitant
ICS used by unknown % of participants, but all withdrawn during the run-in period
Inclusion criteria: aged 18 to 50 years with a history of reversible airways obstruction;
received short-acting beta -agonist alone or beclomethasone dipropionate or budesonide
at a constant daily dose of up to 400 µg per day (excluding any CFC-free formulation),
or fluticasone propionate at a constant daily dose of up to 200 µg per day via any device
for at least 4 weeks before the first visit. In addition, patients had to have had a fall in FEV
≥ 20% with a histamine challenge test at the first visit and a post-bronchodilator FEV
> 60% of predicted normal. To be randomised, participants had to have a fall in FEV
≥ 20% with a standardised histamine challenge test, and at least 1 of the following
criteria: recorded symptoms on at least 4 of the last 7 days of the preventer-free run-in
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period; recorded using their inhaled short-acting beta -agonist on at least 2 occasions
on at least 4 of the last 7 days of the preventer-free run-in period; have a period variation
≥ 10% over the last 7 days of the preventer-free run-in period
Exclusion criteria: not reported
Interventions • Fluticasone propionate and salmeterol 100/50 µg twice daily throughout
• Placebo initially, and then fluticasone propionate/salmeterol 100/50 µg twice daily
• Fluticasone propionate 100 µg twice daily throughout
Delivery as DPI
Outcomes Primary efficacy endpoint: level of airway hyperreactivity (as measured by histamine
PC20); response of induced airway spasm to bronchodilator (post-bronchodilator FEV
)
SAE datawere used for the 52-week extension period, as reported.No SAEswere reported
in the 16-week initial period
Notes Sponsored by GSK
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind
Independent Assessment of causation (de-
tection bias)
Asthma-related events
High risk Causation of SAEs not independently as-
sessed
Incomplete outcome data (attrition bias)
All outcomes
High risk 37/63 (59%) completed the study
Selective reporting (reporting bias) Low risk Data on GSK website
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Methods A multi-centre, randomised, double-blind, parallel-group comparison of the efficacy
of SERETIDE* twice daily and fluticasone propionate twice daily (both via Diskus*/
ACCUHALER*, Inhaler) when tapering the inhaled corticosteroid dose in asthmatic
adults
Carried out over 26 weeks from May 2000 to July 2001, at 34 centres in 10 coun-
tries (Australia, Estonia, Finland, France, Germany, Israel, Latvia, New Zealand, Spain,
United Kingdom)
Participants Population: 186 adults (18+ years) with persistent asthma
Baseline characteristics: mean age 50 years; FEV unknown % predicted
Concomitant ICS used by 100% of participants
Inclusion criteria: 18 years of age or older with documented evidence of asthma within
previous 2 years who were receiving 1500 to 2000 µg/d of BUD or equivalent ICS,
excluding fluticasone propionate, for at least 3 months before the start of baseline
Exclusion criteria: not reported
Interventions • Fluticasone propionate and salmeterol 500/50 µg twice daily
• Fluticasone propionate 500 µg twice daily
Delivery as DPI
Outcomes Primary efficacy endpoint: minimum acceptable daily dose of ICS
Notes Sponsored by GSK. High dropout rate. Only 8% completed the study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind
Independent Assessment of causation (de-
tection bias)
Asthma-related events
High risk Causation of SAEs not independently as-
sessed
Incomplete outcome data (attrition bias)
All outcomes
High risk Only 14/186 (8%) completed the study
Selective reporting (reporting bias) Low risk Data on GSK website
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Methods A randomised, double-blind, double-dummy, multi-centre, parallel-group study over
24 weeks from June 2000 to June 2001, at 38 centres in 7 countries (Bulgaria, Hungary,
Israel, Poland, Russia, Spain, United Kingdom). Run-in 2 weeks
Comparison of 3 treatments: (1) salmeterol/fluticasone propionate (SFC) (50/100 µg
strength) twice daily via Diskus/ACCUHALER inhaler, (2) fluticasone propionate 200
µg twice daily via Diskus/ACCUHALER inhaler, (3) fluticasone propionate 100 µg
twice daily via Diskus/ACCUHALER inhaler in children aged 4 to 11 years with asthma
Participants Population: 548 children (4 to 11 years) with asthma
Baseline characteristics: mean age 8 years; FEV not reported % predicted
Concomitant ICS used by 100% of participants
Inclusion criteria: aged 4 to 11 years, inclusive, with documented evidence of asthma
and receiving BDP, BUD, or equivalent at a dose of 400 to 500 µg/d or fluticasone
propionate at a dose of 200 to 250 µg/d for at least 4 weeks before visit 1. Recorded
symptom score (i.e. total score of daytime and night-time scores) of at least 2 on the
electronic daily record card on at least 3 of the last 7 consecutive days of the run-in period
and had a mean morning PEF (calculated from the last 7 days of the run-in period) of
between 50% and 85% of the PEF measured 15 minutes after administration of 400 µg
of salbutamol at the randomisation visit. In addition, patients had to have recorded at
least 70% of data into their electronic daily record cards
Exclusion criteria: not reported
Interventions • Fluticasone propionate and salmeterol 100/50 µg twice daily
• Fluticasone propionate 100 µg twice daily
• Fluticasone propionate 200 µg twice daily
Delivery was Diskus device (third arm not used in this review)
Outcomes Primary efficacy endpoint: percentage of combined symptom-free days and nights
during weeks 1 to 24
Notes Sponsored by GSK
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind
Independent Assessment of causation (de-
tection bias)
Asthma-related events
High risk Causation of SAEs not independently as-
sessed
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Incomplete outcome data (attrition bias)
All outcomes
Low risk 513/548 (94%) completed the study
Selective reporting (reporting bias) Low risk Data on GSK website
SAM40031
Methods A 1-year, randomised, double-blind, parallel-group comparison of the efficacy of Seretide
(fluticasone propionate/salmeterol combination Accuhaler) and Flixotide (fluticasone
propionate Accuhaler) when ICS dose is down-titrated in adults with asthma who have
previously received Seretide 500/50 µg twice daily for at least 4 weeks
Study conducted over 52 weeks from March 2002 to February 2006, at 3 centres in
Australia
Participants Population: 82 adolescents and adults (18 to 80 years) with asthma
Baseline characteristics: mean age 47 years; FEV unknown % predicted
Concomitant ICS used by 100% of participants
Inclusion criteria: between 18 and 80 years of age with clinical diagnosis of asthma
according to ATS criteria for at least 6 months before enrolment; currently receiving
fluticasone propionate/salmeterol via dry powder inhaler or metered dose inhaler (with
or without spacer) at a dose of 500/50 µg twice daily or 250/25 µg 2 inhalations twice
daily for a minimum of 4 weeks before enrolment
Exclusion criteria: not reported
Interventions • Fluticasone propionate and salmeterol 500/50, 250/50, or 100/50 µg twice daily
(reduced incrementally)
• Fluticasone propionate 500, 250, or 100 µg twice daily (reduced incrementally)
Delivery was DPI
Outcomes Primary efficacy endpoint: average daily fluticasone propionate dose (µg/d) fromweek
0 to completion/withdrawal, including study medication and exacerbation medication
Notes SAE data included run-in
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind
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Independent Assessment of causation (de-
tection bias)
Asthma-related events
High risk Causation of SAEs not independently as-
sessed
Incomplete outcome data (attrition bias)
All outcomes
Low risk 60/82 (73%) completed the study
Selective reporting (reporting bias) Low risk Data on GSK website
SAM40065
Methods A randomised, double-blind, double-dummy, multi-centre, parallel-group study for 40
weeks from January 2003 to October 2004, at 44 centres (United States (39), Brazil (3)
, Bulgaria (2)). Run-in 2 weeks
Comparison of asthma control using bronchial hyperresponsiveness as an additional
guide to long-term treatment in adolescents and adults receiving fluticasone propionate/
salmeterol Diskus twice daily or fluticasone propionate Diskus twice daily (or placebo
twice daily if asymptomatic)
Participants Population: 449 adults (12+ years) with asthma
Baseline characteristics: mean age 34 years; FEV not reported % predicted
Concomitant ICS used by 100% of participants
Inclusion criteria: 12 years of age or older with diagnosis of asthma, as defined by
the ATS, for at least 3 months before visit 1; must have been treated with a SABA, an
anticholinergic, or an allowed ICS at a fixed dosing regimen (within an allowed total
daily dose) for at least 4 weeks before the screening visit; FEV % predicted between
60% and 95%; bronchodilator reversibility by an increase≥ 12% in FEV over baseline
within 30 minutes following 2 puffs of albuterol inhalation aerosol at the screening visit.
Documentation of historical reversibility within 24 months was allowed
Exclusion criteria: history of life-threatening asthma; current unstable asthma; current
respiratory tract infection or clinically significant concurrent disease that would put the
patient at risk during the study if the condition was exacerbated
Interventions • Fluticasone propionate and salmeterol 100/50, 250/50, or 500/50 µg twice daily
• Fluticasone propionate 100, 250, or 500 µg twice daily (BHR strategy)
• Fluticasone propionate 100, 250, or 500 µg twice daily (reference strategy)
Delivery was Diskus device (third arm not used in this review)
Outcomes Primary efficacy endpoint: average ICS treatment dose over the treatment period; SAE
data included run-in
Notes Sponsored by GSK
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind
Independent Assessment of causation (de-
tection bias)
Asthma-related events
High risk Causation of SAEs not independently as-
sessed
Incomplete outcome data (attrition bias)
All outcomes
Low risk 322/449 (72%) completed the study
Selective reporting (reporting bias) Low risk Data on GSK website
SAS30021
Methods A stratified, randomised, double-blind, placebo-controlled, parallel-group study for 12
weeks from November 2001 to February 2004, at 164 centres (United States (153),
Latin America (11))
A stratified, randomised, double-blind, placebo-controlled, parallel-group, 12-week trial
evaluating the safety and efficacy of the fluticasone propionate/salmeterol Diskus com-
bination product 100/50 µg once daily vs fluticasone propionate Diskus 100 µg once
daily and placebo in symptomatic paediatric subjects (4 to 11 years) with asthma
Participants Population: 908 children (4 to 11 years) with asthma
Baseline characteristics: mean age 8 years; FEV not reported % predicted
Concomitant ICS used by 0% of participants
Inclusion criteria: 4 to 11 years of age with diagnosis of asthma for at least 6 months
and treated with SABA only or non-ICS controller medications for at least 1 month
before screening; FEV %predicted between 50%and 85%; bronchodilator reversibility
by an increase of at least 15% in FEV over baseline within 30 minutes following 2
puffs of albuterol at screening. At the randomisation visit, participants were required to
demonstrate AM PEF reproducibility of +15% of the screening visit pre-albuterol PEF,
to demonstrate a PM PEF 50% to 90% of predicted normal, and to have an asthma
symptom score of at least 2 on 4 or more days in the week before randomisation, or to
have used albuterol on at least 4 days in the week before randomisation
Exclusion criteria: not reported
Interventions • Fluticasone propionate and salmeterol 100/50 µg once daily
• Fluticasone propionate 100 µg once daily
Delivery was Diskus device
Outcomes Primary efficacy endpoint: change from baseline in % predicted PM PEF over weeks
1 to 12
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Notes Sponsored by GSK
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind
Independent Assessment of causation (de-
tection bias)
Asthma-related events
High risk Causation of SAEs not independently as-
sessed
Incomplete outcome data (attrition bias)
All outcomes
Low risk 715/908 (79%) completed the study
Selective reporting (reporting bias) Low risk Data on GSK website
SAS30022
Methods A randomised, double-blind, placebo-controlled, parallel-group study for 12 weeks from
November 2001 to June 2003, at 121 centres (US (103), Canada (18))
A trial evaluating the efficacy and safety of the fluticasone propionate/salmeterol Diskus
combination product 250/50 µg once daily vs fluticasone propionate/salmeterol Diskus
combination product 100/50 µg twice daily vs fluticasone propionate Diskus 250 µg
once daily vs placebo in symptomatic adolescent and adult patients with asthma that is
not controlled on short-acting beta -agonists alone
Participants Population: 844 adolescents and adults (12+ years) with asthma that was not controlled
on SABA alone
Baseline characteristics: mean age 33 years; FEV not reported % predicted
Concomitant ICS used by 0% of participants
Inclusion criteria: 12 years of age or older with diagnosis of asthma for at least 3months
and treated with short-acting beta -agonists only for at least 1 month before screening;
FEV % predicted between 50% and 85%; bronchodilator reversibility by an increase
of at least 15% in FEV over baseline within 30 minutes following 2 puffs of albuterol
at screening. At the randomisation visit, participants were required to demonstrate FEV
reproducibility of ±15% of the screening visit pre-ventolin FEV , to demonstrate a
PM PEF 50% to 90% of predicted normal, and to have an asthma symptom score ≥ 2
on ≥ 4 days in the week before randomisation or to have used ventolin on ≥ 4 days in
the week before randomisation
Exclusion criteria: not reported
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Interventions • Fluticasone propionate and salmeterol 250/50 µg once daily
• Fluticasone propionate and salmeterol 100/50 µg twice daily
• Fluticasone propionate 250 µg once daily
(second arm not used in this review)
Outcomes Primary outcome/efficacy variable: change from baseline in % predicted PM PEF over
weeks 1 to 12
Notes Sponsored by GSK
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind
Independent Assessment of causation (de-
tection bias)
Asthma-related events
High risk Causation of SAEs not independently as-
sessed
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 698/844 (83%) completed the study
Selective reporting (reporting bias) Low risk Data on GSK website
SAS30023
Methods A randomised, double-blind, multi-centre, placebo-controlled, parallel-group study over
12 weeks from April 2002 to April 2003, at 69 centres in 9 countries (Australia, France,
UK, Hungary, Ukraine, Italy, Philippines, Thailand, Russia)
Study to compare the efficacy and tolerability of fluticasone propionate/salmeterol com-
bination (SERETIDE/VIANI/ADVAIR) 88/42 µg once daily in the morning with flu-
ticasone propionate 88 µg once daily in the morning and placebo (short-acting beta
-agonist as required only) once daily in the morning, all via the HFA MDI as initial
maintenance therapy in mild asthmatic patients
Participants Population: 464 adolescents and adults (12 to 80 years) with mild asthma
Baseline characteristics: mean age 34 years; FEV not reported % predicted
Concomitant ICS used by 0% of participants
Inclusion criteria: documented clinical history of asthma for ≥ 6 months who were
currently receiving short-acting beta -agonists alone
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Exclusion criteria: not reported
Interventions • Fluticasone propionate and salmeterol 50/25 µg 2 puffs once daily
• Fluticasone propionate 50 µg 2 puffs once daily
Delivery was MDI device with HFA propellant
Outcomes Primary efficacy endpoint: morning PEF
Notes No SAEs at all were reported in the double-blind phase of the study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind
Independent Assessment of causation (de-
tection bias)
Asthma-related events
High risk Causation of SAEs not independently as-
sessed
Incomplete outcome data (attrition bias)
All outcomes
Low risk 433/464 (93%) completed the study
Selective reporting (reporting bias) Low risk Data on GSK website
SAS40036
Methods A randomised, double-blind, double-dummy, multi-centre, parallel-group study for 16
weeks from October 2001 to May 2003, at 85 centres in the United States. Run-in 2
weeks
Participants Population: 331 adolescents and adults (15+ years) with persistent asthma
Baseline characteristics: mean age 41 years; FEV not reported (% predicted)
Concomitant ICS used by 100% of participants
Inclusion criteria: 15 years of age or older with diagnosis of asthma, as defined by the
ATS, for at least 6 months before visit 1; must have been treated with an allowed ICS at
a fixed dosing regimen (within an allowed total daily dose) for at least 4 weeks before the
screening visit; FEV % predicted between 40% and 85%; bronchodilator reversibility
by an increase of ≥ 12% in FEV over baseline within 30 minutes following 2 to 4
puffs of albuterol inhalation aerosol at the screening visit. Documentation of historical
reversibility within 24 months was allowed
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Exclusion criteria: not reported
Interventions • Fluticasone propionate and salmeterol 100/50 µg twice daily
• Fluticasone propionate 100 µg twice daily
Delivery was Diskus device (other arms of trial not considered for this review)
Outcomes Primary efficacy endpoint: mean change from baseline at endpoint in morning PEF.
No SAEs at all were reported in the double-blind phase of the study
Notes Sponsored by GSK
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind, double-dummy
Independent Assessment of causation (de-
tection bias)
Asthma-related events
High risk Causation of SAEs not independently as-
sessed
Incomplete outcome data (attrition bias)
All outcomes
Low risk 243/331 (73%) completed the study
Selective reporting (reporting bias) Low risk Data on GSK website
SAS40037
Methods A randomised, double-blind, double-dummy, multi-centre, parallel-group study for 16
weeks from October 2001 to May 2003, at 87 centres in the United States. Run-in 2
weeks
Participants Population: 331 adolescents and adults (15+ years) with persistent asthma
Baseline characteristics: mean age 41 years; FEV not reported (% predicted)
Concomitant ICS used by 100% of participants
Inclusion criteria: 15 years of age or older with diagnosis of asthma, as defined by the
ATS, for at least 6 months before visit 1; must have been treated with an allowed ICS at
a fixed dosing regimen (within an allowed total daily dose) for at least 4 weeks before the
screening visit; FEV % predicted between 40% and 85%; bronchodilator reversibility
by an increase of ≥ 12% in FEV over baseline within 30 minutes following 2 to 4
puffs of albuterol inhalation aerosol at the screening visit. Documentation of historical
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reversibility within 24 months was allowed
Exclusion criteria: diagnosis of life-threatening asthma, hospitalised for asthma within
previous 6 months, concurrent respiratory disease or intermittent or seasonal asthma
alone, respiratory tract infection or used antibiotics for treatment of a suspected or
diagnosed respiratory tract infection within 14 days of visit 1
Interventions • Fluticasone propionate and salmeterol 100/50 µg twice daily
• Fluticasone propionate 100 µg twice daily
Delivery was Diskus device (other arms of trial not considered for this review)
Outcomes Primary efficacy endpoint: mean change from baseline at endpoint in morning PEF
Notes Sponsored by GSK
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind, double-dummy
Independent Assessment of causation (de-
tection bias)
Asthma-related events
High risk Causation of SAEs not independently as-
sessed
Incomplete outcome data (attrition bias)
All outcomes
Low risk 230/322 (71%) completed the study
Selective reporting (reporting bias) Low risk Data on GSK website
SAS40068
Methods A randomised, double-blind, multi-centre, parallel-group study for 24 weeks from Oc-
tober 2002 to February 2004, at 58 centres in Canada
Trial to compare the efficacy and tolerability of salmeterol/fluticasone propionate (AD-
VAIR) Diskus inhalation device 50/100 µg twice daily with fluticasone propionate
Diskus inhalation device 100 µg twice daily as initial maintenance treatment in adult
and adolescent patients with symptomatic persistent asthma not controlled on short-
acting bronchodilators alone
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SAS40068 (Continued)
Participants Population: 532 adolescents and adults (12+ years) with symptomatic persistent asthma
Baseline characteristics: mean age 35 years; FEV not reported % predicted
Concomitant ICS used by 0% of participants
Inclusion criteria: 12 years of age or older with symptomatic persistent mild asthma
(defined as FEV ≥ 80% predicted over the last 7 consecutive days of run-in, asthma
symptom score ≥ 2 on ≥ 3 days, disruptions of normal sleep patterns on≥ 2 occasions,
or had used rescue bronchodilator medication on ≥ 4 days) treated with inhaled short-
acting bronchodilators alone
Exclusion criteria: taken any other asthma therapy (e.g. ICS, leukotriene modifiers,
inhaled long-acting beta -agonists) within 1 month before screening, smoking history
≥ 10 pack-years, acute asthma exacerbation requiring emergency room treatment within
last 6 weeks, or hospitalisation within last 12 weeks before screening
Interventions • Fluticasone propionate and salmeterol 100/50 µg twice daily
• Fluticasone propionate100 µg twice daily
Delivery was Diskus device
Outcomes Primary efficacy endpoint: change from baseline in daily record card (DRC) mean
morning PEF over 24 weeks
One death due to aorta hypoplasia and ventricular hypertrophy on fluticasone
Notes Sponsored by GSK
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind
Independent Assessment of causation (de-
tection bias)
Asthma-related events
High risk Causation of SAEs not independently as-
sessed
Incomplete outcome data (attrition bias)
All outcomes
Low risk 433/532 (81%) completed the study
Selective reporting (reporting bias) Low risk Data in GSK website
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SFA103153
Methods A randomised, double-blind, multi-centre, parallel-group study for 52 weeks from
November 2004 to April 2007, at 59 centres in the United States. Run-in 4 weeks
Participants Population:475 adolescents and adults (12 to 65 years) of African descentwith persistent
asthma
Baseline characteristics: mean age 32 years; FEV 78% predicted
Concomitant ICS used by 100% of participants
Inclusion criteria: patients were of African descent, 12 to 65 years of age, with persistent
asthma, and were symptomatic while taking an ICS
Exclusion criteria: not reported
Interventions • Fluticasone propionate and salmeterol 100/50 µg twice daily
• Fluticasone propionate 100 µg twice daily
Delivery was Diskus device
Outcomes Primary efficacy endpoint: asthma exacerbation rate per patient per year
Notes Sponsored by GSK
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind
Independent Assessment of causation (de-
tection bias)
Asthma-related events
High risk Causation of SAEs not independently as-
sessed
Incomplete outcome data (attrition bias)
All outcomes
Low risk 320/475 (67%) completed the study
Selective reporting (reporting bias) Low risk Data on GSK website
95Inhaled steroids with and without regular salmeterol for asthma: serious adverse events (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
SFCF4026
Methods A randomised, double-blind, multi-centre, parallel-group study for 24 weeks fromMay
2002 to November 2003, at 124 centres in France. Run-in 8 weeks
Maintenance of asthma control in adults: comparison of 3 therapeutic strategies in
patients whose asthma was controlled by a medium dose of inhaled corticosteroid and a
long-acting inhaled beta -agonist
Participants Population: 476 adolescents and adults (18+ years) with asthma
Baseline characteristics: mean age 45 years; FEV not reported % predicted
Concomitant ICS used by 100% of participants
Inclusion criteria: 18 years of age or older with a documented history of asthma (for
at least 6 months) and with asthma controlled by current treatment (inhaled corticos-
teroid at a dose of 1000 µg of CFC beclomethasone dipropionate or equivalent and a
long-acting beta -agonist at recommended dose) at a stable dose for ≥ 4 weeks before
the run-in period. Randomised if fulfilled the following criteria: ≥ 2 of the following:
diurnal symptoms≥ 2 days per week, use of rescue short-acting bronchodilator no more
than 2 days per week and no more than 4 occasions per week, PEF ≥ 80% predicted
every day. Plus all of the following criteria: no night-time awakenings due to asthma,
no exacerbations, no emergency visits, no treatment-related adverse events enforcing a
change in asthma therapy
Exclusion criteria: for entry into the run-in period: smoking history of≥ 10 pack-years,
respiratory tract infection during the last 4 weeks before visit 1 (the last 2 weeks after
amendment number 1), acute asthma exacerbation requiring emergency room treatment
or hospitalisation within 4 weeks before visit 1, use of oral/parenteral corticosteroids
during the last 4 weeks before visit 1 or any change in maintenance treatment, use of
depot corticosteroid within 12 weeks of visit 1. For entry into the treatment period:
changes in asthmamedication (excluding study rescuemedication), use of oral/parenteral
or depot corticosteroids, respiratory tract infection, insufficient asthma control according
to daily record card, asthma control questionnaire, and investigator’s judgement to allow
a reduction in maintenance treatment
Interventions • Fluticasone propionate and salmeterol 250/50 µg twice daily
• Fluticasone propionate and salmeterol 100/50 µg twice daily
• Fluticasone propionate 250 µg twice daily
Delivery was Diskus device (arm 2 not used in this review)
Outcomes Primary efficacy endpoint: morning PEF over first 12 weeks of the treatment period
Notes Sponsored by GSK
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
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SFCF4026 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind
Independent Assessment of causation (de-
tection bias)
Asthma-related events
High risk Causation of SAEs not independently as-
sessed
Incomplete outcome data (attrition bias)
All outcomes
Low risk 413/476 (87%) completed the study
Selective reporting (reporting bias) Low risk Data on GSK website
Shapiro 2000
Methods Multi-centre study, USA
Participants 349 adults and adolescents randomised (4-treatment arm study; fluticasone propionate/
salmeterol: 84; fluticasone propionate: 84). Data from 13 participants excluded from
analysis due to poor procedure at 1 site
Inclusion criteria: ≥ 12 years of age; ATS-defined asthma of ≥ 6 months’ duration
requiring pharmacotherapy for ≥ 6 months; FEV between 40% and 85% predicted;
≥ 15% increase in FEV 30 minutes after 2 puffs of albuterol; use of ICS 12 weeks
before the study
Exclusion criteria: females with positive pregnancy tests; life-threatening asthma; hy-
persensitivity to sympathomimetic drugs/steroids; smoking within previous year; smok-
ing history > 10 pack-years; use of oral/injectable steroid therapy within 1 month of
study; use of daily OCS within 6 months before the study; use of any prescription or
over-the-counter medication that could have affected asthma or course of treatment;
abnormal chest x-ray; clinically significant abnormal 12-lead electrocardiogram; history
of concurrent disease
Interventions • Fluticasone propionate and salmeterol 250/50 µg twice daily
• Fluticasone 250 µg twice daily
Third arm not used in this review
Outcomes 83% in the fluticasone propionate/salmeterol arm and 73% in the fluticasone propionate
arm completed the study
Paper reports: “no serious drug-related adverse events. Two patients treated with salme-
terol withdrew from the study because of adverse events; however, these adverse events
were considered by the investigator to be unrelated to study drug (bilateral subcapsular
cataracts and postsurgical infection)”
Website SFCA3003: no fatal adverse events. No serious adverse events in fluticasone
propionate/salmeterol arm; 1 in fluticasone propionate arm (asthma exacerbation)
Notes Sponsored by GSK
Risk of bias
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Shapiro 2000 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind
Independent Assessment of causation (de-
tection bias)
Asthma-related events
High risk Causation of SAEs not independently assessed
Incomplete outcome data (attrition bias)
All outcomes
Low risk 131/168 (78%) completed the study
Selective reporting (reporting bias) Low risk Full data on GSK website
Sher 2017
Methods A randomised, double-blind,multi-centre, parallel-group study carried out over 12weeks
Participants Population: 728 adults and older children (> 12 years) with persistent asthma who
previously took an ICS with or without a LABA
Baseline characteristics: mean age was 44.7 years; 45% were receiving inhaled gluco-
corticoids at baseline and 55% were on combined IC/LABA; 40% of the cohort were
male and 81% were white
Inclusion criteria: patients were eligible if they had FEV of 40% and 85% of predicted
value for age, height, sex, and race per National Health and Nutrition Examination
Survey III reference values; 15 exhibited 15% reversibility in FEV (all patients) and
200-mL increase in FEV from baseline (patients 12 years of age) within 30 minutes of
exposure to a short-acting agonist, and had a treatment regimen that included albuterol
or salbutamol for use as needed for 8 weeks before screening and an ICS (either ICS
monotherapy or ICS/LABA) at a qualifying dose of fluticasoneDPI 200 g/d or equivalent
for 1month. Patients who received ICS/LABA therapy had a pre-screening visit to change
to a comparable dose of ICS monotherapy
Exclusion criteria: history of life-threatening asthma exacerbation, asthma exacerbation
that required systemic corticosteroidswithin 30days before screening, any hospitalisation
for asthma within 2 months before screening
Interventions • Fluticasone propionate and salmeterol (100 or 200 µg/12.5 µg salmeterol) twice daily
• Fluticasone propionate (100 or 200 µg) twice daily
A novel, inhalation-driven, multi-dose dry powder inhaler (RespiClick MDPI; Teva
Pharmaceuticals, Inc., Frazer, PA) was used in all arms of the study
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Sher 2017 (Continued)
Outcomes Safety was assessed by monitoring of vital signs, physical and oropharyngeal examina-
tions, electrocardiograms, concomitant medication usage, and AEs. An SAE was defined
as an AE that occurred at any dose and resulted in death, a life-threatening AE, inpatient
hospitalisation or prolongation of existing hospitalisation, persistent or significant dis-
ability or incapacity, congenital anomaly, or a birth defect. An asthma exacerbation was
defined as worsening asthma that required any significant treatment other than study
medication or rescue albuterol/salbutamol, including systemic corticosteroids, urgent
care and/or emergency department visit, or hospitalisation. An asthma exacerbation was
considered an AE only if it met the criteria for an SAE
Notes Sponsored by Teva Pharmaceuticals
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “For the double-blind treatment period,
the patients were randomized in a 1:1:1:1:
1 ratio to one of five double-blind treat-
ment groups”; how they were assigned to
each was not specified
Allocation concealment (selection bias) Unclear risk No details
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Reported to be carried out in a double-
blind manner, but further information de-
tailing how this was maintained through-
out the study was not readily available in
the publication
Independent Assessment of causation (de-
tection bias)
Asthma-related events
High risk Noclear documentationof independent as-
sessment of causation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Clear reasons for participant withdrawal
were detailed in the study report: “Overall,
78 patients (11%) discontinued the study,
most frequently from the placebo group
and most commonly due to disease pro-
gression (n=24 [3%]) or lack of efficacy (n
9 [1%])”
With attrition rates of 0.3% in the flutica-
sone propionate treatment arm and 1% in
the fluticasone propionate and salmeterol
arm in a populationof 583 Safety outcomes
were reported in all included participants
apart from 8 patients, including 2 (1.4%)
in the placebo group and 6 (1.0%) in the
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Sher 2017 (Continued)
active treatment groups who discontinued
due to AEs
Selective reporting (reporting bias) Low risk Study was registered with an NCT num-
ber and had clearly pre-specified primary
and secondary outcomes. All safety-related
outcomes were reported and were easily at-
tainable
Slankard 2016
Methods A randomised, double-blind, multi-centre study conducted in patients with moderate
to severe asthma who were being treated with combined inhaled corticosteroids/LABA
over 16 weeks
Participants Population: 61 (67 randomised) participants age 18 years or older with physician-diag-
nosedmoderate or severe persistent asthma whowere receiving treatment with combined
ICS/LABA
Baseline characteristics: mean age of participants with Arg/Arg genotype (n = 28) was
47.2, and for those with Gly/Gly genotype (n = 33) 43.1. 23% of the Arg/Arg subgroup
and 24% of the Gly/Gly subgroup were female. 15% (Arg/Arg) and 17% (Gly/Gly)were
of white ethnic origin, and 8% (Arg/Arg) and 10% (Arg/Arg) were of African American
origin
Inclusion criteria: after providing informed consent, all potential study participants
underwent genetic screening for beta -adrenergic receptor genotype, and those homozy-
gous for the arginine or glycine variant at the 16th amino acid position (Arg/Arg or Gly/
Gly) were eligible to participate
Exclusion criteria: pregnancy at the time of enrolment, active tobacco use or > 10-pack-
year history of tobacco use, history of intubation for asthma within past 10 years, FEV
< 60% of predicted on screening spirometry before the run-in or < 70% predicted
at the randomisation visit, major comorbidity (symptomatic coronary artery disease,
ongoing treatment for malignancy, poorly controlled diabetes)
Interventions • Fluticasone propionate and salmeterol (Advair HFAR, 45 µg, 115 µg, or 230 µg of
fluticasone propionate with 21 µg of salmeterol, 2 puffs every 12 hours)
• Fluticasone propionate (Flovent HFAR, 44 µg, 110 µg, or 220 µg) twice daily
Advair HFA devices were used to deliver ICS/LABA fixed dose and Flovent HFA for
fluticasone propionate alone
Outcomes Participants who experienced more than 2 exacerbations during the course of the study
were withdrawn according to pre-determined safety parameters. (Exacerbation is defined
in Selected Methods of the Supplementary Appendix.) Adverse events were defined as
any untoward events or symptoms reported by the participant, whether related or not
related to the study drug
Notes
Risk of bias
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Slankard 2016 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomization was carried out by the
Columbia University Research Pharmacy
using the Microsoft Excel random number
generator”
Allocation concealment (selection bias) Unclear risk Further details regarding allocation con-
cealment were not described, but it appears
that participants were blinded to their allo-
cation
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Investigators and research staff were kept
blinded to the genotype and study drug as-
signment. HFA devices were blinded and
distributed by theColumbiaUniversityRe-
search Pharmacy”
Independent Assessment of causation (de-
tection bias)
Asthma-related events
High risk Independent assessment of causation was
not clearly documented
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rates were quite high due to the
small overall sample size (N = 90), but
most withdrawals occurred following ini-
tial (genotype) screening, whereas the level
of attritionwasmuch lower following treat-
ment allocations, suggesting this was less
likely to influence subsequent outcomes.
Furthermore, reasons for withdrawal were
clearly detailed in the trial flow chart (Fig.
2 of the paper)
Selective reporting (reporting bias) Low risk Study was registered with an NCT num-
ber and had clearly pre-specified primary
and secondary outcomes. All safety-related
outcomes were reported and were easily at-
tainable
SLGF75
Methods A randomised, double-blind, multi-centre, parallel-group study for 12 weeks from Jan-
uary 1998 to December 1998, at 7 centres in Italy. Run-in 4 weeks, follow-up 2 weeks
Salmeterol plus low-dose fluticasone propionate vs high-dose fluticasone propionate
in naive patients with mild to moderate asthma: effects on pulmonary function and
inflammatory markers of induced sputum
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SLGF75 (Continued)
Participants Population: 46 adolescents and adults (16 to 65 years) with mild to moderate asthma
Baseline characteristics: mean age 39 years; FEV unreported % predicted
Concomitant ICS used by 0% of participants
Inclusion criteria: performed on 3 study visits:
• Pre-study visit: all patients with asthma disease for ≥ 6 months
• Visit 2: 16 to 65 years old with asthma at moderate level (score of severity≥ 6), did not
use anti-inflammatory drugs for last month before visit 1, FEV % predicted ≥ 60%,
eosinophils ≥ 5% in induced sputum
• Visit 4: bronchial asthma assessed up to 6 (severity classes value) and with persistence
of eosinophils ≥ 5% (or ≥ 3% in sites where an amendment was applicable) in induced
sputum
Exclusion criteria: inhaled steroids or cromones in last 3 months, more than 1 short
course of OCS in last 3 months or 1 short course of OCS in last month before pre-
study visit; respiratory tract infection in the last 1 month pre-study visit, with lung or
other important disease, or on beta-blocker therapy; hypersensitivity to beta -agonist
and suspected to abuse drug or alcohol
Interventions • Fluticasone propionate 100 + salmeterol 50 µg twice daily
• Fluticasone propionate 100 µg twice daily
• Fluticasone propionate 250 µg twice daily
Delivery was Diskus (third arm not used in this review)
Outcomes Primary efficacy endpoint: daily morning PEF
Notes Sponsored by GSK
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind
Independent Assessment of causation (de-
tection bias)
Asthma-related events
High risk Causation of SAEs not independently as-
sessed
Incomplete outcome data (attrition bias)
All outcomes
Low risk 42/46 (91%) completed the study
Selective reporting (reporting bias) Low risk Data on GSK website
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Strand 2004
Methods A randomised, double-blind, comparative, multi-centre, parallel-group study over 12
weeks from May 2001 to September 2002, at 45 centres in Denmark. Run-in 2 weeks
Participants Population: 150 adults with persistent asthma
Baseline characteristics: mean age 39 years; PEF 80% predicted
Concomitant ICS used by 0% of participants
Inclusion criteria: at least 18 years old with asthma medical history ≥ 3 months, either
diurnal PEF variation 20% on at least 2 days or 1 of the following must have been
determined within 3 years before baseline: FEV reversibility > 15% in response to
bronchodilator, provocative concentration of methacholine causing a 20% fall in FEV
(PC20) < 4 mg/mL, diurnal PEF variation ≥ 20%; mean relief medication (albuterol)
use ≥ 1 episode/week; and daytime or night-time symptom score ≥ 1 at least once per
week
Exclusion criteria: upper or lower respiratory tract infection or middle ear infection
within 1 month before visit 1; lung disease other than asthma; known or suspected
other diseases or situations likely to affect outcomes or study results; known serious
cardiovascular disease, diabetes mellitus, untreated hypokalaemia, or thyrotoxicosis; use
of long-acting bronchodilators, ICS, or other long-acting asthma medication within 2
months before visit 1; use of daily oral corticosteroid treatment within 2 months of visit
1 or oral corticosteroid therapy within 1 month before the visit
Interventions • Fluticasone propionate and salmeterol 100/50 µg twice daily
• Fluticasone propionate 100 µg twice daily
Outcomes Primary efficacy variable: symptom-free days and nights
“1 patient in the fluticasone propionate/salmeterol group and 2 patients in the fluticasone
propionate group had a serious adverse event. None of these serious adverse events was
considered related to the study drug”
One death reported on the website in the fluticasone propionate/arm but no cause given
Notes Sponsored by GSK
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind
Independent Assessment of causation (de-
tection bias)
Asthma-related events
High risk Causation of SAEs not independently as-
sessed
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Strand 2004 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 126/150 completed the study
Selective reporting (reporting bias) Low risk Full data from GSK website
van Noord 2001
Methods A randomised, double-blind, double-dummy, multi-centre, placebo-controlled, parallel-
group study over 3 months from December 1997 to March 1999, at 61 centres in 13
countries. Run-in 2 weeks
Participants Population: 509 adolescents and adults (12 to 82 years) with moderate to severe asthma
Baseline characteristics: mean age 47 years; FEV 72% predicted
Concomitant ICS used by 100% of participants
Inclusion criteria: 12 years old or older with documented clinical history of reversible
airways obstruction and symptomatic on ICS therapy (beclomethasone dipropionate,
budesonide, or flunisolide at a dose of 1500 to 2000 µg/d or fluticasone propionate
750 to 1000 µg d) for at least 4 weeks before the start of the study. FEV % predicted
between 50% and 100%
During the last 7 days of the run-in period, required to have had a mean morning PEF
> 50% and < 85% of PEF measured 15 minutes after administration of 400 µg of
salbutamol at the randomisation visit, and a cumulative total symptom score (daytime
plus night-time) in the daily record card ≥ 8
Exclusion criteria: received a LABA or an oral beta -agonist with 2 weeks of the run-in
period, changed asthmamedication, had a lower respiratory tract infection in the 4weeks
preceding the run-in period, had an acute asthma exacerbation requiring hospitalisation
in the 12 weeks preceding study entry
Interventions • Fluticasone propionate and salmeterol 500/50 µg HFA twice daily via MDI
• Fluticasone propionate and salmeterol 500/50 µg HFA twice daily via Diskus
• Fluticasone propionate 500 µg CFC twice daily via MDI
Outcomes Primary efficacy variable: mean morning PEF over the 12-week treatment period
Paper reports 8 participants with SAE in fluticasone propionate/salmeterol groups and 2
on fluticasone propionate. These included 3 asthma exacerbations. Web report indicates
that 2 of these were on fluticasone propionate/salmeterol and 1 on fluticasone propionate
One death reported on fluticasone propionate/salmeterol via MDI due to leukaemia
Notes Sponsored by GSK
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
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van Noord 2001 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind, double-dummy
Independent Assessment of causation (de-
tection bias)
Asthma-related events
High risk Causation of SAEs not independently as-
sessed
Incomplete outcome data (attrition bias)
All outcomes
Low risk 447/509 (88%) completed the study
Selective reporting (reporting bias) Low risk Full data on GSK website
VESTRI 2016
Methods A randomised, double-blind,multi-centre, parallel-group study carried out over 26weeks
Participants Population: 6208 boys or girls aged 4 to 11 attending daycare or school, with persistent
asthma and a history of asthma exacerbation in the previous 12 months, with no exac-
erbation occurring during the 30 days before randomisation
Baseline characteristics: mean age was 7.6 years; 61.8% were male and 64.3% were
white
Inclusion criteria: consistent use of asthma medication during the 4 weeks before en-
rolment, and a history of 1 to 4 asthma exacerbations in the past 12 months
Exclusion criteria: history of life-threatening asthma or unstable asthma; taking high-
dose ICS or ICS/LABA; concurrent respiratory disease, respiratory infection, exercise-
induced asthma as the only asthma-related diagnosis; asthma exacerbation in previous
4 weeks or > 4 exacerbations in previous 12 months; asthma hospitalisation in previous
4 weeks or > 2 asthma hospitalisations in previous 12 months; clinically significant
uncontrolled disease; neurological or psychiatric disease or drug or alcohol abuse (in the
patient or the parent/guardian); use of investigational medication; drug allergy; severe
hypersensitivity to cow’s milk proteins; concomitant medications that could significantly
affect the course of asthma; use of potent cytochrome P450 3A4 inhibitors; affiliation
with investigator’s site; child in care
Interventions • Fluticasone propionate (100 or 250 µg) twice daily via Diskus
• Fluticasone propionate and salmeterol (a fixed-dose combination of 100 µg fluticasone
propionate plus salmeterol at a dose of 50 µg or a fixed-dose combination of fluticasone
at a dose of 250 µg plus salmeterol at a dose of 50 µg) twice daily via Diskus
Outcomes Primary endpoint: first serious asthma-related event (defined as hospitalisation, intu-
bation, or death)
Notes Sponsored by GSK
Risk of bias
Bias Authors’ judgement Support for judgement
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VESTRI 2016 (Continued)
Random sequence generation (selection
bias)
Low risk Central randomisation procedure
Allocation concealment (selection bias) Low risk Centralised Registration and Medication
Ordering System (RAMOS-NG)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind with respect to salmeterol
but not to dose of ICS
Independent Assessment of causation (de-
tection bias)
Asthma-related events
Low risk Independent adjudication committee for
asthma outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk Only 2 children in each group failed to
complete the trial
Selective reporting (reporting bias) Low risk Datawere extracted for all review outcomes
Wallin 2003
Methods A randomised, double-blind, parallel-group study over 12 weeks. Run-in 2 to 4 weeks
Participants Population: 56 patients, previously not well controlled on ICS
Baseline characteristics: mean age 42 years; FEV 88% predicted
Concomitant ICS used by 100% of participants
Inclusion criteria: asthma symptoms on ≥ 6 days or ≥ 4 nights; need for rescue salbu-
tamol on ≥ 6 days or ≥ 4 nights; > 20% variation between AM and PM PEF on ≥ 4
days; pulmonary function, ≥ 1 of the following: ≥ 15% increase in FEV 15 minutes
after inhalation of 400 to 800 µg salbutamol, ≥ 15% increase in PEF 15 minutes af-
ter inhalation of 400 to 800 µg salbutamol compared to mean AM PEF values in the
preceding week, > 20% variation between AM and PM PEF on ≥ 4 consecutive days,
PC20 methacholine < 4 mg/mL
Exclusion criteria: not reported as such
Interventions • Fluticasone propionate 200 + salmeterol 50 µg twice daily
• Fluticasone propionate 200 µg twice daily
• Fluticasone propionate 500 µg twice daily (not used in this review)
Delivery was Diskus device
Outcomes Primary endpoints: submucosal eosinophil and mast cell counts
No information in the paper, but no SAEs reported on the GSK website
Notes Sponsored by GSK
Risk of bias
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Wallin 2003 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind
Independent Assessment of causation (de-
tection bias)
Asthma-related events
High risk Causation of SAEs not independently as-
sessed
Incomplete outcome data (attrition bias)
All outcomes
Low risk 46/56 (82%) completed the study
Selective reporting (reporting bias) Low risk SAE data on GSK website
ACQ: Asthma Control Questionnaire; AE: adverse event; ATS: American Thoracic Society; AUC: area under the curve; BDP: be-
clomethasone dipropionate; BHR: bronchial hyperresponsiveness; BUD: budesonide; CFC: chlorofluorocarbon; DPI: dry powder
inhaler; DRC: daily record card; ECG: electrocardiogram; ECP: eosinophil cationic protein; FEV : forced expiratory volume in one
second; GSK: GlaxoSmithKline; HFA: hydrofluoroalkane; ICS: inhaled corticosteroid; LABA: long-acting beta -agonist; LTRA:
leukotriene receptor antagonist; MAD: minimum acceptable dose; MDI: metered dose inhaler; NCT: National Clinical Trial; OCS:
oral corticosteroid; PC20: concentration needed to produce a 20% fall in FEV ; PEF: peak expiratory flow; SABA: short-acting
beta -agonist; SAE: serious adverse event.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Adinoff 1998 Not randomised to ICS
Adolfsson 2005 Dose-response study
Bateman 1998 Device comparison
Bateman 2006 Higher-dose ICS in control arm
Bateman 2011 ICS was not a randomised treatment
107Inhaled steroids with and without regular salmeterol for asthma: serious adverse events (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Baumgarten 2002 4-week study
Bergmann 2004 Higher-dose ICS in control arm
Bjermer 2000 Salmeterol vs LTRA
Bjermer 2003 Salmeterol vs LTRA
Bleecker 2006 Salmeterol vs salmeterol/fluticasone
Bleecker 2007 Review
Bleecker 2008 Salmeterol vs LTRA
Bracamonte 2005 Device comparison
Busse 2006 Cross-over study
Calhoun 2001 Salmeterol vs LTRA
Chapman 1999 Device comparison
Condemi 1999 Higher-dose ICS in control arm
Cook 1998 Higher-dose ICS in control arm
D’Urzo 2001 6-week duration
Del 2001 Salmeterol vs LTRA
Deykin 2007 Comparison between different combined inhalers
Didier 1997 No ICS control arm
Dorinsky 2004 Comparison between different combined inhalers
Faurschou 1994 3-week cross-over study
Fish 2001 Salmeterol vs LTRA
Fujimoto 2006 Salmeterol vs tulobuterol
GlaxoSmithKline 2004 Higher-dose ICS in control arm
GlaxoSmithKline 2005a Salmeterol vs LTRA
GlaxoSmithKline 2005b Higher-dose ICS in control arm
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GlaxoSmithKline 2005c Device comparison
GlaxoSmithKline 2005d Higher-dose ICS in control arm
GlaxoSmithKline 2005e Cross-over study
Greening 1994 Higher-dose ICS in control arm
Grutters 1999 8-week duration
House 2004 2-week duration
Ilowite 2004 Salmeterol vs LTRA
Isabelle 2001 Device comparison
Jarjour 2006 FSC compared to higher-dose FP
Johansson 2001 Different ICS in control arm
Juniper 2002 Different ICS in control arm
Kelsen 1999 Higher-dose ICS in control arm
Kerstjens 2015 ICS was not a randomised treatment
Koopmans 2005 Single-dose study
Lazarus 2001 Not randomised to ICS
Lemanske 2001 Not randomised to ICS
Lotvall 2006 Single-dose study
Lotvall 2014 ICS was not a randomised treatment
Lundback 2000 Different ICS in control arm
Martinat 2003 Device comparison
Murray 1999 Higher-dose ICS in control arm
Nan 2004 Different ICS in control arm
Nathan 2001 Review of SAS30003 and SAS30004
NCT01172808 ICS was not a randomised treatment
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NCT01172821 ICS was not a randomised treatment
Nelson 2000 Salmeterol vs LTRA
Nelson 2001 Salmeterol vs LTRA
O’Byrne 2005 Different ICS in control arm
O’Connor 2004 Salmeterol vs LTRA
Pauwels 1998 Different ICS in control arm and salmeterol given in both groups
Pearlman 1999 4-week study
Peters 2007 Higher-dose ICS in control arm
Reddel 2010 Down-titration study designed to allow uneven fluticasone dose between the 2 arms of the trial
Ringdal 2003 Salmeterol vs LTRA
Rosenthal 1999 No randomisation to ICS
Russell 1995 No randomisation to ICS
SAM30002 FSC compared to budesonide at higher dose
SAM30013 FSC compared with higher-dose fluticasone
SAM40116 Patients with asthma and COPD given higher-dose fluticasone
SAS30015 FSC compared to BDP
Schermer 2007 Higher-dose ICS in control arm
Schlosser 1998 Device comparison
Scott 2005 Device comparison
SLGA5021 FSC comparison with higher-dose fluticasone
Tonnel 2004 Device comparison in acute asthma
Van den 2000 Device comparison
Van Noord 1999 Higher-dose ICS in control arm
Vermetten 1999 Higher-dose ICS in control arm
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Woolcock 1996 Higher-dose ICS in control arm
You-Ning 2005 Device comparison
Zhong 2002 Device comparison
Zhong 2005 Comparison to different ICS in control arm
BDP: beclomethasone dipropionate; COPD: chronic obstructive pulmonary disease; FP: fluticasone propionate; FSC: fluticasone
propionate/salmeterol; ICS: inhaled corticosteroid; LTRA: leukotriene receptor antagonist.
Characteristics of ongoing studies [ordered by study ID]
NCT02980133
Trial name or title A 12-week, randomized, double-blind, placebo-controlled, efficacy and safety study of fluticasone propionate
multidose dry powder inhaler compared with fluticasone propionate/salmeterol multidose dry powder inhaler
in patients aged 4 through 11 years with persistent asthma
Methods Parallel-arm randomised trial
Participants Children aged 4 to 11 with persistent asthma
Interventions Fluticasone propionate/salmeterol multidose dry powder inhaler
Outcomes Fluticasone propionate multidose dry powder inhaler
Starting date 16 December 2016
Contact information Teva
Notes
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D A T A A N D A N A L Y S E S
Comparison 1. Regular salmeterol in addition to regular inhaled corticosteroids
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All-cause mortality 49 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
1.1 Adults and adolescents 41 27951 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.80 [0.36, 1.78]
1.2 Children 8 8453 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 All-cause non-fatal SAE 49 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
2.1 Adults and adolescents 41 27951 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.14 [0.97, 1.33]
2.2 Children 8 8453 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.04 [0.73, 1.48]
3 All-cause SAE (fatal and
non-fatal)
49 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
3.1 Adults and adolescents 41 27951 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.12 [0.96, 1.31]
3.2 Children 8 8453 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.04 [0.73, 1.48]
4 Asthma-related SAE 49 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
4.1 Adults and adolescents 41 27951 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.15 [0.83, 1.59]
4.2 Children 8 8453 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.25 [0.72, 2.16]
Comparison 2. Risk difference meta-analysis: regular salmeterol in addition to regular ICS
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All-cause mortality 49 Risk Difference (M-H, Fixed, 95% CI) Subtotals only
1.1 Adults and adolescents 41 27951 Risk Difference (M-H, Fixed, 95% CI) -0.00 [-0.00, 0.00]
1.2 Children 8 8453 Risk Difference (M-H, Fixed, 95% CI) 0.0 [-0.00, 0.00]
2 All-cause non-fatal SAE 49 Risk Difference (M-H, Fixed, 95% CI) Subtotals only
2.1 Adults and adolescents 41 27951 Risk Difference (M-H, Fixed, 95% CI) 0.00 [-0.00, 0.01]
2.2 Children 8 8453 Risk Difference (M-H, Fixed, 95% CI) 0.00 [-0.00, 0.01]
3 All-cause SAE (fatal and
non-fatal)
49 Risk Difference (M-H, Fixed, 95% CI) Subtotals only
3.1 Adults and adolescents 41 27951 Risk Difference (M-H, Fixed, 95% CI) 0.00 [-0.00, 0.01]
3.2 Children 8 8453 Risk Difference (M-H, Fixed, 95% CI) 0.00 [-0.00, 0.01]
4 Asthma-related SAE 49 Risk Difference (M-H, Fixed, 95% CI) Subtotals only
4.1 Adults and adolescents 41 27951 Risk Difference (M-H, Fixed, 95% CI) 0.00 [-0.00, 0.00]
4.2 Children 8 8453 Risk Difference (M-H, Fixed, 95% CI) 0.00 [-0.00, 0.00]
5 Asthma-related mortality 49 Risk Difference (M-H, Fixed, 95% CI) Subtotals only
5.1 Adults and adolescents 41 27951 Risk Difference (M-H, Fixed, 95% CI) 0.0 [-0.00, 0.00]
5.2 Children 8 8453 Risk Difference (M-H, Fixed, 95% CI) 0.0 [-0.00, 0.00]
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Analysis 1.1. Comparison 1 Regular salmeterol in addition to regular inhaled corticosteroids, Outcome 1
All-cause mortality.
Review: Inhaled steroids with and without regular salmeterol for asthma: serious adverse events
Comparison: 1 Regular salmeterol in addition to regular inhaled corticosteroids
Outcome: 1 All-cause mortality
Study or subgroup Salmeterol and ICS ICS
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Adults and adolescents
Aubier 1999 1/338 0/165 3.7 % 4.43 [ 0.07, 287.95 ]
AUSTRI 2016 3/5834 6/5845 37.9 % 0.51 [ 0.14, 1.90 ]
Bailey 2008 0/239 0/236 Not estimable
Bateman 2001 0/333 0/165 Not estimable
Bernstein 2017 0/501 0/499 Not estimable
GOAL 2004 3/1709 2/1707 21.0 % 1.49 [ 0.26, 8.61 ]
Godard 2008 0/159 0/159 Not estimable
Ind 2003 1/171 0/160 4.2 % 6.93 [ 0.14, 349.94 ]
Katial 2011 0/306 0/315 Not estimable
Kavuru 2000 0/92 0/90 Not estimable
Kerwin 2011 1/310 1/318 8.4 % 1.03 [ 0.06, 16.44 ]
Koenig 2008 0/156 1/156 4.2 % 0.14 [ 0.00, 6.82 ]
Koopmans 2006 0/27 0/27 Not estimable
Lundback 2006 0/95 0/92 Not estimable
Mansfield 2017 0/338 0/335 Not estimable
Murray 2004 0/88 0/89 Not estimable
Nathan 2006 0/94 0/91 Not estimable
Nelson 2003 0/95 0/97 Not estimable
Pearlman 2004 0/92 0/89 Not estimable
Raphael 2017 0/254 0/258 Not estimable
Renzi 2010 0/262 1/270 4.2 % 0.14 [ 0.00, 7.03 ]
Rojas 2007 0/180 0/182 Not estimable
SAM30007 0/29 0/32 Not estimable
SAM40004 0/42 0/21 Not estimable
0.001 0.01 0.1 1 10 100 1000
Favours Salmeterol % ICS Favours ICS
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Study or subgroup Salmeterol and ICS ICS
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
SAM40008 0/93 0/93 Not estimable
SAM40031 0/41 0/41 Not estimable
SAM40065 0/150 0/150 Not estimable
SAS30022 0/210 0/212 Not estimable
SAS30023 0/151 0/155 Not estimable
SAS40036 0/172 0/159 Not estimable
SAS40037 0/161 0/161 Not estimable
SAS40068 0/262 1/270 4.2 % 0.14 [ 0.00, 7.03 ]
SFA103153 0/239 0/236 Not estimable
SFCF4026 0/159 0/159 Not estimable
Shapiro 2000 0/84 0/84 Not estimable
Sher 2017 1/288 0/291 4.2 % 7.47 [ 0.15, 376.30 ]
Slankard 2016 0/32 0/29 Not estimable
SLGF75 0/14 0/17 Not estimable
Strand 2004 0/78 1/72 4.2 % 0.12 [ 0.00, 6.29 ]
van Noord 2001 1/337 0/172 3.8 % 4.53 [ 0.07, 285.45 ]
Wallin 2003 0/18 0/19 Not estimable
Subtotal (95% CI) 14233 13718 100.0 % 0.80 [ 0.36, 1.78 ]
Total events: 11 (Salmeterol and ICS), 13 (ICS)
Heterogeneity: Chi2 = 7.86, df = 10 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.55 (P = 0.58)
2 Children
Li 2010 0/173 0/177 Not estimable
Malone 2005 0/101 0/102 Not estimable
MASCOT 2013 0/23 0/19 Not estimable
NCT01192178 0/171 0/168 Not estimable
Ploszczuk 2014 0/169 0/172 Not estimable
SAM40012 0/181 0/181 Not estimable
SAS30021 0/304 0/304 Not estimable
VESTRI 2016 0/3107 0/3101 Not estimable
Subtotal (95% CI) 4229 4224 Not estimable
Total events: 0 (Salmeterol and ICS), 0 (ICS)
Heterogeneity: not applicable
0.001 0.01 0.1 1 10 100 1000
Favours Salmeterol % ICS Favours ICS
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Study or subgroup Salmeterol and ICS ICS
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Test for overall effect: not applicable
0.001 0.01 0.1 1 10 100 1000
Favours Salmeterol % ICS Favours ICS
Analysis 1.2. Comparison 1 Regular salmeterol in addition to regular inhaled corticosteroids, Outcome 2
All-cause non-fatal SAE.
Review: Inhaled steroids with and without regular salmeterol for asthma: serious adverse events
Comparison: 1 Regular salmeterol in addition to regular inhaled corticosteroids
Outcome: 2 All-cause non-fatal SAE
Study or subgroup Salmeterol and ICS ICS
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Adults and adolescents
Aubier 1999 10/338 5/165 2.2 % 0.98 [ 0.33, 2.91 ]
AUSTRI 2016 131/5834 119/5845 41.2 % 1.11 [ 0.86, 1.42 ]
Bailey 2008 6/239 11/236 2.8 % 0.54 [ 0.20, 1.41 ]
Bateman 2001 6/333 3/165 1.3 % 0.99 [ 0.24, 4.02 ]
Bernstein 2017 4/501 5/499 1.5 % 0.80 [ 0.21, 2.96 ]
GOAL 2004 64/1709 51/1707 18.7 % 1.26 [ 0.87, 1.83 ]
Godard 2008 3/159 1/159 0.7 % 2.74 [ 0.38, 19.67 ]
Ind 2003 9/171 5/160 2.3 % 1.69 [ 0.58, 4.93 ]
Katial 2011 14/306 10/315 3.9 % 1.46 [ 0.64, 3.29 ]
Kavuru 2000 2/92 1/90 0.5 % 1.92 [ 0.20, 18.69 ]
Kerwin 2011 6/310 8/318 2.3 % 0.77 [ 0.27, 2.21 ]
Koenig 2008 1/156 1/156 0.3 % 1.00 [ 0.06, 16.06 ]
Koopmans 2006 0/27 1/27 0.2 % 0.14 [ 0.00, 6.82 ]
0.002 0.1 1 10 500
Favours Salmeterol % ICS Favours ICS
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Study or subgroup Salmeterol and ICS ICS
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Lundback 2006 4/95 3/92 1.1 % 1.30 [ 0.29, 5.86 ]
Mansfield 2017 24/338 20/335 6.9 % 1.20 [ 0.65, 2.22 ]
Murray 2004 0/88 0/89 Not estimable
Nathan 2006 0/94 0/91 Not estimable
Nelson 2003 2/95 0/97 0.3 % 7.63 [ 0.47, 122.85 ]
Pearlman 2004 0/92 1/89 0.2 % 0.13 [ 0.00, 6.60 ]
Raphael 2017 1/254 1/258 0.3 % 1.02 [ 0.06, 16.29 ]
Renzi 2010 4/262 2/270 1.0 % 2.02 [ 0.40, 10.09 ]
Rojas 2007 1/180 2/182 0.5 % 0.52 [ 0.05, 5.00 ]
SAM30007 0/29 1/32 0.2 % 0.15 [ 0.00, 7.53 ]
SAM40004 1/42 1/21 0.3 % 0.47 [ 0.02, 9.04 ]
SAM40008 3/93 0/93 0.5 % 7.55 [ 0.78, 73.51 ]
SAM40031 2/41 3/41 0.8 % 0.66 [ 0.11, 3.96 ]
SAM40065 2/150 3/150 0.8 % 0.67 [ 0.11, 3.89 ]
SAS30022 4/210 0/212 0.7 % 7.57 [ 1.06, 54.11 ]
SAS30023 0/151 1/155 0.2 % 0.14 [ 0.00, 7.00 ]
SAS40036 0/172 0/159 Not estimable
SAS40037 1/161 2/161 0.5 % 0.51 [ 0.05, 4.95 ]
SAS40068 4/262 2/270 1.0 % 2.02 [ 0.40, 10.09 ]
SFA103153 6/239 11/236 2.8 % 0.54 [ 0.20, 1.41 ]
SFCF4026 3/159 1/159 0.7 % 2.74 [ 0.38, 19.67 ]
Shapiro 2000 0/84 1/84 0.2 % 0.14 [ 0.00, 6.82 ]
Sher 2017 5/288 2/291 1.2 % 2.40 [ 0.54, 10.65 ]
Slankard 2016 0/32 0/29 Not estimable
SLGF75 0/14 0/17 Not estimable
Strand 2004 1/78 2/72 0.5 % 0.47 [ 0.05, 4.58 ]
van Noord 2001 8/337 2/172 1.5 % 1.87 [ 0.50, 7.03 ]
Wallin 2003 0/18 0/19 Not estimable
Subtotal (95% CI) 14233 13718 100.0 % 1.14 [ 0.97, 1.33 ]
Total events: 332 (Salmeterol and ICS), 282 (ICS)
Heterogeneity: Chi2 = 27.28, df = 34 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 1.55 (P = 0.12)
0.002 0.1 1 10 500
Favours Salmeterol % ICS Favours ICS
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Study or subgroup Salmeterol and ICS ICS
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
2 Children
Li 2010 1/173 0/177 0.8 % 7.56 [ 0.15, 381.19 ]
Malone 2005 0/101 0/102 Not estimable
MASCOT 2013 3/23 2/19 3.6 % 1.26 [ 0.20, 8.07 ]
NCT01192178 2/171 1/168 2.4 % 1.92 [ 0.20, 18.59 ]
Ploszczuk 2014 0/169 1/172 0.8 % 0.14 [ 0.00, 6.94 ]
SAM40012 2/181 1/181 2.4 % 1.95 [ 0.20, 18.91 ]
SAS30021 1/304 3/304 3.2 % 0.37 [ 0.05, 2.61 ]
VESTRI 2016 56/3107 54/3101 86.8 % 1.04 [ 0.71, 1.51 ]
Subtotal (95% CI) 4229 4224 100.0 % 1.04 [ 0.73, 1.48 ]
Total events: 65 (Salmeterol and ICS), 62 (ICS)
Heterogeneity: Chi2 = 3.71, df = 6 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.22 (P = 0.83)
Test for subgroup differences: Chi2 = 0.20, df = 1 (P = 0.65), I2 =0.0%
0.002 0.1 1 10 500
Favours Salmeterol % ICS Favours ICS
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Analysis 1.3. Comparison 1 Regular salmeterol in addition to regular inhaled corticosteroids, Outcome 3
All-cause SAE (fatal and non-fatal).
Review: Inhaled steroids with and without regular salmeterol for asthma: serious adverse events
Comparison: 1 Regular salmeterol in addition to regular inhaled corticosteroids
Outcome: 3 All-cause SAE (fatal and non-fatal)
Study or subgroup Salmeterol and ICS ICS
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Adults and adolescents
Aubier 1999 11/338 5/165 2.2 % 1.08 [ 0.37, 3.10 ]
AUSTRI 2016 134/5834 125/5845 41.1 % 1.08 [ 0.84, 1.38 ]
Bailey 2008 6/239 11/236 2.7 % 0.54 [ 0.20, 1.41 ]
Bateman 2001 6/333 3/165 1.3 % 0.99 [ 0.24, 4.02 ]
Bernstein 2017 4/501 5/499 1.4 % 0.80 [ 0.21, 2.96 ]
GOAL 2004 67/1709 53/1707 18.8 % 1.27 [ 0.88, 1.83 ]
Godard 2008 3/159 1/159 0.6 % 2.74 [ 0.38, 19.67 ]
Ind 2003 10/171 5/160 2.3 % 1.87 [ 0.67, 5.27 ]
Katial 2011 14/306 10/315 3.8 % 1.46 [ 0.64, 3.29 ]
Kavuru 2000 2/92 1/90 0.5 % 1.92 [ 0.20, 18.69 ]
Kerwin 2011 7/310 9/318 2.5 % 0.79 [ 0.29, 2.14 ]
Koenig 2008 1/156 2/156 0.5 % 0.51 [ 0.05, 4.95 ]
Koopmans 2006 0/27 1/27 0.2 % 0.14 [ 0.00, 6.82 ]
Lundback 2006 4/95 3/92 1.1 % 1.30 [ 0.29, 5.86 ]
Mansfield 2017 24/338 20/335 6.7 % 1.20 [ 0.65, 2.22 ]
Murray 2004 0/88 0/89 Not estimable
Nathan 2006 0/94 0/91 Not estimable
Nelson 2003 2/95 0/97 0.3 % 7.63 [ 0.47, 122.85 ]
Pearlman 2004 0/92 1/89 0.2 % 0.13 [ 0.00, 6.60 ]
Raphael 2017 1/254 1/258 0.3 % 1.02 [ 0.06, 16.29 ]
Renzi 2010 4/262 3/270 1.1 % 1.38 [ 0.31, 6.11 ]
Rojas 2007 1/180 2/182 0.5 % 0.52 [ 0.05, 5.00 ]
SAM30007 0/29 1/32 0.2 % 0.15 [ 0.00, 7.53 ]
SAM40004 1/42 1/21 0.3 % 0.47 [ 0.02, 9.04 ]
0.002 0.1 1 10 500
Favours Salmeterol % ICS Favours ICS
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Study or subgroup Salmeterol and ICS ICS
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
SAM40008 3/93 0/93 0.5 % 7.55 [ 0.78, 73.51 ]
SAM40031 2/41 3/41 0.8 % 0.66 [ 0.11, 3.96 ]
SAM40065 2/150 3/150 0.8 % 0.67 [ 0.11, 3.89 ]
SAS30022 4/210 0/212 0.6 % 7.57 [ 1.06, 54.11 ]
SAS30023 0/151 1/155 0.2 % 0.14 [ 0.00, 7.00 ]
SAS40036 0/172 0/159 Not estimable
SAS40037 1/161 2/161 0.5 % 0.51 [ 0.05, 4.95 ]
SAS40068 4/262 3/270 1.1 % 1.38 [ 0.31, 6.11 ]
SFA103153 6/239 11/236 2.7 % 0.54 [ 0.20, 1.41 ]
SFCF4026 3/159 1/159 0.6 % 2.74 [ 0.38, 19.67 ]
Shapiro 2000 0/84 1/84 0.2 % 0.14 [ 0.00, 6.82 ]
Sher 2017 6/288 2/291 1.3 % 2.78 [ 0.69, 11.21 ]
Slankard 2016 0/32 0/29 Not estimable
SLGF75 0/14 0/17 Not estimable
Strand 2004 1/78 3/72 0.6 % 0.33 [ 0.05, 2.41 ]
van Noord 2001 9/337 2/172 1.6 % 2.04 [ 0.58, 7.20 ]
Wallin 2003 0/18 0/19 Not estimable
Subtotal (95% CI) 14233 13718 100.0 % 1.12 [ 0.96, 1.31 ]
Total events: 343 (Salmeterol and ICS), 295 (ICS)
Heterogeneity: Chi2 = 29.13, df = 34 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 1.41 (P = 0.16)
2 Children
Li 2010 1/173 0/177 0.8 % 7.56 [ 0.15, 381.19 ]
Malone 2005 0/101 0/102 Not estimable
MASCOT 2013 3/23 2/19 3.6 % 1.26 [ 0.20, 8.07 ]
NCT01192178 2/171 1/168 2.4 % 1.92 [ 0.20, 18.59 ]
Ploszczuk 2014 0/169 1/172 0.8 % 0.14 [ 0.00, 6.94 ]
SAM40012 2/181 1/181 2.4 % 1.95 [ 0.20, 18.91 ]
SAS30021 1/304 3/304 3.2 % 0.37 [ 0.05, 2.61 ]
VESTRI 2016 56/3107 54/3101 86.8 % 1.04 [ 0.71, 1.51 ]
Subtotal (95% CI) 4229 4224 100.0 % 1.04 [ 0.73, 1.48 ]
Total events: 65 (Salmeterol and ICS), 62 (ICS)
Heterogeneity: Chi2 = 3.71, df = 6 (P = 0.72); I2 =0.0%
0.002 0.1 1 10 500
Favours Salmeterol % ICS Favours ICS
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Study or subgroup Salmeterol and ICS ICS
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Test for overall effect: Z = 0.22 (P = 0.83)
Test for subgroup differences: Chi2 = 0.15, df = 1 (P = 0.70), I2 =0.0%
0.002 0.1 1 10 500
Favours Salmeterol % ICS Favours ICS
Analysis 1.4. Comparison 1 Regular salmeterol in addition to regular inhaled corticosteroids, Outcome 4
Asthma-related SAE.
Review: Inhaled steroids with and without regular salmeterol for asthma: serious adverse events
Comparison: 1 Regular salmeterol in addition to regular inhaled corticosteroids
Outcome: 4 Asthma-related SAE
Study or subgroup Salmeterol and ICS ICS
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Adults and adolescents
Aubier 1999 1/338 0/165 0.6 % 4.43 [ 0.07, 287.95 ]
AUSTRI 2016 34/5834 33/5845 46.1 % 1.03 [ 0.64, 1.67 ]
Bailey 2008 2/239 2/236 2.8 % 0.99 [ 0.14, 7.05 ]
Bateman 2001 5/333 0/165 3.0 % 4.52 [ 0.70, 29.29 ]
Bernstein 2017 0/501 0/499 Not estimable
GOAL 2004 8/1709 12/1707 13.8 % 0.67 [ 0.28, 1.61 ]
Godard 2008 0/159 0/159 Not estimable
Ind 2003 1/171 3/160 2.7 % 0.34 [ 0.05, 2.44 ]
Katial 2011 3/306 0/315 2.1 % 7.66 [ 0.79, 73.92 ]
Kavuru 2000 0/92 0/90 Not estimable
Kerwin 2011 1/310 0/318 0.7 % 7.58 [ 0.15, 382.24 ]
Koenig 2008 1/156 0/156 0.7 % 7.39 [ 0.15, 372.38 ]
Koopmans 2006 0/27 0/27 Not estimable
0.001 0.01 0.1 1 10 100 1000
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Study or subgroup Salmeterol and ICS ICS
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Lundback 2006 0/95 0/92 Not estimable
Mansfield 2017 14/338 10/335 16.0 % 1.40 [ 0.62, 3.16 ]
Murray 2004 0/88 0/89 Not estimable
Nathan 2006 0/94 0/91 Not estimable
Nelson 2003 1/95 0/97 0.7 % 7.55 [ 0.15, 380.39 ]
Pearlman 2004 0/92 0/89 Not estimable
Raphael 2017 1/254 1/258 1.4 % 1.02 [ 0.06, 16.29 ]
Renzi 2010 0/262 0/270 Not estimable
Rojas 2007 0/180 0/182 Not estimable
SAM30007 0/29 1/32 0.7 % 0.15 [ 0.00, 7.53 ]
SAM40004 0/42 0/21 Not estimable
SAM40008 1/93 0/93 0.7 % 7.39 [ 0.15, 372.38 ]
SAM40031 0/41 0/41 Not estimable
SAM40065 0/150 1/150 0.7 % 0.14 [ 0.00, 6.82 ]
SAS30022 0/210 0/212 Not estimable
SAS30023 0/151 0/155 Not estimable
SAS40036 0/172 0/159 Not estimable
SAS40037 0/161 0/161 Not estimable
SAS40068 0/262 0/270 Not estimable
SFA103153 2/239 2/236 2.8 % 0.99 [ 0.14, 7.05 ]
SFCF4026 0/159 0/159 Not estimable
Shapiro 2000 0/84 1/84 0.7 % 0.14 [ 0.00, 6.82 ]
Sher 2017 2/288 0/291 1.4 % 7.49 [ 0.47, 120.08 ]
Slankard 2016 0/32 0/29 Not estimable
SLGF75 0/14 0/17 Not estimable
Strand 2004 1/78 0/72 0.7 % 6.84 [ 0.14, 345.90 ]
van Noord 2001 2/337 1/172 1.9 % 1.02 [ 0.09, 11.22 ]
Wallin 2003 0/18 0/19 Not estimable
Subtotal (95% CI) 14233 13718 100.0 % 1.15 [ 0.83, 1.59 ]
Total events: 80 (Salmeterol and ICS), 67 (ICS)
Heterogeneity: Chi2 = 17.94, df = 19 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 0.82 (P = 0.41)
0.001 0.01 0.1 1 10 100 1000
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Study or subgroup Salmeterol and ICS ICS
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
2 Children
Li 2010 0/173 0/177 Not estimable
Malone 2005 0/101 0/102 Not estimable
MASCOT 2013 1/23 1/19 3.7 % 0.82 [ 0.05, 13.76 ]
NCT01192178 1/171 0/168 1.9 % 7.26 [ 0.14, 365.96 ]
Ploszczuk 2014 0/169 0/172 Not estimable
SAM40012 0/181 0/181 Not estimable
SAS30021 0/304 1/304 1.9 % 0.14 [ 0.00, 6.82 ]
VESTRI 2016 27/3107 21/3101 92.4 % 1.28 [ 0.73, 2.27 ]
Subtotal (95% CI) 4229 4224 100.0 % 1.25 [ 0.72, 2.16 ]
Total events: 29 (Salmeterol and ICS), 23 (ICS)
Heterogeneity: Chi2 = 2.10, df = 3 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 0.80 (P = 0.42)
Test for subgroup differences: Chi2 = 0.07, df = 1 (P = 0.79), I2 =0.0%
0.001 0.01 0.1 1 10 100 1000
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Analysis 2.1. Comparison 2 Risk difference meta-analysis: regular salmeterol in addition to regular ICS,
Outcome 1 All-cause mortality.
Review: Inhaled steroids with and without regular salmeterol for asthma: serious adverse events
Comparison: 2 Risk difference meta-analysis: regular salmeterol in addition to regular ICS
Outcome: 1 All-cause mortality
Study or subgroup Salmeterol and ICS ICS
Risk
Difference Weight
Risk
Difference
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Adults and adolescents
Aubier 1999 1/338 0/165 1.6 % 0.00 [ -0.01, 0.01 ]
AUSTRI 2016 3/5834 6/5845 42.1 % 0.00 [ 0.00, 0.00 ]
Bailey 2008 0/239 0/236 1.7 % 0.0 [ -0.01, 0.01 ]
Bateman 2001 0/333 0/165 1.6 % 0.0 [ -0.01, 0.01 ]
Bernstein 2017 0/501 0/499 3.6 % 0.0 [ 0.00, 0.00 ]
GOAL 2004 3/1709 2/1707 12.3 % 0.00 [ 0.00, 0.00 ]
Godard 2008 0/159 0/159 1.1 % 0.0 [ -0.01, 0.01 ]
Ind 2003 1/171 0/160 1.2 % 0.01 [ -0.01, 0.02 ]
Katial 2011 0/306 0/315 2.2 % 0.0 [ -0.01, 0.01 ]
Kavuru 2000 0/92 0/90 0.7 % 0.0 [ -0.02, 0.02 ]
Kerwin 2011 1/310 1/318 2.3 % 0.00 [ -0.01, 0.01 ]
Koenig 2008 0/156 1/156 1.1 % -0.01 [ -0.02, 0.01 ]
Koopmans 2006 0/27 0/27 0.2 % 0.0 [ -0.07, 0.07 ]
Lundback 2006 0/95 0/92 0.7 % 0.0 [ -0.02, 0.02 ]
Mansfield 2017 0/338 0/335 2.4 % 0.0 [ -0.01, 0.01 ]
Murray 2004 0/88 0/89 0.6 % 0.0 [ -0.02, 0.02 ]
Nathan 2006 0/94 0/91 0.7 % 0.0 [ -0.02, 0.02 ]
Nelson 2003 0/95 0/97 0.7 % 0.0 [ -0.02, 0.02 ]
Pearlman 2004 0/92 0/89 0.7 % 0.0 [ -0.02, 0.02 ]
Raphael 2017 0/254 0/258 1.8 % 0.0 [ -0.01, 0.01 ]
Renzi 2010 0/262 1/270 1.9 % 0.00 [ -0.01, 0.01 ]
Rojas 2007 0/180 0/182 1.3 % 0.0 [ -0.01, 0.01 ]
SAM30007 0/29 0/32 0.2 % 0.0 [ -0.06, 0.06 ]
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Study or subgroup Salmeterol and ICS ICS
Risk
Difference Weight
Risk
Difference
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
SAM40004 0/42 0/21 0.2 % 0.0 [ -0.07, 0.07 ]
SAM40008 0/93 0/93 0.7 % 0.0 [ -0.02, 0.02 ]
SAM40031 0/41 0/41 0.3 % 0.0 [ -0.05, 0.05 ]
SAM40065 0/150 0/150 1.1 % 0.0 [ -0.01, 0.01 ]
SAS30022 0/210 0/212 1.5 % 0.0 [ -0.01, 0.01 ]
SAS30023 0/151 0/155 1.1 % 0.0 [ -0.01, 0.01 ]
SAS40036 0/172 0/159 1.2 % 0.0 [ -0.01, 0.01 ]
SAS40037 0/161 0/161 1.2 % 0.0 [ -0.01, 0.01 ]
SAS40068 0/262 1/270 1.9 % 0.00 [ -0.01, 0.01 ]
SFA103153 0/239 0/236 1.7 % 0.0 [ -0.01, 0.01 ]
SFCF4026 0/159 0/159 1.1 % 0.0 [ -0.01, 0.01 ]
Shapiro 2000 0/84 0/84 0.6 % 0.0 [ -0.02, 0.02 ]
Sher 2017 1/288 0/291 2.1 % 0.00 [ -0.01, 0.01 ]
Slankard 2016 0/32 0/29 0.2 % 0.0 [ -0.06, 0.06 ]
SLGF75 0/14 0/17 0.1 % 0.0 [ -0.12, 0.12 ]
Strand 2004 0/78 1/72 0.5 % -0.01 [ -0.05, 0.02 ]
van Noord 2001 1/337 0/172 1.6 % 0.00 [ -0.01, 0.01 ]
Wallin 2003 0/18 0/19 0.1 % 0.0 [ -0.10, 0.10 ]
Subtotal (95% CI) 14233 13718 100.0 % 0.00 [ 0.00, 0.00 ]
Total events: 11 (Salmeterol and ICS), 13 (ICS)
Heterogeneity: Chi2 = 4.43, df = 40 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.34 (P = 0.73)
2 Children
Li 2010 0/173 0/177 4.1 % 0.0 [ -0.01, 0.01 ]
Malone 2005 0/101 0/102 2.4 % 0.0 [ -0.02, 0.02 ]
MASCOT 2013 0/23 0/19 0.5 % 0.0 [ -0.09, 0.09 ]
NCT01192178 0/171 0/168 4.0 % 0.0 [ -0.01, 0.01 ]
Ploszczuk 2014 0/169 0/172 4.0 % 0.0 [ -0.01, 0.01 ]
SAM40012 0/181 0/181 4.3 % 0.0 [ -0.01, 0.01 ]
SAS30021 0/304 0/304 7.2 % 0.0 [ -0.01, 0.01 ]
VESTRI 2016 0/3107 0/3101 73.4 % 0.0 [ 0.00, 0.00 ]
Subtotal (95% CI) 4229 4224 100.0 % 0.0 [ 0.00, 0.00 ]
Total events: 0 (Salmeterol and ICS), 0 (ICS)
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Study or subgroup Salmeterol and ICS ICS
Risk
Difference Weight
Risk
Difference
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heterogeneity: Chi2 = 0.0, df = 7 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Chi2 = 0.05, df = 1 (P = 0.83), I2 =0.0%
-0.1 -0.05 0 0.05 0.1
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Analysis 2.2. Comparison 2 Risk difference meta-analysis: regular salmeterol in addition to regular ICS,
Outcome 2 All-cause non-fatal SAE.
Review: Inhaled steroids with and without regular salmeterol for asthma: serious adverse events
Comparison: 2 Risk difference meta-analysis: regular salmeterol in addition to regular ICS
Outcome: 2 All-cause non-fatal SAE
Study or subgroup Salmeterol and ICS ICS
Risk
Difference Weight
Risk
Difference
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Adults and adolescents
Aubier 1999 10/338 5/165 1.6 % 0.00 [ -0.03, 0.03 ]
AUSTRI 2016 131/5834 119/5845 42.1 % 0.00 [ 0.00, 0.01 ]
Bailey 2008 6/239 11/236 1.7 % -0.02 [ -0.05, 0.01 ]
Bateman 2001 6/333 3/165 1.6 % 0.00 [ -0.03, 0.02 ]
Bernstein 2017 4/501 5/499 3.6 % 0.00 [ -0.01, 0.01 ]
GOAL 2004 64/1709 51/1707 12.3 % 0.01 [ 0.00, 0.02 ]
Godard 2008 3/159 1/159 1.1 % 0.01 [ -0.01, 0.04 ]
Ind 2003 9/171 5/160 1.2 % 0.02 [ -0.02, 0.06 ]
Katial 2011 14/306 10/315 2.2 % 0.01 [ -0.02, 0.04 ]
Kavuru 2000 2/92 1/90 0.7 % 0.01 [ -0.03, 0.05 ]
Kerwin 2011 6/310 8/318 2.3 % -0.01 [ -0.03, 0.02 ]
Koenig 2008 1/156 1/156 1.1 % 0.0 [ -0.02, 0.02 ]
-0.1 -0.05 0 0.05 0.1
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Study or subgroup Salmeterol and ICS ICS
Risk
Difference Weight
Risk
Difference
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Koopmans 2006 0/27 1/27 0.2 % -0.04 [ -0.13, 0.06 ]
Lundback 2006 4/95 3/92 0.7 % 0.01 [ -0.04, 0.06 ]
Mansfield 2017 24/338 20/335 2.4 % 0.01 [ -0.03, 0.05 ]
Murray 2004 0/88 0/89 0.6 % 0.0 [ -0.02, 0.02 ]
Nathan 2006 0/94 0/91 0.7 % 0.0 [ -0.02, 0.02 ]
Nelson 2003 2/95 0/97 0.7 % 0.02 [ -0.01, 0.06 ]
Pearlman 2004 0/92 1/89 0.7 % -0.01 [ -0.04, 0.02 ]
Raphael 2017 1/254 1/258 1.8 % 0.00 [ -0.01, 0.01 ]
Renzi 2010 4/262 2/270 1.9 % 0.01 [ -0.01, 0.03 ]
Rojas 2007 1/180 2/182 1.3 % -0.01 [ -0.02, 0.01 ]
SAM30007 0/29 1/32 0.2 % -0.03 [ -0.12, 0.05 ]
SAM40004 1/42 1/21 0.2 % -0.02 [ -0.13, 0.08 ]
SAM40008 3/93 0/93 0.7 % 0.03 [ -0.01, 0.07 ]
SAM40031 2/41 3/41 0.3 % -0.02 [ -0.13, 0.08 ]
SAM40065 2/150 3/150 1.1 % -0.01 [ -0.04, 0.02 ]
SAS30022 4/210 0/212 1.5 % 0.02 [ 0.00, 0.04 ]
SAS30023 0/151 1/155 1.1 % -0.01 [ -0.02, 0.01 ]
SAS40036 0/172 0/159 1.2 % 0.0 [ -0.01, 0.01 ]
SAS40037 1/161 2/161 1.2 % -0.01 [ -0.03, 0.01 ]
SAS40068 4/262 2/270 1.9 % 0.01 [ -0.01, 0.03 ]
SFA103153 6/239 11/236 1.7 % -0.02 [ -0.05, 0.01 ]
SFCF4026 3/159 1/159 1.1 % 0.01 [ -0.01, 0.04 ]
Shapiro 2000 0/84 1/84 0.6 % -0.01 [ -0.04, 0.02 ]
Sher 2017 5/288 2/291 2.1 % 0.01 [ -0.01, 0.03 ]
Slankard 2016 0/32 0/29 0.2 % 0.0 [ -0.06, 0.06 ]
SLGF75 0/14 0/17 0.1 % 0.0 [ -0.12, 0.12 ]
Strand 2004 1/78 2/72 0.5 % -0.01 [ -0.06, 0.03 ]
van Noord 2001 8/337 2/172 1.6 % 0.01 [ -0.01, 0.03 ]
Wallin 2003 0/18 0/19 0.1 % 0.0 [ -0.10, 0.10 ]
Subtotal (95% CI) 14233 13718 100.0 % 0.00 [ 0.00, 0.01 ]
Total events: 332 (Salmeterol and ICS), 282 (ICS)
Heterogeneity: Chi2 = 23.88, df = 40 (P = 0.98); I2 =0.0%
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Study or subgroup Salmeterol and ICS ICS
Risk
Difference Weight
Risk
Difference
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Test for overall effect: Z = 1.54 (P = 0.12)
2 Children
Li 2010 1/173 0/177 4.1 % 0.01 [ -0.01, 0.02 ]
Malone 2005 0/101 0/102 2.4 % 0.0 [ -0.02, 0.02 ]
MASCOT 2013 3/23 2/19 0.5 % 0.03 [ -0.17, 0.22 ]
NCT01192178 2/171 1/168 4.0 % 0.01 [ -0.01, 0.03 ]
Ploszczuk 2014 0/169 1/172 4.0 % -0.01 [ -0.02, 0.01 ]
SAM40012 2/181 1/181 4.3 % 0.01 [ -0.01, 0.02 ]
SAS30021 1/304 3/304 7.2 % -0.01 [ -0.02, 0.01 ]
VESTRI 2016 56/3107 54/3101 73.4 % 0.00 [ -0.01, 0.01 ]
Subtotal (95% CI) 4229 4224 100.0 % 0.00 [ 0.00, 0.01 ]
Total events: 65 (Salmeterol and ICS), 62 (ICS)
Heterogeneity: Chi2 = 2.81, df = 7 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 0.21 (P = 0.83)
Test for subgroup differences: Chi2 = 0.45, df = 1 (P = 0.50), I2 =0.0%
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Analysis 2.3. Comparison 2 Risk difference meta-analysis: regular salmeterol in addition to regular ICS,
Outcome 3 All-cause SAE (fatal and non-fatal).
Review: Inhaled steroids with and without regular salmeterol for asthma: serious adverse events
Comparison: 2 Risk difference meta-analysis: regular salmeterol in addition to regular ICS
Outcome: 3 All-cause SAE (fatal and non-fatal)
Study or subgroup Salmeterol and ICS ICS
Risk
Difference Weight
Risk
Difference
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Adults and adolescents
Aubier 1999 11/338 5/165 1.6 % 0.00 [ -0.03, 0.03 ]
AUSTRI 2016 134/5834 125/5845 42.1 % 0.00 [ 0.00, 0.01 ]
Bailey 2008 6/239 11/236 1.7 % -0.02 [ -0.05, 0.01 ]
Bateman 2001 6/333 3/165 1.6 % 0.00 [ -0.03, 0.02 ]
Bernstein 2017 4/501 5/499 3.6 % 0.00 [ -0.01, 0.01 ]
GOAL 2004 67/1709 53/1707 12.3 % 0.01 [ 0.00, 0.02 ]
Godard 2008 3/159 1/159 1.1 % 0.01 [ -0.01, 0.04 ]
Ind 2003 10/171 5/160 1.2 % 0.03 [ -0.02, 0.07 ]
Katial 2011 14/306 10/315 2.2 % 0.01 [ -0.02, 0.04 ]
Kavuru 2000 2/92 1/90 0.7 % 0.01 [ -0.03, 0.05 ]
Kerwin 2011 7/310 9/318 2.3 % -0.01 [ -0.03, 0.02 ]
Koenig 2008 1/156 2/156 1.1 % -0.01 [ -0.03, 0.02 ]
Koopmans 2006 0/27 1/27 0.2 % -0.04 [ -0.13, 0.06 ]
Lundback 2006 4/95 3/92 0.7 % 0.01 [ -0.04, 0.06 ]
Mansfield 2017 24/338 20/335 2.4 % 0.01 [ -0.03, 0.05 ]
Murray 2004 0/88 0/89 0.6 % 0.0 [ -0.02, 0.02 ]
Nathan 2006 0/94 0/91 0.7 % 0.0 [ -0.02, 0.02 ]
Nelson 2003 2/95 0/97 0.7 % 0.02 [ -0.01, 0.06 ]
Pearlman 2004 0/92 1/89 0.7 % -0.01 [ -0.04, 0.02 ]
Raphael 2017 2/254 2/258 1.8 % 0.00 [ -0.02, 0.02 ]
Renzi 2010 4/262 3/270 1.9 % 0.00 [ -0.02, 0.02 ]
Rojas 2007 1/180 2/182 1.3 % -0.01 [ -0.02, 0.01 ]
SAM30007 0/29 1/32 0.2 % -0.03 [ -0.12, 0.05 ]
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Study or subgroup Salmeterol and ICS ICS
Risk
Difference Weight
Risk
Difference
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
SAM40004 1/42 1/21 0.2 % -0.02 [ -0.13, 0.08 ]
SAM40008 3/93 0/93 0.7 % 0.03 [ -0.01, 0.07 ]
SAM40031 2/41 3/41 0.3 % -0.02 [ -0.13, 0.08 ]
SAM40065 2/150 3/150 1.1 % -0.01 [ -0.04, 0.02 ]
SAS30022 4/210 0/212 1.5 % 0.02 [ 0.00, 0.04 ]
SAS30023 0/151 1/155 1.1 % -0.01 [ -0.02, 0.01 ]
SAS40036 0/172 0/159 1.2 % 0.0 [ -0.01, 0.01 ]
SAS40037 1/161 2/161 1.2 % -0.01 [ -0.03, 0.01 ]
SAS40068 4/262 3/270 1.9 % 0.00 [ -0.02, 0.02 ]
SFA103153 6/239 11/236 1.7 % -0.02 [ -0.05, 0.01 ]
SFCF4026 3/159 1/159 1.1 % 0.01 [ -0.01, 0.04 ]
Shapiro 2000 0/84 1/84 0.6 % -0.01 [ -0.04, 0.02 ]
Sher 2017 6/288 2/291 2.1 % 0.01 [ -0.01, 0.03 ]
Slankard 2016 0/32 0/29 0.2 % 0.0 [ -0.06, 0.06 ]
SLGF75 0/14 0/17 0.1 % 0.0 [ -0.12, 0.12 ]
Strand 2004 1/78 3/72 0.5 % -0.03 [ -0.08, 0.02 ]
van Noord 2001 9/337 2/172 1.6 % 0.02 [ -0.01, 0.04 ]
Wallin 2003 0/18 0/19 0.1 % 0.0 [ -0.10, 0.10 ]
Subtotal (95% CI) 14233 13718 100.0 % 0.00 [ 0.00, 0.01 ]
Total events: 344 (Salmeterol and ICS), 296 (ICS)
Heterogeneity: Chi2 = 26.05, df = 40 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 1.40 (P = 0.16)
2 Children
Li 2010 1/173 0/177 4.1 % 0.01 [ -0.01, 0.02 ]
Malone 2005 0/101 0/102 2.4 % 0.0 [ -0.02, 0.02 ]
MASCOT 2013 3/23 2/19 0.5 % 0.03 [ -0.17, 0.22 ]
NCT01192178 2/171 1/168 4.0 % 0.01 [ -0.01, 0.03 ]
Ploszczuk 2014 0/169 1/172 4.0 % -0.01 [ -0.02, 0.01 ]
SAM40012 2/181 1/181 4.3 % 0.01 [ -0.01, 0.02 ]
SAS30021 1/304 3/304 7.2 % -0.01 [ -0.02, 0.01 ]
VESTRI 2016 56/3107 54/3101 73.4 % 0.00 [ -0.01, 0.01 ]
Subtotal (95% CI) 4229 4224 100.0 % 0.00 [ 0.00, 0.01 ]
Total events: 65 (Salmeterol and ICS), 62 (ICS)
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Study or subgroup Salmeterol and ICS ICS
Risk
Difference Weight
Risk
Difference
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heterogeneity: Chi2 = 2.81, df = 7 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 0.21 (P = 0.83)
Test for subgroup differences: Chi2 = 0.37, df = 1 (P = 0.54), I2 =0.0%
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Analysis 2.4. Comparison 2 Risk difference meta-analysis: regular salmeterol in addition to regular ICS,
Outcome 4 Asthma-related SAE.
Review: Inhaled steroids with and without regular salmeterol for asthma: serious adverse events
Comparison: 2 Risk difference meta-analysis: regular salmeterol in addition to regular ICS
Outcome: 4 Asthma-related SAE
Study or subgroup Salmeterol and ICS ICS
Risk
Difference Weight
Risk
Difference
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Adults and adolescents
Aubier 1999 1/338 0/165 1.6 % 0.00 [ -0.01, 0.01 ]
AUSTRI 2016 34/5834 33/5845 42.1 % 0.00 [ 0.00, 0.00 ]
Bailey 2008 2/239 2/236 1.7 % 0.00 [ -0.02, 0.02 ]
Bateman 2001 5/333 0/165 1.6 % 0.02 [ 0.00, 0.03 ]
Bernstein 2017 0/501 0/499 3.6 % 0.0 [ 0.00, 0.00 ]
GOAL 2004 8/1709 12/1707 12.3 % 0.00 [ -0.01, 0.00 ]
Godard 2008 0/159 0/159 1.1 % 0.0 [ -0.01, 0.01 ]
Ind 2003 1/171 3/160 1.2 % -0.01 [ -0.04, 0.01 ]
Katial 2011 3/306 0/315 2.2 % 0.01 [ 0.00, 0.02 ]
Kavuru 2000 0/92 0/90 0.7 % 0.0 [ -0.02, 0.02 ]
Kerwin 2011 1/310 0/318 2.3 % 0.00 [ -0.01, 0.01 ]
Koenig 2008 1/156 0/156 1.1 % 0.01 [ -0.01, 0.02 ]
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(. . . Continued)
Study or subgroup Salmeterol and ICS ICS
Risk
Difference Weight
Risk
Difference
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Koopmans 2006 0/27 0/27 0.2 % 0.0 [ -0.07, 0.07 ]
Lundback 2006 0/95 0/92 0.7 % 0.0 [ -0.02, 0.02 ]
Mansfield 2017 14/338 10/335 2.4 % 0.01 [ -0.02, 0.04 ]
Murray 2004 0/88 0/89 0.6 % 0.0 [ -0.02, 0.02 ]
Nathan 2006 0/94 0/91 0.7 % 0.0 [ -0.02, 0.02 ]
Nelson 2003 1/95 0/97 0.7 % 0.01 [ -0.02, 0.04 ]
Pearlman 2004 0/92 0/89 0.7 % 0.0 [ -0.02, 0.02 ]
Raphael 2017 1/254 1/258 1.8 % 0.00 [ -0.01, 0.01 ]
Renzi 2010 0/262 0/270 1.9 % 0.0 [ -0.01, 0.01 ]
Rojas 2007 0/180 0/182 1.3 % 0.0 [ -0.01, 0.01 ]
SAM30007 0/29 1/32 0.2 % -0.03 [ -0.12, 0.05 ]
SAM40004 0/42 0/21 0.2 % 0.0 [ -0.07, 0.07 ]
SAM40008 1/93 0/93 0.7 % 0.01 [ -0.02, 0.04 ]
SAM40031 0/41 0/41 0.3 % 0.0 [ -0.05, 0.05 ]
SAM40065 0/150 1/150 1.1 % -0.01 [ -0.02, 0.01 ]
SAS30022 0/210 0/212 1.5 % 0.0 [ -0.01, 0.01 ]
SAS30023 0/151 0/155 1.1 % 0.0 [ -0.01, 0.01 ]
SAS40036 0/172 0/159 1.2 % 0.0 [ -0.01, 0.01 ]
SAS40037 0/161 0/161 1.2 % 0.0 [ -0.01, 0.01 ]
SAS40068 0/262 0/270 1.9 % 0.0 [ -0.01, 0.01 ]
SFA103153 2/239 2/236 1.7 % 0.00 [ -0.02, 0.02 ]
SFCF4026 0/159 0/159 1.1 % 0.0 [ -0.01, 0.01 ]
Shapiro 2000 0/84 1/84 0.6 % -0.01 [ -0.04, 0.02 ]
Sher 2017 2/288 0/291 2.1 % 0.01 [ 0.00, 0.02 ]
Slankard 2016 0/32 0/29 0.2 % 0.0 [ -0.06, 0.06 ]
SLGF75 0/14 0/17 0.1 % 0.0 [ -0.12, 0.12 ]
Strand 2004 1/78 0/72 0.5 % 0.01 [ -0.02, 0.05 ]
van Noord 2001 2/337 1/172 1.6 % 0.00 [ -0.01, 0.01 ]
Wallin 2003 0/18 0/19 0.1 % 0.0 [ -0.10, 0.10 ]
Subtotal (95% CI) 14233 13718 100.0 % 0.00 [ 0.00, 0.00 ]
Total events: 80 (Salmeterol and ICS), 67 (ICS)
Heterogeneity: Chi2 = 13.84, df = 40 (P = 1.00); I2 =0.0%
-0.1 -0.05 0 0.05 0.1
Favours Salmeterol % ICS Favours ICS
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(. . . Continued)
Study or subgroup Salmeterol and ICS ICS
Risk
Difference Weight
Risk
Difference
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Test for overall effect: Z = 0.75 (P = 0.46)
2 Children
Li 2010 0/173 0/177 4.1 % 0.0 [ -0.01, 0.01 ]
Malone 2005 0/101 0/102 2.4 % 0.0 [ -0.02, 0.02 ]
MASCOT 2013 1/23 1/19 0.5 % -0.01 [ -0.14, 0.12 ]
NCT01192178 1/171 0/168 4.0 % 0.01 [ -0.01, 0.02 ]
Ploszczuk 2014 0/169 0/172 4.0 % 0.0 [ -0.01, 0.01 ]
SAM40012 0/181 0/181 4.3 % 0.0 [ -0.01, 0.01 ]
SAS30021 0/304 1/304 7.2 % 0.00 [ -0.01, 0.01 ]
VESTRI 2016 27/3107 21/3101 73.4 % 0.00 [ 0.00, 0.01 ]
Subtotal (95% CI) 4229 4224 100.0 % 0.00 [ 0.00, 0.00 ]
Total events: 29 (Salmeterol and ICS), 23 (ICS)
Heterogeneity: Chi2 = 1.59, df = 7 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.76 (P = 0.45)
Test for subgroup differences: Chi2 = 0.10, df = 1 (P = 0.75), I2 =0.0%
-0.1 -0.05 0 0.05 0.1
Favours Salmeterol % ICS Favours ICS
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Analysis 2.5. Comparison 2 Risk difference meta-analysis: regular salmeterol in addition to regular ICS,
Outcome 5 Asthma-related mortality.
Review: Inhaled steroids with and without regular salmeterol for asthma: serious adverse events
Comparison: 2 Risk difference meta-analysis: regular salmeterol in addition to regular ICS
Outcome: 5 Asthma-related mortality
Study or subgroup Salmeterol and ICS ICS
Risk
Difference Weight
Risk
Difference
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Adults and adolescents
Aubier 1999 0/338 0/165 1.6 % 0.0 [ -0.01, 0.01 ]
AUSTRI 2016 0/5834 0/5845 42.1 % 0.0 [ 0.00, 0.00 ]
Bailey 2008 0/239 0/236 1.7 % 0.0 [ -0.01, 0.01 ]
Bateman 2001 0/333 0/165 1.6 % 0.0 [ -0.01, 0.01 ]
Bernstein 2017 0/501 0/499 3.6 % 0.0 [ 0.00, 0.00 ]
GOAL 2004 0/1709 0/1707 12.3 % 0.0 [ 0.00, 0.00 ]
Godard 2008 0/159 0/159 1.1 % 0.0 [ -0.01, 0.01 ]
Ind 2003 0/171 0/160 1.2 % 0.0 [ -0.01, 0.01 ]
Katial 2011 0/306 0/315 2.2 % 0.0 [ -0.01, 0.01 ]
Kavuru 2000 0/92 0/90 0.7 % 0.0 [ -0.02, 0.02 ]
Kerwin 2011 0/310 0/318 2.3 % 0.0 [ -0.01, 0.01 ]
Koenig 2008 0/156 0/156 1.1 % 0.0 [ -0.01, 0.01 ]
Koopmans 2006 0/27 0/27 0.2 % 0.0 [ -0.07, 0.07 ]
Lundback 2006 0/95 0/92 0.7 % 0.0 [ -0.02, 0.02 ]
Mansfield 2017 0/338 0/335 2.4 % 0.0 [ -0.01, 0.01 ]
Murray 2004 0/88 0/89 0.6 % 0.0 [ -0.02, 0.02 ]
Nathan 2006 0/94 0/91 0.7 % 0.0 [ -0.02, 0.02 ]
Nelson 2003 0/95 0/97 0.7 % 0.0 [ -0.02, 0.02 ]
Pearlman 2004 0/92 0/89 0.7 % 0.0 [ -0.02, 0.02 ]
Raphael 2017 0/254 0/258 1.8 % 0.0 [ -0.01, 0.01 ]
Renzi 2010 0/262 0/270 1.9 % 0.0 [ -0.01, 0.01 ]
Rojas 2007 0/180 0/182 1.3 % 0.0 [ -0.01, 0.01 ]
SAM30007 0/29 0/32 0.2 % 0.0 [ -0.06, 0.06 ]
-0.1 -0.05 0 0.05 0.1
Favours Salmeterol % ICS Favours ICS
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(. . . Continued)
Study or subgroup Salmeterol and ICS ICS
Risk
Difference Weight
Risk
Difference
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
SAM40004 0/42 0/21 0.2 % 0.0 [ -0.07, 0.07 ]
SAM40008 0/93 0/93 0.7 % 0.0 [ -0.02, 0.02 ]
SAM40031 0/41 0/41 0.3 % 0.0 [ -0.05, 0.05 ]
SAM40065 0/150 0/150 1.1 % 0.0 [ -0.01, 0.01 ]
SAS30022 0/210 0/212 1.5 % 0.0 [ -0.01, 0.01 ]
SAS30023 0/151 0/155 1.1 % 0.0 [ -0.01, 0.01 ]
SAS40036 0/172 0/159 1.2 % 0.0 [ -0.01, 0.01 ]
SAS40037 0/161 0/161 1.2 % 0.0 [ -0.01, 0.01 ]
SAS40068 0/262 0/270 1.9 % 0.0 [ -0.01, 0.01 ]
SFA103153 0/239 0/236 1.7 % 0.0 [ -0.01, 0.01 ]
SFCF4026 0/159 0/159 1.1 % 0.0 [ -0.01, 0.01 ]
Shapiro 2000 0/84 0/84 0.6 % 0.0 [ -0.02, 0.02 ]
Sher 2017 0/288 0/291 2.1 % 0.0 [ -0.01, 0.01 ]
Slankard 2016 0/32 0/29 0.2 % 0.0 [ -0.06, 0.06 ]
SLGF75 0/14 0/17 0.1 % 0.0 [ -0.12, 0.12 ]
Strand 2004 0/78 0/72 0.5 % 0.0 [ -0.03, 0.03 ]
van Noord 2001 0/337 0/172 1.6 % 0.0 [ -0.01, 0.01 ]
Wallin 2003 0/18 0/19 0.1 % 0.0 [ -0.10, 0.10 ]
Subtotal (95% CI) 14233 13718 100.0 % 0.0 [ 0.00, 0.00 ]
Total events: 0 (Salmeterol and ICS), 0 (ICS)
Heterogeneity: Chi2 = 0.0, df = 40 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.0 (P = 1.0)
2 Children
Li 2010 0/173 0/177 4.1 % 0.0 [ -0.01, 0.01 ]
Malone 2005 0/101 0/102 2.4 % 0.0 [ -0.02, 0.02 ]
MASCOT 2013 0/23 0/19 0.5 % 0.0 [ -0.09, 0.09 ]
NCT01192178 0/171 0/168 4.0 % 0.0 [ -0.01, 0.01 ]
Ploszczuk 2014 0/169 0/172 4.0 % 0.0 [ -0.01, 0.01 ]
SAM40012 0/181 0/181 4.3 % 0.0 [ -0.01, 0.01 ]
SAS30021 0/304 0/304 7.2 % 0.0 [ -0.01, 0.01 ]
VESTRI 2016 0/3107 0/3101 73.4 % 0.0 [ 0.00, 0.00 ]
Subtotal (95% CI) 4229 4224 100.0 % 0.0 [ 0.00, 0.00 ]
Total events: 0 (Salmeterol and ICS), 0 (ICS)
-0.1 -0.05 0 0.05 0.1
Favours Salmeterol % ICS Favours ICS
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Study or subgroup Salmeterol and ICS ICS
Risk
Difference Weight
Risk
Difference
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heterogeneity: Chi2 = 0.0, df = 7 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Chi2 = 0.0, df = 1 (P = 1.00), I2 =0.0%
-0.1 -0.05 0 0.05 0.1
Favours Salmeterol % ICS Favours ICS
A D D I T I O N A L T A B L E S
Table 1. Dose of salmeterol and fluticasone
Study ID Age of par-
ticipants
(Years)
N on FSC N on ICS Daily
dose of fluti-
casone (µg)
Daily dose
of salme-
terol (µg)
Combined
inhaler
Separate in-
halers
Duration
(weeks)
Aubier 1999 12+ 338 165 1000 100
√ √
28
AUSTRI
2016
12+ 5834 5845 200/500/
1000
100
√
26
Bailey 2008 12+ 239 236 200 100
√
52
Bateman
2001
12+ 333 165 200 100
√
52
Bernstein
2017
12+ 501 499 500 100
√
24
GOAL2004 12+ 1709 1707 200/500/
1000
100
√
12
Godard
2008
18+ 159 159 500 100
√
24
Ind 2003 16+ 171 160 500 100
√
28
Katial 2011 12+ 306 315 500 100
√
52
Kavuru
2000
12+ 92 90 200 100
√
52
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Table 1. Dose of salmeterol and fluticasone (Continued)
Kerwin
2011
12+ 310 318 500 100
√
12
Koenig
2008
12+ 156 156 200/500/
1000
100
√
40
Koopmans
2006
18+ 27 27 500 100
√
12
Li 2010 4 to 11 173 177 200 100
√
12
Lundback
2006
18+ 95 92 500 100
√
12
Malone
2005
4 to 11 101 102 200 100
√
12
Mansfield
2017
12+ 338 335 200/400/
500/1000
25/100
√
26
MASCOT
2013
4 to 11 23 19 200 100
√
48
Murray
2004
12+ 88 89 200 100
√
12
Nathan
2006
12+ 94 91 220 100
√
16
NCT01192178
4 to 11 171 168 200 100
√
16
Nelson
2003
12+ 95 97 200 100
√
12
Pearlman
2004
12+ 92 89 200 100
√
12
Ploszczuk
2014
2 to 11 169 172 200 100
√
12
Raphael
2017
12+ 254 258 100/200 25
√
12
Renzi 2010 12+ 262 270 200 100
√
24
Rojas 2007 12+ 180 182 500 100
√
12
SAM30007 18+ 29 32 200/500/
1000
100
√
30
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Table 1. Dose of salmeterol and fluticasone (Continued)
SAM40004 18+ 42 21 200 100
√
52
SAM40008 18+ 93 93 1000 100
√
26
SAM40012 4 to 11 181 181 200 100
√
24
SAM40031 18+ 41 41 200/500/
1000
100
√
52
SAM40065 12+ 150 150 200/500/
1000
100
√
40
SAS30021 4 to 11 304 304 100 50
√
12
SAS30022 12+ 210 212 500 50
√
12
SAS30023 12+ 151 155 100 50
√
12
SAS40036 15+ 172 159 200 100
√
16
SAS40037 15+ 161 161 200 100
√
16
SAS40068 12+ 262 270 200 100
√
24
SFA103153 12+ 239 236 200 100
√
52
SFCF4026 18+ 159 159 500 100
√
24
Shapiro
2000
12+ 84 84 500 100
√
12
Sher 2017 12+ 288 291 200/400 25
√
12
Slankard
2016
18+ 32 29 88/220/440 42
√
16
SLGF75 16+ 14 17 200 100
√
12
Strand 2004 18+ 78 72 200 100
√
12
van Noord
2001
12+ 337 172 1000 100
√
12
VESTRI
2016
4 to 11 3107 3101 200/500 100
√
26
Wallin 2003 12+ 18 19 400 100
√
12
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FSC: salmeterol/fluticasone; ICS: inhaled corticosteroid.
Table 2. Mortality
Study ID Treatment arm Cause of death in adults (n)
AUSTRI 2016 salmeterol and fluticasone Heroin overdose (1), stroke (1), and dyspnoea due to metastatic
hepatic carcinoma (1)
AUSTRI 2016 fluticasone Aortic dissection (1), sudden cardiac death (1), gastroenteritis (1)
, sepsis (1), and stroke (2)
Aubier 1999 salmeterol and fluticasone
(separate inhalers)
Bronchial carcinoma (1)
GOAL 2004 salmeterol and fluticasone Myocardial infarction (2) and pneumonia (1)
GOAL 2004 fluticasone Myocardial infarction (2)
Ind 2003 salmeterol and fluticasone
(separate inhalers)
Pneumothorax (1)
Kerwin 2011 salmeterol and fluticasone Cardiac disease (1)
Kerwin 2011 fluticasone Breast cancer (1)
Koenig 2008 fluticasone Cardiac arrest and deep vein thrombosis (1)
Renzi 2010 fluticasone Cardiac arrest (1)
SAS40068 fluticasone Ventricular hypertrophy and aortic hypoplasia (1)
Sher 2017 salmeterol and fluticasone A female patient developed severe jaundice onday 30,which led to
withdrawal of the study drug, and she died 6 weeks later. She had
begun taking an herbal supplement before the onset of jaundice
and then declined recommended interventions and investigations
into her condition. The death was considered not related to study
treatment
Strand 2004 fluticasone Unknown cause (1)
van Noord 2001 salmeterol and fluticasone Leukaemia (1)
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Table 3. Summary of pooled odds ratios
Peto OR meta-analysis: regular salmeterol in addition to regular ICS vs ICS alone
All-cause
mortality
Events Rx Total Rx Events con-
trol
Total
control
Peto OR CI start CI end Worst-case NNTHa
(from OR CI end)
Adults and
adolescents
11 14,233 13 13,718 0.80 0.36 1.78 1661
Children 0 4229 0 4224 - - - -
All
cause non-
fatal SAE
Adults and
adolescents
332 14,233 282 13,718 1.14 0.97 1.33 152
Children 65 4229 62 4224 1.04 0.73 1.48 139
Asthma-re-
lated mor-
tality
Adults and
adolescents
0 14,233 0 13,718 - - - -
Children 0 4229 0 4224 - - - -
Asthma-
related SAE
Adults and
adolescents
80 14,233 67 13,718 1.15 0.83 1.59 351
Children 29 4229 23 4224 1.25 0.72 2.16 128
aNNTH (number needed to treat for an additional harmful outcome) calculated using Visual Rx to transform the upper end of the
95% confidence interval of the Peto OR, respectively.
Table 4. Summary of pooled risk difference
Risk difference meta-analysis: regular salmeterol in addition to regular ICS vs ICS alone
All-cause
mortality
Events Rx Total Rx Events con-
trol
Total
control
Risk differ-
ence
CI start CI end Worst-case NNTHa
(from RD 95% CI
end)
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Table 4. Summary of pooled risk difference (Continued)
Adults and
adolescents
11 14,233 13 13,718 -0.0002 -0.0013 0.0009 1099
Children 0 4229 0 4224 0.0000 -0.0013 0.0013 763
All-
cause non-
fatal SAE
Adults and
adolescents
333 14,233 283 13,718 0.0027 -0.0008 0.0062 161
Children 65 4229 62 4224 0.0006 -0.0047 0.0058 172
Asthma-re-
lated mor-
tality
Adults and
adolescents
0 14,233 0 13,718 0.0000 -0.0009 0.0009 1099
Children 0 4229 0 4224 0.0000 -0.0013 0.0013 763
Asthma-re-
lated non-
fatal SAE
Adults and
adolescents
82 14,233 67 13,718 0.0007 -0.0012 0.0026 385
Children 29 4229 23 4224 0.0014 -0.0022 0.0049 205
aNNTH (number needed to treat for an additional harmful outcome) calculated from the inverse of the upper end of the 95%
confidence interval (CI end) of the risk difference.
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A P P E N D I C E S
Appendix 1. Pharmacology of beta2-agonists
Beta2-agonists are thought to cause bronchodilation primarily through binding beta2-adrenoceptors on airways smooth muscle (ASM),
with subsequent activation of both membrane-bound potassium channels and a signalling cascade involving enzyme activation and
changes in intracellular calcium levels following a rise in cyclic adenosine monophosphate (cAMP) (Barnes 1993). However, beta2-
adrenoceptors are also expressed on a wide range of cell types where beta2-agonists may have a clinically significant effect including
airway epithelium (Morrison 1993), mast cells, post-capillary venules, sensory and cholinergic nerves, and dendritic cells (Anderson
2006). Beta2-agonists will also cross-react to some extent with other beta-adrenoceptors including beta1-adrenoceptors on the heart.
The in vivo effect of any beta2-agonist will depend on a number of factors relating to both the drug and the patient. The degree to
which a drug binds to one receptor over another is known as selectivity, which can be defined as absolute binding ratios to different
receptors in vitro, whilst functional selectivity is measured from downstream effects of drugs in different tissue types in vitro or in vivo.
All of the beta2-agonists described thus far are more beta2-selective than their predecessor isoprenaline in vitro. However, because
attempts to differentiate selectivity between the newer agents are confounded by so many factors, it is difficult to draw conclusions
about in vitro selectivity studies and is probably best to concentrate on specific adverse side effects in human subjects at doses that
cause the same degree of bronchodilatation. The potency of a drug refers to the concentration that achieves half the maximal receptor
activation of which that drug is capable but it is not very important clinically, as for each drug, manufacturers will alter the dose to try
to achieve a therapeutic ratio of desired to undesired effects. In contrast, efficacy refers to the ability of a drug to activate its receptor
independent of drug concentration. Drugs that fully activate a receptor are known as full agonists, and those that partially activate a
receptor are known as partial agonists. Efficacy also is very much dependent on the system in which it is being tested and is affected
by factors including the number of receptors available and the presence of other agonists and antagonists. Thus whilst salmeterol acts
as a partial agonist in vitro, it causes a similar degree of bronchodilation to the strong agonist formoterol in stable asthmatic patients
(vanNoord 1996), presumably because there is an abundance of well-coupled beta2-adrenoceptors available with few downstream
antagonising signals. In contrast, with repetitive dosing, formoterol is significantly better than salmeterol in preventing methacholine-
induced bronchoconstriction (Palmqvist 1999). These differences have led to attempts to define the “intrinsic efficacy” of a drug
independent of tissue conditions (Hanania 2002), as shown in Table 1. The clinical significance of intrinsic efficacy remains unclear.
Appendix 2. Possible mechanisms of increased asthma mortality with beta-agonists
Direct toxicity
This hypothesis states that direct adverse effects of beta2-agonists are responsible for an associated increase in mortality, and most
research in the area has concentrated on effects detrimental to the heart. Whilst it is often assumed that cardiac side effects of beta2-
agonists are due to cross-reactivity with beta1-adrenoceptors (i.e. poor selectivity), it is worth noting that human myocardium also
contains an abundance of beta2-adrenoceptors capable of triggering positive chronotropic and inotropic responses (Lipworth 1992).
Indeed, there is good evidence that cardiovascular side effects of isoprenaline - Arnold 1985 - and other beta2-agonists including
salbutamol - Hall 1989 - are mediated predominantly via cardiac beta2-adrenoceptors, thus making the concept of in vitro selectivity
less relevant. Generalised beta2-adrenoceptor activation can also cause hypokalaemia (Brown 1983), and it has been proposed that,
through these and other actions, beta2-agonists may predispose to life-threatening dysrhythmias or may cause other adverse cardiac
effects.
During the 1960s epidemic, most deaths occurred in patients with severe asthma, and it was originally assumed that asthma and its
sequelae, including hypoxia, were the primary cause of death. However, mucus plugging and hypoxia do not preclude a cardiac event as
the final cause of death, and one might expect those with severe asthma to take more doses of a prescribed inhaler. As noted by Speizer
and Doll, most deaths in the 1960s were seen in the 10 to 19-year age group, and “at these ages children have begun to act independently
and may be particularly prone to misuse a self-administered form of treatment” (Speizer 1968). If toxicity were related to increasing
doses of beta2-agonists, one might expect most deaths to occur in hospitals, where high doses are typically used, and this was not the
case. One possible explanation for this anomaly was provided by animal experiments in which large doses of isoprenaline caused little ill
effect in anaesthetised dogs with normal arterial oxygenation, whereas much smaller doses caused fatal cardiac depression and asystole
(although no obvious dysrhythmia) when hypoxic (Collins 1969; McDevitt 1974). It has been hypothesised, therefore, that such events
would be less likely in hospitals, where supplemental oxygen is routinely given. The clinical relevance of these studies remains unclear,
although there is some evidence of a synergistic effect between hypoxia and salbutamol use in asthmatic patients for reducing total
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peripheral vascular resistance (Burggraaf 2001) - another beta2-mediated effect that could be detrimental to the heart during an acute
asthma attack through a reduction in diastolic blood pressure. Other potential mechanisms of isoprenaline toxicity include a potential
increase in mucus plugging and worsening of ventilation-perfusion mismatch despite bronchodilation (Pearce 1990).
Further concerns about a possible toxic effect of beta2-agonists were raised during the New Zealand epidemic in the 1970s. In 1981
Wilson et al, who first reported the epidemic, reviewed 22 fatal cases of asthma and noted: “In 16 patients death was seen to be sudden
and unexpected. Although all were experiencing respiratory distress, most were not cyanosed and the precipitate nature of their death
suggested a cardiac event, such as an arrest, inappropriate to the severity of their respiratory problem” (Wilson 1981). In humans,
fenoterol causes significantly greater chronotropic, inotropic, and electrocardiographic side effects than salbutamol in asthmatic patients
(Wong 1990). Interestingly, across the same parameters, fenoterol also causes more side effects than isoprenaline (Burgess 1991).
In patients with mild asthma without a bronchoconstrictor challenge, salmeterol and salbutamol cause a similar degree of near maximal
bronchodilation at low doses (Bennett 1994). However, whilst as a one-off dose, salbutamol is typically used at 2 to 4 times the
concentration of salmeterol, dose equivalencies for salmeterol versus salbutamol in increasing heart rate and decreasing potassium
concentration and diastolic blood pressure were 17.7, 7.8, and 7.6, respectively (i.e. salmeterol had a greater effect across all parameters).
Given the lower intrinsic efficacy of salmeterol, these results highlight the importance of in vivo factors; one possible explanation for
the difference is the increased lipophilicity of salmeterol compared to salbutamol, contributing to higher systemic absorption (Bennett
1994).
When increasing actuations of standard doses of formoterol and salmeterol inhalers are compared in stable asthmatic patients, relatively
similar cardiovascular effects are seen at lower doses (Guhan 2000). However, at the highest doses (above those recommended by
the manufacturers), there were trends towards an increase in systolic blood pressure with formoterol; in comparison there was a trend
towards a decrease in diastolic blood pressure and an increase in QTc interval with salmeterol, although no statistical analysis of the
difference was performed. In contrast, in asthmatic patients with methacholine-induced bronchoconstriction, there was no significant
difference between salmeterol and formoterol in causing increased heart rate and QTc interval, although formoterol caused significantly
greater bronchodilation and hypokalaemia (Palmqvist 1999). Whilst there is good evidence of cardiovascular and metabolic side effects
with increasing doses of beta2-agonists, it is a little difficult to envisage serious adverse effects of this nature when LABAs are used at
manufacturer-recommended preventative doses. However, it is possible that some patients may choose to use repeated doses of LABAs
during exacerbations.
Tolerance
In this setting, the term tolerance refers to an impaired response to beta2-agonists in patients who have been using regular beta2-
agonist treatment previously (Haney 2006). Tolerance is likely to result from a combination of reduced receptor numbers secondary to
receptor internalisation and reduced production and also uncoupling of receptors to downstream signalling pathways following repeated
activation (Barnes 1995). This phenomenon is likely to explain the beneficial reduction in systemic side effects seen with regular use of
beta2-agonists including salbutamol after 1 to 2 weeks (Lipworth 1989). However, the same effect on beta2-adrenoceptors in the lung
might be expected to produce a diminished response to the bronchodilating activity of beta2-agonists following regular use. In patients
with stable asthma, whilst there is some evidence of tolerance to both salbutamol - Nelson 1977 - and terbutaline - Weber 1982 -
other studies have been less conclusive (Harvey 1982; Lipworth 1989). However, evidence of tolerance to short- and long-acting beta2-
agonists in both protecting against and reducing bronchoconstriction is much stronger in the setting of an acute bronchoconstrictor
challenge with chemical, allergen, and ’natural’ stimuli (Haney 2006; Lipworth 1997).
Studies comparing salmeterol and formoterol have shown that both cause tolerance compared to placebo but show no significant
differences between the drugs (van der Woude 2001). There also appears to be little difference in the tolerance induced by regular
formoterol and regular salbutamol treatment (Hancox 1999; Jones 2001). To the review authors’ knowledge, no studies have looked
specifically at the degree of tolerance caused by isoprenaline and fenoterol in the setting of acute bronchoconstriction. Tolerance to
bronchodilation has been shown to clearly occur with addition of inhaled corticosteroids to salmeterol and formoterol - Lee 2003 -
and terbutaline - Yates 1996. There is conflicting evidence as to whether high-dose steroids can reverse tolerance in the acute setting
(Jones 2001; Lipworth 2000).
At first glance, the toxicity and tolerance hypotheses might appear incompatible, as systemic and cardiovascular tolerance ought to
protect against toxicity in the acute setting, and there is good evidence that such tolerance occurs in stable asthmatic patients (Lipworth
1989). However, although this study showed that changes in heart rate and potassium levels were blunted by previous beta2-agonist use,
they were not abolished; furthermore, at the doses studied, these side effects appear to follow an exponential pattern (Lipworth 1989).
In contrast, in the presence of bronchoconstrictor stimuli, the bronchodilator response to beta2-agonists follows a flatter curve (Hancox
1999; Wong 1990), and as previously discussed, this curve is shifted downwards by previous beta2-agonist exposure (Hancox 1999).
Thus, it is theoretically possible that in the setting of an acute asthmatic attack and strong bronchoconstricting stimuli, bronchodilator
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tolerance could lead to repetitive beta2-agonist use and ultimately more systemic side effects than would otherwise have occurred. Of
course, other sequelae of inadequate bronchodilation including airway obstruction will be detrimental in this setting.
Whilst the tolerance hypothesis is often cited as contributing towards asthma mortality epidemics, it is difficult to argue that reduced
efficacy of a drug can cause increased mortality relative to a time when that drug was not used at all. However, tolerance to the bron-
chodilating effect of endogenous circulating adrenaline is theoretically possible, and there is also evidence of rebound bronchoconstric-
tion when fenoterol is stopped (Sears 1990), which may be detrimental. Furthermore, it appears that regular salbutamol treatment can
actually increase airway responsiveness to allergen (Cockcroft 1993); this is a potentially important effect that could form a variant of the
toxicity hypothesis. Differences between beta2-agonists in this regard are unclear, but the combination of rebound hyperresponsiveness
and tolerance of the bronchodilator effect with regular beta2-agonist exposure has been recently advocated as a possible mechanism to
explain the association between beta2-agonists and asthma mortality (Hancox 2006).
Other explanations
Confounding by severity
Historically, this hypothesis has been used extensively to try to explain the association between mortality and the use of fenoterol during
the 1970s New Zealand epidemic (see Pearce 2007), and it is still quoted today. The hypothesis essentially relies on the supposition
that patients with more severe asthma are more likely to take either higher doses of beta2-agonists or a particular beta2-agonist (such
as fenoterol), thereby explaining the association. This hypothesis was carefully ruled out in the three case-control studies by comparing
the association between fenoterol and mortality in patients with varying severity of disease (Crane 1989; Grainger 1991; Pearce 1990).
Furthermore, the hypothesis cannot explain the overall increase in mortality in the 1960s and 1970s, nor can it explain any significant
increase in mortality (whether taking inhaled steroids or not) from randomised controlled trial data.
The delay hypothesis
This hypothesis accepts that beta2-agonists or a particular beta2-agonist can cause increased risk of mortality, but indirectly by causing
patients to delay before gettingmedical help and further treatments including high-dose steroids and oxygen. There is evidence that both
salmeterol and formoterol can reduce awareness of worsening underlying inflammation (Bijl-Hofland 2001;McIvor 1998). It is difficult
to rule out the delay hypothesis in explaining or contributing towards both asthma mortality epidemics and an association with regular
use of LABAs. There is evidence that beta2-agonists with higher intrinsic efficacy are more effective in relieving bronchoconstriction
in the acute setting (Hanania 2007), and that they could paradoxically cause patients to delay longer in seeking medical help. For the
delay hypothesis to explain the increase in mortality during the 1960s and 1970s, one has to imply that hospital treatment of asthma
when mortality rates were low during the earlier years of the 20th century was effective. It is difficult to say exactly how effective such
treatment is likely to have been.
Reduced corticosteroid treatment
A slight but significant variation of the delay hypothesis suggests that patients who have separate beta2-agonists and corticosteroid
inhalers may choose to take less corticosteroid because of better symptom control from the inhaled beta2-agonists, and it is reduced
corticosteroid treatment that contributes to a rise in mortality. It is rather difficult to see how this hypothesis explains the epidemics
of asthma deaths in the 1960s and 1970s relative to the 1920s and 1930s, given that corticosteroids were not used for the treatment
of asthma in earlier decades. If this hypothesis were to explain increased mortality from more recent randomised controlled trial data,
one would not expect to see an increase in mortality among those taking LABAs alone.
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Appendix 3. Sources and search methods for the Cochrane Airways Group Specialised Register
(CAGR)
Electronic searches: core databases
Database Dates searched Frequency of search
CENTRAL (via the Cochrane Register of
Studies (CRS))
From inception Monthly
MEDLINE (Ovid) 1946 onwards Weekly
Embase (Ovid) 1974 onwards Weekly
PsycINFO (Ovid) 1967 onwards Monthly
CINAHL (EBSCO) 1937 onwards Monthly
AMED (EBSCO) From inception Monthly
Handsearches: core respiratory conference abstracts
Conference Years searched
AmericanAcademyofAllergy, Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
Asia Pacific Society of Respirology (APSR) 2004 onwards
British Thoracic Society Winter Meeting (BTS) 2000 onwards
Chest Meeting 2003 onwards
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International PrimaryCareRespiratoryGroupCongress (IPCRG) 2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards
144Inhaled steroids with and without regular salmeterol for asthma: serious adverse events (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
MEDLINE search strategy used to identify trials for the CAGR
Asthma search
1. exp Asthma/
2. asthma$.mp.
3. (antiasthma$ or anti-asthma$).mp.
4. Respiratory Sounds/
5. wheez$.mp.
6. Bronchial Spasm/
7. bronchospas$.mp.
8. (bronch$ adj3 spasm$).mp.
9. bronchoconstrict$.mp.
10. exp Bronchoconstriction/
11. (bronch$ adj3 constrict$).mp.
12. Bronchial Hyperreactivity/
13. Respiratory Hypersensitivity/
14. ((bronchial$ or respiratory or airway$ or lung$) adj3 (hypersensitiv$ or hyperreactiv$ or allerg$ or insufficiency)).mp.
15. ((dust or mite$) adj3 (allerg$ or hypersensitiv$)).mp.
16. or/1-15
Filter to identify RCTs
1. exp “clinical trial [publication type]”/
2. (randomised or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. Animals/
10. Humans/
11. 9 not (9 and 10)
12. 8 not 11
The MEDLINE strategy and RCT filter are adapted to identify trials in other electronic databases.
Appendix 4. Search strategy to identify relevant trials from the Cochrane Airways Trials Register
#1 AST:MISC1
#2 MeSH DESCRIPTOR Asthma Explode All
#3 asthma*:ti,ab
#4 #1 or #2 or #3
#5 MeSH DESCRIPTOR Adrenergic beta-2 Receptor Agonists
#6 (long-acting or “long acting”) NEAR ((beta* NEAR3 (agonist* OR adrenergic*)) OR bronchodilat*)
#7 LABA:TI,AB
#8 MESH DESCRIPTOR Salmeterol Xinafoate
#9 salmeterol:ti,ab,kw
#10 MESH DESCRIPTOR Formoterol Fumarate
#11 formoterol:ti,ab,kw
#12 eformoterol:ti,ab,kw
#13 (Advair OR Symbicort OR Serevent OR Foradil OR Oxis):ti,ab,kw
#14 #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13
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#15 #4 AND #14
#16 MESH DESCRIPTOR Drug-Related Side Effects and Adverse Reactions EXPLODE ALL
#17 MESH DESCRIPTOR Drug Monitoring
#18 MESH DESCRIPTOR Adverse Drug Reaction Reporting Systems
#19 MESH DESCRIPTOR Product Surveillance, Postmarketing EXPLODE ALL
#20 MESH DESCRIPTOR Mortality EXPLODE ALL
#21 serious or safety or surveillance or mortality or death or intubat* or adverse or toxic* or complication* or tolerability or harm*
#22 #16 OR #17 OR #18 OR #19 OR #20 OR #21
#23 #15 AND #22
#24 INREGISTER
#25 #23 AND #24
Appendix 5. Quality of life considerations
To compare outcomes measured in different units has been always a challenge. To address this problem, economists developed quality-
adjusted life years (QALYs), which allow us to balance fatal and not fatal results of a specific intervention. Regarding treatment with
salmeterol and inhaled corticosteroids, we can assume that the number of QALYs lost by one death could never be greater than the
number of QALYs gained with the benefits in health-related quality of life. First, since the QALYs lost by one person’s death depend
on his or her age, we have selected as potential scenarios the two asthma-related deaths that occurred in the budesonide-formoterol
group of the recent safety trial of formoterol and inhaled steroids (Peters 2016). The death of a 22-year-old woman equates to 59.998
QALYs, and the death of a 68-year-old woman equals to 11.480 QALYs, considering life expectancy at birth of women in OECD (84
years) and English population norms of EQ-5D index (Janssen 2014). Second, the average QALY gained for each patient receiving
salmeterol/fluticasone propionate fixed combination within one year ranges from 0.01 to 0.0152 (GOAL 2004 Ismaila 2014). Third,
it is therefore necessary that 6000-3960 patients-year benefit from treatment to compensate the death of the 22-year-old woman (60
QALYs), and it is necessary that 1150-759 patients-year benefit from treatment to compensate the death of a 68-year-old woman (11.5
QALYs). Thus, translating these estimates to the current systematic review, a death over six months on salmeterol would need from
two to ten thousand people to benefit from the treatment.
WH A T ’ S N E W
Date Event Description
10 October 2018 New search has been performed New literature search was run
10 October 2018 New citation required and conclusions have changed We added 6 additional studies including 14,504 adults
(AUSTRI 2016; Bernstein 2017; Mansfield 2017;
Raphael 2017; Sher 2017; Slankard 2016), as well
as 3 additional studies including 6591 children (
MASCOT 2013; Ploszczuk 2014; VESTRI 2016). The
2 large ongoing studies identified at the last update
(NCT01462344; NCT01475721) are now included as
AUSTRI 2016 and VESTRI 2016
Roman Jaeschke stepped down as an author of the re-
view, and SamWaterson and Ben Sayer joined as review
authors
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H I S T O R Y
Protocol first published: Issue 1, 2008
Review first published: Issue 3, 2009
Date Event Description
1 August 2012 New search has been performed New literature search was run
1 August 2012 New citation required but conclusions have not changed The 2012 update identified 5 additional studies includ-
ing 2574 adults and adolescents (Bailey 2008; Godard
2008; Katial 2011; Kerwin 2011; Renzi 2010), along
with 2 additional studies including 689 children (Li
2010; NCT01192178). Also identified were 2 large on-
going studies, which aim to recruit 6000 children and
11,000 adults. They were expected to report results in
2017 (NCT01462344; NCT01475721)
Current evidence is insufficient to show that regular sal-
meterol in combination with fluticasone is safe for use in
adults or children
C O N T R I B U T I O N S O F A U T H O R S
CJC: conception of the idea and co-writing of the protocol (Cates 2009). First author for data extraction and co-writing of both updates
MF and SS: data extraction and co-writing the 2013 and 2018 updates.
BS and SW: trial selection, data extraction, and co-writing of the 2018 update.
Previous versions
Toby Lasserson: co-writing of the protocol (Cates 2009), trial selection, data extraction, and co-writing of the original review (Cates
2009b).
Roman Jaeschke: trial selection, data extraction, and co-writing of the original review (Cates 2009b), as well as the update (Cates 2013).
Matthew J Cates: co-writing of the protocol, data extraction, and co-writing of the original review (Cates 2009b).
D E C L A R A T I O N S O F I N T E R E S T
CJC: joint co-ordinating editor of the Cochrane Airways Group.
SS: none known.
MF: none known.
BS: none known.
SW: none known.
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Previous versions
Roman Jaeschke receivedhonoraria for lectures fromBoehringer Ingelheim (2006;USD4000) andGlaxoSmithKline (2007; EUR2000),
as well as travel support from Boehringer Ingelheim and GlaxoSmithKline (2006 and 2007; up to USD1000). This occurred more
than five years before publication of the review.
Mattthew Cates and Toby Lasserson: none known.
S O U R C E S O F S U P P O R T
Internal sources
• NHS R&D, UK.
External sources
• NIHR, UK.
Programme Grant (10/4001/01)
• European Union (FP7), Other.
ASTROLAB project (EC HEALTH-F5-2011-282593)
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Although the protocol originally included studies comparing salmeterol and ICS versus higher doses of ICS (Cates 2009), we restricted
this review and update to studies randomising participants to the same dose of ICS with and without salmeterol. Due to problems
with fixed continuity corrections for zero cells, we used the Peto OR as the primary metric for analysis of relative measures, and the
risk difference for absolute measures. We did not attempt subgroup analysis on the basis of asthma severity or dose of ICS.
For the 2018 update, we assessed the safety of adding salmeterol to ICS from the worst case number needed to treat for an additional
harmful outcome (NNTH) for one additional serious adverse event or death to occur. We calculated the NNTH using Visual Rx to
transform the upper end of the 95% CI of the pooled Peto OR, by applying it to the mean event rate in control arms of the trials.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Adrenal CortexHormones [administration & dosage; ∗adverse effects]; Adrenergic beta-2 Receptor Agonists [administration & dosage;
∗adverse effects]; Albuterol [administration & dosage; adverse effects; ∗analogs & derivatives]; Anti-Asthmatic Agents [administration
& dosage; ∗adverse effects]; Asthma [drug therapy; ∗mortality]; Randomized Controlled Trials as Topic; Salmeterol Xinafoate
MeSH check words
Adolescent; Adult; Child; Humans; Young Adult
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